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‘All parts of the body which have a function, if used in 
moderation and exercised in labours in which each is 
accustomed, become thereby healthy, well-developed, 
and age more slowly, but if unused and left idle they 
become quickly liable to disease, defective in growth, 
and age more quickly’ 
 
Hippocrates, 460 BC-370 BC 
 
 
 
 
 
 
 
 
 
 
Hjertemuskelcellefunksjon og kalsiumhåndtering i dyremodeller med 
medfødt og ervervet maksimalt oksygenopptak 
 
Hjerte-karsykdommer er i dag årsaken til flest dødsfall i Europa. Selv om det er kjent at et 
høyt maksimalt oksygenopptak kan virke beskyttende mot hjerte-karsykdom både hos friske 
og de med økt risiko, vil studier av de underliggende mekanismene bidra med verdifull 
informasjon til utvikling av fremtidige retningslinjer for behandling og forebygging av hjerte-
karsykdom. Maksimalt oksygenopptak er hos de fleste av oss avhengig av hjertets slagvolum 
som igjen bestemmes av hjertemuskelcellenes kontraksjonsevne. For at hjertemuskelcellene 
skal kunne kontrahere kraftig er kalsiumhåndteringen i cellene avgjørende. Ett av de 
proteinene som er med bidrar til å styre dette er kalsium/ kalmodulin avhengig protein kinase 
II (CaMKII). CaMKII aktiviteten øker når hjertefrekvensen øker og det ser ut til at den økte 
aktiviteten er viktig for treningsresponsen i hjertemuskelcellene, mens hos hjertesvikt er det 
motsatt og den økte aktiviteten fører til funksjonsnedsettelse.  
 
De overordnede formålene med denne doktorgradsavhandlingen var å undersøke betydningen 
av et høyt medfødt oksygenopptak på hjertets remodellering etter infarkt, eventuelle 
forskjeller i treningsrelaterte tilpasninger i hjertemuskelceller fra rotter med ulik medfødt evne 
til å respondere på trening og om CaMKII er nødvendig for treningsrelaterte forbedringer i 
maksimalt oksygenopptak, hjertemuskelcellens kontraksjon og kalsiumhåndtering.  
 
Resultatene viste at rotter med høyt og rotter med lavt medfødt maksimalt oksygenopptak fikk 
like stor remodellering av hjerte og funksjonsnedsettelse etter infarkt, men at et høyt 
utgangspunkt fungerte som en ”buffer” på funksjonsnedsettelsen. Videre fant vi at høy 
intensitets aerobe intervaller ikke forbedret maksimalt oksygenopptak, 
hjertemuskelcellefunksjon eller kalsiumhåndtering i rotter med lav medfødt respons til 
trening. Dette indikerer at mangel på plastisitet i hjertet bidro til å hindre treningsrespons på 
maksimalt oksygenopptak. Det siste studiet viste at i friske mus er CaMKII nødvendig for å 
opprettholde kalsiumhomeostase i hjertemuskelcellene og for å oppnå optimal treningsrespons 
på hjertemuskelcellehypertrofi, funksjon og kalsiumhåndtering. Men paradoksalt nok førte 
CaMKII inhibering allikevel til en større økning i maksimalt oksygenopptak. 
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function and calcium handling after myocardial infarction. Submitted. 
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DEFINITIONS 
 
Aerobic fitness: The ability of the circulatory and respiratory system to supply oxygen during 
sustained physical activity. 
  
Cardiovascular disease: A disease of the heart and/or blood vessels. 
 
Calcium handling: The handling of calcium fluxes in the cardiomyocyte leading to the 
transient changes in intracellular calcium concentration during contraction and relaxation of 
the cardiomyocyte. 
 
Contractile function: The intrinsic capacity of the myocardium/cardiomyocyte to contract, 
independent of changes in pre- or after load, or other “external factors”. 
 
Ejection fraction: The fraction of blood pumped out of the left ventricle with each stroke 
(stroke volume/ left ventricle end-diastolic volume). 
 
Excitation- contraction coupling: The process from electrical excitation of the myocyte to 
contraction of the heart. 
 
Fractional shortening: The decrease in cardiomyocyte length from end-diastole to end-
systole divided by end-diastolic length. 
 
Heart failure: The hearts inability to generate adequate pumping of blood to the peripheral 
organs in order to meet their metabolic demand.  
 
Maximal oxygen uptake: The highest oxygen uptake that can be achieved by an individual 
during exercise with dynamic use of a large muscle mass; considered as the best indication of 
cardio respiratory capacity. 
 
Myofilament calcium sensitivity: The myofilament contractile response to a given amount 
of activating calcium in the cardiomyocyte. 
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Ventricular remodelling: Most commonly refers to changes in the hearts size, shape and/or 
function following myocardial infarction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11
FREQUENTLY USED ABBREVIATIONS 
 
Ca2+:   calcium 
CaMKII:  calcium/calmodulin-dependent protein kinase II 
CVD:  cardiovascular disease 
ECC:   excitation- contraction coupling 
HCR:  high capacity runners 
HRT:  high responder training 
Hz:   hertz 
LCR:   low capacity runners 
LRT:   low responder training 
LTCC:  L-type calcium channel 
LV:   left ventricle 
MI:   myocardial infarction 
NCX:   sodium/calcium - exchanger 
PLB:   phospholamban 
PKA:   protein kinase A 
RyR2:   ryanodine receptor type 2 
SERCA-2a:  sarcoplasmic reticulum calcium ATPase 
SR:   sarcoplasmic reticulum 
T-tubules:  transverse tubules 
VO2max:  maximal oxygen uptake 
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BACKGROUND  
As early as the 1970s low aerobic fitness was recognized as a significant prognostic marker in 
patients with cardiovascular disease (CVD) (1). Since then substantial evidence has confirmed 
that aerobic fitness is a major independent predictor of morbidity and mortality (2-15) in both 
asymptomatic (3,16-18) and symptomatic men and women (9,13,19-22). Physical activity is 
also associated with reductions in CVD risk factors (10,14,23,24), however, aerobic fitness is 
shown to be the strongest predictor (6,17,21,25,26). For instance, Lee et al (17) recently 
reported that being fit but less active resulted in higher protection against mortality compared 
to being unfit and more active.  
 
Considering the importance of aerobic fitness in health and longevity, studying the underlying 
mechanisms of aerobic fitness may provide valuable information for developing future 
guidelines for CVD prevention and treatment. 
 
Maximal oxygen uptake 
Maximal oxygen uptake (VO2max) is considered the single best indicator and golden standard 
measure of aerobic fitness. VO2max was defined by Hill and Lupton (27) in 1923 as “the 
oxygen intake during an exercise intensity at which actual oxygen intake reaches a maximum 
beyond which no increase in effort can raise it”, and is a precise measure of whole-body 
capacity to transport and utilize oxygen during severe dynamic exercise with large muscle 
mass (28-30). VO2max is a physiological characteristic, expressed by the Fick equation: 
 
VO2max  = (HR · SV) · a-vO2 difference, 
 
where HR indicates heart rate, SV indicates stroke volume, and a-vO2 indicates arterio-venous 
oxygen difference (31). Stroke volume is the major determinant of improvements in cardiac 
output and therefore VO2max, as maximal heart rate remains unchanged or slightly decreased 
after long-term exercise training (32,33). 
 
According to Hills postulate, VO2max is limited by the cardiorespiratory systems’ capacity for 
oxygen transport to the working muscle mass, thus, VO2max is supply limited (27). This 
allegation has raised numerous disputes ever since, however today there seems to be a general 
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consensus of the original paradigm by Hill for healthy individuals. This is evidenced by the 
much larger capacity for oxygen extraction and utilization in the peripheral muscles compared 
to the central oxygen transport capacity in healthy individuals (31,34-37). However, some 
patients and untrained humans seem to be demand limited, making VO2max dependent on 
“peripheral factors” (37).  
 
VO2max as a predictor of health 
VO2max reflects several important prognostic markers for CVD. These markers include cardiac 
function, pulmonary function, endothelial function, oxygen-carrying capacity and utilization, 
and the autonomic nervous system (5,18), together this markers makes VO2max a valuable 
prognostic evaluator for morbidity and mortality (3,5,18). Recent studies suggest that holding 
a moderate to high VO2max prevents development of several life-style related diseases 
(6,17,38). Rats artificially bread for high and low capacity running (HCR and LCR) has 
provided proof for this concept. LCR rats have higher scores on CVD risk factors that 
constitute the metabolic syndrome (39) and also decreased longevity (24 vs. 32 months, 
respectively) compared to HCR rats (40). However, in humans even a small increase in 
VO2max of 1 metabolic equivalent (3.5 ml-1 · kg-1 · min-1) is sufficient to elicit substantial 
improvements in cardiovascular health and reductions in risk factors (6,41), whereas a 
decrease in VO2max of 5 ml-1 · kg-1 · min-1 corresponds to almost 56% higher prevalence of 
CVD risk factor clustering (42). Moreover, Aspenes et al (42) recently reported a VO2max 
threshold level of 44 ml-1 · kg-1 · min-1 in men and 35 ml-1 · kg-1 · min-1 in women, whereupon 
values below the threshold was associated with an unfavourable CVD risk profile. However, a 
association between VO2max and conventional CVD risk factors were still present in subjects 
above the threshold and those considered being fit (42).  
 
Factors influencing VO2max  
Intrinsic and acquired elements of VO2max 
Inherited components cause large variations in intrinsic and acquired (exercise response) 
VO2max among individuals (43-47). In healthy individuals VO2max has a heritability of ~50% 
even when data are adjusted for age, sex, body mass and body composition (44,48). VO2max 
response to exercise training also has a heritability of ~50% when adjusted for the parameters 
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mentioned above (45,49). Still, different combinations of genes appear to determine intrinsic 
VO2max (48,50,51) and exercise responsiveness (43,45,46,49,51), although, some studies have 
suggested the contrary (52,53). However, among the 720 healthy participants in the large 
HERITAGE Family Study, age, gender, race, and baseline VO2max combined contributed to 
only 11% of the variance in VO2max exercise response after 20 weeks of exercise training 
(45,46). Moreover, variations in VO2max response to standardized exercise programs has been 
shown to range from no gain to a doubling of VO2max, regardless of baseline values (43,46). 
Thus, the idea that more exercise produces greater response is not always true, even though 
exercise training is considered the main principal for improvements in VO2max (43,45,49,54). 
 
Although genetic components are known to determine a large portion of both intrinsic and 
acquired VO2max (50,55), the majority of studies on exercise training focus on mean effects 
and group results, ignoring the individual variability and the significance of these. Recently, 
some studies have focused on targeting genomic predictors of VO2max response to exercise for 
the purpose of genotyping human exercise responsiveness to promote genotype-tailored 
interventions to prevent and treat life-style related diseases in low responders (54,56). This is 
an important contribution; however, some basic physiological questions still remain. For 
example it is acknowledged that VO2max level is more related to morbidity and mortality than 
general physical activity, but the effect of intrinsic VO2max on cardioprotection is currently 
unknown. In addition, it is known that there are large individual differences in VO2max 
response to standardized exercise programs, but the cardiac mechanisms underlying exercise 
response have not been investigated despite the strong association between cardiac function 
and VO2max. 
 
Exercise training to improve VO2max  
Exercise training regimes have been extensively studied to determine the duration, intensity 
and frequency that provide the most optimal results on performance and health. High intensity 
interval training has been increasingly acknowledged to produce larger aerobic and 
cardiovascular improvements in both healthy individuals (57,58), patients with CVD and 
metabolic syndrome (22,23,59-61) compared to moderate intensity exercise. However, health 
recommendations of exercise intensity still vary from 40% to 90% of VO2max (62).  
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The basic principle of increasing VO2max through high intensity interval training was 
established in the early 1970s (63-65), and is physiologically based on the fact that, especially 
in endurance trained subjects, stroke volume does not plateau but rather increase up to 
intensities close to VO2max (28,32,37,66). Cardiac adaptations to high intensity exercise in 
healthy individuals include physiological hypertrophy of the heart, increased cardiac output 
due to improved systolic emptying rate, and enhanced diastolic filling, providing increased 
oxygen transport to the working muscles (14,58,67). High intensity exercise training (85-90% 
of VO2max) is bound to be performed as interval training as lactic acid starts accumulating 
after a few minutes, eventually resulting in fatigue of the skeletal muscles. Using intermittent 
active recovery periods at 50-60% of VO2max accumulated lactic acid is effectively removed 
and exercise intensity can be maintained for the remaining interval periods (68). Hence, the 
optimal interval duration to improve VO2max is suggested to be 3-5 minute intervals with 
active recovery periods in between (28,69).  
 
Myocardial infarction, cardiac function and VO2max  
Myocardial infarction (MI) is a common form of CVD. MI reduces oxygen supply to the 
cardiomyocytes, which in turn results in reduced stroke volume and insufficient oxygen 
supply to peripheral tissue. These MI-induced changes in cardiac and peripheral function also 
cause a reduction in VO2max. MI is most often caused by atherosclerotic plaque formation in 
one or more major coronary arteries, resulting in occlusion of the arteries. The subsequent 
ischemia results in MI which causes apoptosis if perfusion is not restored (70). The 
endocardium dies faster than the epicardium, as it is more vulnerable to energy-starvation, and 
the extent of MI is determined mainly upon how distal the occlusion occurs (71). MI induces 
ventricular remodelling that involves changes in ventricular structure, shape, and size, such as 
myocardial wall thinning, expansion of the infarcted area, and left ventricle (LV) chamber 
dilatation (72,73). These progressive changes contribute to the overall process of chamber 
enlargement due to pathological hypertrophy with elongation and widening of 
cardiomyocytes. The extent of remodelling is directly proportional to infarct size (74). 
Reduced LV contractile function after MI causes decreased systolic blood pressure and 
increased LV end-diastolic pressure, leading to a rightward-shift of the diastolic pressure-
volume relationship and subsequent reduced VO2max (73,75).  
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Cellular mechanisms of alterations in VO2max  
Although cardiomyocytes only account for ~20% of the total cardiac cell population they 
account for 70-90% of the myocardial mass (33,76), and have been widely used to study the 
cellular basis of ventricular function. Exercise-induced improvements in VO2max partly derive 
from alterations in cardiomyocyte function (77) as cardiomyocyte dimension, contractility and 
calcium (Ca2+) handling are associated with whole-body VO2max (69,77-80). 
 
Cardiomyocyte hypertrophy 
Chronic endurance exercise training is often associated with functional and morphological 
changes in the heart such as physiological hypertrophy, a beneficial mechanical adaptation 
that contributes to increased stroke volume in response to increased demands (81). 
Physiological hypertrophy involves proportional eccentric (elongation) and concentric 
(widening) cardiomyocyte growth, LV chamber enlargement and proportional change in wall 
thickness and mass (82-84). The magnitude of hypertrophy appears to be intensity-dependent 
as high intensity interval training is known to induce larger hypertrophic response than 
moderate intensity training (67,69,85). The Insulin-like Growth Factor 1 (IGF1)/Akt pathway 
has been proposed as the significant signalling pathway in physiological hypertrophy, 
demonstrated by complete absence of exercise-induced hypertrophy when the IGF1/Akt 
signalling cascade was disrupted (86,87). Physiological hypertrophy regresses when exercise 
training is terminated (77).  
 
Pathological hypertrophy is initially a compensatory response to chronic overload that 
normalizes wall stress and permits normal cardiac function. Pathological remodelling occurs 
after cardiac injury including myocardial infarction, pressure overload, inflammatory disease 
and volume overload that increase the mechanical stretch placed on the cardiomyocytes (88). 
The extent of hypertrophy after MI is related to the magnitude of initial damage to the 
myocardium, infarct healing, and ventricular wall stress (89). The most significant pathways 
for pathological hypertrophy include activation MAPK-kinases and several fetal gene 
programs, and release autocrine and paracrine humoral factors such as; angiotensin II, 
endothelin 1 and IGF1 (for detailed review see Bernardo et al (88)) (90). In time, pathological 
hypertrophy becomes detrimental, associated with contractile dysfunction, increased 
interstitial fibrosis, apoptosis (cell death), and potentially dilation of the hypertrophied heart 
that may ultimately lead to heart failure (91). During the transition from compensatory 
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hypertrophy to decompensation, increased activation of calcineurin and Ca2+/calmodulin 
dependent protein kinase II (CaMKII) is prominent features that may cause arrhythmic events 
(92-97). Nuclear CaMKII (together with PKD) can activate myocyte enhancer factor 2 
(MEF2) and cause hypertrophy (98,99). The significance of CaMKII in pathological 
hypertrophy is demonstrated by the reduced remodelling during pressure overload in CaMKII 
inhibited mice (97,100). Moreover, exercise training has been shown to attenuate cellular 
hypertrophy in failing cardiomyocytes from post MI rats (79,101). Preliminary data suggest 
that exercise reduce cardiomyocyte volume in an intensity dependent manner (unpublished 
work). However, the cellular mechanisms for exercise-induced attenuation of pathological 
hypertrophy remain unclear. 
 
Cardiomyocyte contractile function 
Improved systolic and diastolic functions of the heart are central features associated with 
regular exercise training (32,33). Exercise-induced adaptations in cardiomyocyte function 
provide the cellular rationale for improved stroke volume with enhanced ejection of blood at 
systole and improved relaxation and filling rate during diastole. A widely held hypothesis is 
that exercise-induced alterations in cardiomyocyte contractile function are intensity-
dependent (69,77,79,80,102-104). This hypothesis is supported by Kemi et al (69) who 
reported larger effect on cardiomyocyte contractile function after high intensity exercise (85-
90% of VO2max) compared to moderate intensity exercise (65-70% of VO2max). There are also 
a few studies that report unaltered cardiomyocyte contractile function after exercise training 
(105,106). However, this discrepancy is most likely explained by differences in exercise 
intensity. 
 
Cardiomyocytes from failing hearts have reduced contraction and slowed relaxation compared 
to healthy cardiomyocytes. This contractile dysfunction in failing ventricles is caused by a 
combined effect of abnormal loading in vivo (107) and intrinsic properties of the 
cardiomyocytes (108). In rats, exercise training has been demonstrated to restore 
cardiomyocyte contractility from failing hearts to levels comparable to sham-operated rats, 
both after high intensity aerobic interval training and high intensity sprint training (79,109). 
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Cardiomyocyte Ca2+ handling  
Ca2+ handling in healthy cardiomyocytes 
Cardiomyocyte contractile function is closely related to Ca2+ handling (108,110) and 
contraction can be changed either by altering amplitude or duration of Ca2+ transients or 
altering myofilament Ca2+ sensitivity (110). The process from electrical excitation of the 
myocyte to cardiomyocyte contraction, excitation-contraction coupling (ECC) (Figure 1), is 
mainly regulated by Ca2+ (110,111). Depolarization of the sarcolemma and the transverse (T-) 
tubules during action potential cause Ca2+ entry through the voltage-dependent L-type Ca2+ 
channels (LTCC). In addition a small amount of Ca2+ enters the cell through the Na+/Ca2+ 
exchanger (NCX) in reverse mode (112). These Ca2+ currents activates the ryanodine receptor 
type 2  (RyR2) and triggers the release of larger amounts of Ca2+ from the sarcoplasmic 
reticulum (SR) through RyR2, termed Ca2+ induced Ca2+ release. This raises the cytosolic 
Ca2+ concentration, and Ca2+ binds to troponin C activating the myofilaments leading to the 
cardiomyocyte contraction (systole).  
 
 
Figure 1. Ca2+ cycling during excitation- contraction coupling. Inset; the time course of an action potential (AP), 
Ca2+ transient ([Ca]i) and contraction. NCX, Na+/Ca2+ exchange; ATP, ATPase; PLB, phospholamban; SR, 
sarcoplasmic reticulum. Reprinted by permission from Macmillian Publishers Ltd: Nature (110), copyright 2002. 
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Relaxation (diastole) occurs when the cytosolic Ca2+ is removed (110,113,114). To maintain 
Ca2+ homeostasis the same amount of Ca2+ that entered the cell must also be removed out of 
the cell. Ca2+ is transported back to the SR by the SR Ca2+ ATPase (SERCA-2a), or is 
extruded across the sarcolemma by the NCX. A small amount of Ca2+ is also removed by the 
sarcolemmal Ca2+ ATPase (PMCA) and the mitochondrial Ca2+ uniport (110).  
 
CaMKII is a key mediator fine-tuning ECC that has drawn a lot of attention the recent years 
(111,115,116). CaMKII is a serine-threonine kinase that is activated by increased intracellular 
Ca2+ and is expressed abundantly in the heart (For detailed review, see (111,115,117)) 
(115,116). There are four different CaMKII isoformes (α, β, γ, δ), with the δ isoform 
predominant in the heart (115,117-119). CaMKII becomes autophosphorylated at threonine 
(Thr)287 and by oxidation of a pair of methionines 281/282 at the regulatory domain. When 
CaMKII is autophosphorylated it remains active after Ca2+/calmodulin has dissociated from 
its binding region. Once in the autophosphorylated state, dephosphorylation by protein 
phosphatases and reversed oxidation by methionine sulfoxide reductase A is necessary for 
complete inactivation (111). By phosphorylation of several Ca2+ handling proteins in the 
cardiomyocyte, including the LTCC, RyR2 and phospholamban (PLB) on the SERCA-2a, 
CaMKII can regulate/dysregulate Ca2+ cycling in health and disease (Figure 2) (111,115,116).  
 
                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of CaMKII on excitation-contraction coupling. CaMKII phosphorylates several Ca2+ handling 
proteins, including phospholamban (PLB), possibly SR Ca2+ ATPase (SERCA), SR Ca2+ release channels (RyR), 
L-type Ca2+ channels (ICa), Na+ channels and K+ channels. Maier LS & Bers DM 2007 (111), by permission of 
Oxford University Press.  
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Ca2+ handling in healthy exercise-trained cardiomyocytes 
Exercise training is generally proven to enhance Ca2+ handling, in conjunction with 
improvements in cardiomyocyte contractility. Kemi et al (69) observed an association 
between faster contraction-relaxation rates that corresponded with faster Ca2+ rise and decay 
of twitch transients in exercised cardiomyocytes. Several possible mechanisms have been 
suggested to explain the increased rate of rise in Ca2+ transients after exercise training, 
including a more effective coupling between LTCC and RyR2 Ca2+ release (106), and greater 
Ca2+ entry across the plasma membrane due to prolonged action potentials (121). The faster 
diastolic Ca2+ decay is at least partly explained by improved SERCA-2a activity through 
increased SERCA-2a levels and increased SERCA-2a/PLB ratio after exercise training 
(79,80,103,122). This contributes to increased relaxation and improves contraction by 
facilitating SR Ca2+ uptake, making more Ca2+ available for the next contraction (33,103,110). 
Furthermore, when the inhibition of SERCA-2a by phosphorylation of the PLB by protein 
kinase A (PKA) or CaMKII is relived SERCA-2a can increase its activity two- to threefold 
(123-126). The importance of exercise-induced increase in CaMKII activity is currently 
unknown and might be an indirect effect of increased intracellular Ca2+ cycling (103,127). 
Moreover, the exercise-induced increase in myofilament Ca2+ sensitivity in cardiomyocytes 
that enhances Ca2+ handling and thus cardiomyocyte contractility (79,80,103), might be 
related to increased CaMKII activity. Interestingly, acute CaMKII inhibition after an exercise 
training intervention has been found to substantially blunt the exercise-induced improvements 
in cardiomyocyte inotropy and lusitropy (103). This indicates that CaMKII is potentially 
necessary for exercise-induced adaptations in cardiomyocytes. Despite these findings, there 
exists no further literature to support this hypothesis, and whether the outcome of regular 
exercise training is dependent on CaMKII activation is currently not known. 
 
Ca2+ handling in failing cardiomyocytes 
Alternations in normal cardiomyocyte Ca2+ handling are associated with contractile 
dysfunction (128,129), increased propensity for cardiac arrhythmias and sudden cardiac death 
in failing cardiomyocytes (96,108,128,130-135). Abnormal Ca2+ handling is caused by 
defective Ca2+ handling by sarcolemma and/or SR channel proteins, and include prolonged 
Ca2+ transients, depressed SR Ca2+ content and/or SR Ca2+ release and reduced SERCA-2a 
activity (128,130-132,136-138). Recent studies have shown that CaMKII has a functionally 
effect on myocardial pathology (139-141). CaMKII expression and activity is increased in 
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failing hearts (142,143) promoting dysregulation of Ca2+ homeostasis and disruption of ECC 
(97,117,119,143-146), playing an important role in arrhythmogenesis (94,96,143,147).  
 
Increased diastolic SR Ca2+ leak is a common feature in failing cardiomyocytes 
(143,148,149). Spontaneous Ca2+ release from RyR2 cause delayed after-depolarization that 
give rise to a transient inward Ca2+ current during the diastolic period (150), increasing the 
propensity for cardiac arrhythmias and sudden cardiac death (108,130,151). Chronic 
hyperphosphorylation of RyR2 by PKA (149) and CaMKII (152-154) cause increased 
diastolic SR Ca2+ leak via RyR2 by increasing RyR2 Ca2+ sensitivity and open probability 
(143,152,155,156). Combined with effects of depressed SERCA-2a activity (143), and 
increased NCX activity (132,157,158) diastolic SR Ca2+ leak reduces SR Ca2+ load, thereby 
reducing Ca2+ transient amplitude in failing cardiomyocytes (132). Due to the crucial role for 
CaMKII activity on diastolic SR Ca2+ leak (143,152,153,155) inhibition of CaMKII may 
serve as a therapeutic prevention of heart failure progression (95,97).  
 
Ca2+ handling in exercise-trained failing cardiomyocytes 
Exercise training produces several positive effects on a failing heart (22,58,79,159,160). 
These effects include decreased diastolic Ca2+ levels, increased systolic Ca2+ release and 
normalization of β–adrenergic response, myofilament Ca2+ sensitivity, faster rise and decay of 
intracellular Ca2+ transient, and increased SERCA-2a expression (22,33,58,79,161-163). 
Studies on animal models with pathologically increased CaMKII activity report a reduction in 
CaMKII activity after exercise training, associated with improved cardiomyocyte function 
linked to increased SERCA-2a activity and reduced SR Ca2+ leak through RyR2 (104,127). 
Interestingly, CaMKII inhibition restores Ca2+ homeostasis, normalizes ECC function and 
reduces myocardial pathological remodelling by improving a complicated mixture of CaMKII 
regulated pathways, somewhat similar to the effect of exercise training 
(94,95,97,119,139,147,148,164-172). However, the effect of combining pharmacological 
CaMKII inhibition and exercise training has not been explored.  
 
Transverse-tubule network 
T-tubules in mammalian ventricle myocytes are invaginations of the plasma membrane along 
the Z-line regions along the longitudinal axis forming a complex network that facilitates 
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coordinated contractions and efficient ECC with uniform depolarization across the whole cell 
(173,174). Important proteins for ECC such as LTCC and NCX are concentrated at the T-
tubules, while RyR2 and SERCA-2a are located in close proximity at the junctional SR (174). 
Local Ca2+ signalling complexes, called couplons, are present at the junction between 
sarcolemma (both T-tubules and surface) and the SR (110). There is ~20,000 couplons in the 
cardiomyocyte whereupon each couplon consist of 10-25 LTCCs and 100-200 RyR2s (175). 
All couplons are under local control, and activated by action potentials and subsequent inward 
Ca2+ currents (175). Synchronous contraction of the cell requires simultaneous stimulation of 
all couplons. 
 
T-tubules become disorganized and reduced in density in CVD (176,177) causing disruption 
of the ECC with reduced Ca2+ release synchrony (104,177). The structural remodelling of T-
tubules starts at the LV and penetrates to the right ventricle as disease progresses (176). The 
reduced T-tubule density might reflect a differential organization in relation to additional 
sarcomeres caused by pathological hypertrophy or a true loss of T-tubules in the given area. 
However, a recent study indicated that T-tubule density may be independent of cell size as 
exercise-induced physiological hypertrophy did not reduce relative T-tubule density (160). 
Moreover, high intensity exercise training has been demonstrated to partly restore T-tubule 
density and T-tubule function after cardiac remodelling following cardiomyopathy and MI 
(104,160), supporting the idea that T-tubules have a degree of plasticity (177).  
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AIM OF THE THESIS AND HYPOTHESIS 
The overall aims of the thesis were 1) to determine the role of intrinsic VO2max upon cardiac 
remodelling after MI and 2) to determine exercise-induced adaptations in cardiomyocytes 
from rats with different in-born ability to respond to endurance training, 3) to determine 
whether CaMKII is important in defining the exercise-induced improvements in VO2max, 
cardiomyocyte contractile function and Ca2+ handling.  
 
We hypothesized that; 
1) the higher aerobic capacity in HCR rats would yield a cardioprotective effect after MI 
compared to the LCR rats that already have established risk for CVD. 
2) high intensity exercise training would improve VO2max, cardiomyocyte contractility 
and Ca2+ handling and induce cardiac hypertrophy in high responder rats (HRT) but 
not in low responder rats (LRT). 
3) chronic CaMKII inhibition would abolish the normal cardiac exercise response for 
VO2max and cardiomyocyte function. 
 
The specific aims of the individual papers were: 
Paper I:  Determine the role of intrinsic VO2max on cardiac contractile function and Ca2+ 
handling in LCR vs. HCR rats after induction of MI by ligation of the left 
anterior descending coronary artery. 
 
Paper II:  Determine the exercise response on VO2max, cardiomyocyte dimensions, 
function and Ca2+ handling in the HRT/LRT model after a high intensity 
interval training program.   
 
Paper III: Determine the effect of chronic CaMKII inhibition upon VO2max and 
cardiomyocyte function during the course of an exercise training program in 
healthy mice. 
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METHODOLOGICAL CONSIDERATIONS 
The following section contains considerations about the main methodologies used in the 
different studies that are included in this thesis. Detailed method descriptions are presented in 
the original papers. 
 
Animal models 
In-dept studies of cardiomyocyte function in experimental settings require use of animal 
models. In the present studies we chose to use rat and mice models that are supposed to mimic 
human physiology. All in-vivo interventions were done during the animals’ dark cycle, as 
rodents are normally active at night. The experiments were approved by the Norwegian 
Council for Animal Research, which was in accordance with Guide for the Care and Use of 
Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 1996).  
 
Artificial selection of rats 
Two rat models have been established by artificial two-way, selective breeding for high and 
low capacity runners (HCR/LCR) (55,178), and for high and low responders to training 
(HRT/LRT) (51). The initial hypothesis for these rat models was that functional alleles at 
multiple interacting loci affecting intrinsic properties would be enriched or fixed between the 
extreme ends of selection within each animal model. Both rat models are derived from 
genetically heterogeneous rats obtained from the National Institute of Health, USA, (N:NIH 
stock). To maintain the heterogeneous genetic lines a rotational mating paradigm has been 
used that minimizes inbreeding (1.25% per generation) (178). In comparison to inbred strains, 
outbred selected lines maintain genetic complexity (179). Finally, HCR/ LCR and HRT/ LRT 
lines may serve as reciprocal controls for unknown environmental changes due to the 
concurrent breeding of each line in both rat models.  
 
High and low capacity runners (HCR/LCR) 
In paper I we examined the effect of intrinsic VO2max on cardiac remodelling after MI. For 
this purpose we used female HCR and LCR rats from the 22nd generation, described in detail 
elsewhere (178). In brief, rats were selected for breeding based on their intrinsic treadmill 
running capacity. The HCR rats represents a ~400% higher inborn maximal running distance 
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and a ~30% higher inborn VO2max than the LCR rats (Figure 3A & B). As a consequence of 
selecting purely upon running capacity this model gave LCR rats that had a high-risk 
cardiovascular profile (39,180,181). These data obtained from a contrasting heterogeneous 
model system provide strong evidence that genetic segregation for aerobic exercise capacity 
can be linked with cardiovascular disease and is useful for deeper mechanistic exploration.  
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Figure 3. Intrinsic running capacity measured as maximal running distance (A) and as VO2max (B) in high 
capacity runners (HCR) and low capacity runners (LCR), data presented as mean values ± SD. 
 
High and low responders to training (HRT/LRT) 
Female rats from the 7th generation of artificial selection for high or low response to training 
were included for experiments on cardiac exercise response and from the 9th generation for 
experiments on cardiac protein expression and histochemistry in paper II. In contrast to 
HCR/LCR, the HRT/LRT rat model is based on selection for extreme ends of response to 
exercise training measured as change in maximal treadmill running distance after 24 days of 
modest treadmill exercise training (Figure 4) (51). The exercise program resembled the 
general guidelines prescribed for man (moderate brisk walking or jogging for 30 minutes, 3 
times a week) to make sure that all rats were able to complete the entire program independent 
of strain or sex (55). The six highest and six lowest responding rats of each sex was selected 
to mate for the next generation. Over generations these rats have developed contrasting 
phenotypes and gene networks providing a powerful tool to determine mechanisms of 
response to exercise training. 
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Figure 4. Relative gain in running distance as response to exercise training in high responders to training (HRT) 
and low responders to training (LRT), data presented as mean values ± SD. 
 
Chronic CaMKII inhibition in mice 
To examine the impact of CaMKII on normal function and exercise-induced alterations in the 
heart we chronically inhibited CaMKII in C57 BL/6J mice (Møllegaard Breeding Center, 
Lille Skensved, Denmark) in paper III. CaMKII inhibition was obtained by use of the potent, 
selective and cell-permeable KN-93 (2-[N-(2-Hydroxyethyl)-N-(4-methoxybenzenesulfonyl)] 
amino-N-(4-chlorocinnamyl) –N-methylbenzylamine; Alexis-Biochemical, Enzo Life 
Science, PA). KN-93 was first generated as a synthesized methoxybenzenesulfonamide 
compound in the early 1990s, and has been widely used to study CaMKII ever since. KN-93 
inhibits CaMKII by competing for the calmodulin binding site on the regulatory domain 
(182). The dosage administered in paper III was based on previous studies which reported a 
dose-dependent effect of KN-93 on CaMKII inhibition (97,167). Daily injections of 10 
µmol/kg KN-93 have been reported to produce similar effect on LV contraction 
measurements as the genetically CaMKII-inhibited AC3:I mice (97,147).  
 
Potential non-specific effects of KN-93 have been noticed, such as acting as CaMKII-
independent ion channel antagonists, and affecting glucose-induced and forskolin-stimulated 
insulin release. Most important for our study were the potential inhibitory effects on the 
LTCC (167,183,184). We did not control for this side effect, but Sossalla et al (165) have 
controlled for the effect of KN-93 on LTCC against autocamtide-2 related inhibitory peptide 
(AIP) effects and found no change in LTCC current. Moreover, studies reporting LTCC 
inhibition were acute cell experiments, and other studies applying KN-93 injections in vivo 
have not reported any specific side effects (97,147). KN-93 was diluted in dimethyl sulfoxide 
(DMSO; C2H6OS; Sigma-Aldrich, St. Louis, MO), which also has minor concentration-
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dependent adverse effects (185). These side effects were minimized by administering small 
dosages of DMSO in paper III (0.04- 0.05 mL per injection). To control for potential side 
effects of DMSO sham mice were injected with the same amount of DMSO. Therefore, it is 
unlikely that DMSO influenced the observed differences between the groups. Urine sticks 
were used to test for glucose in the urine; there were no indications of such in any of the 
groups. These results suggest that KN-93 did not affect glucose-induced insulin release in the 
present study. After euthanasia mice were sent for pathological examinations of the vital 
organs at the Norwegian Veterinary Institute, Oslo, Norway to control for side effects of 
chronic KN-93 injections on aerobic fitness and cardiac function. All vital organs (including 
hearts) were examined to exclude that any major side effects had influenced the results. In 
brief, necropsy was performed on 17 of the animals, specimens from heart, liver, kidney, 
spleen, intestine and brain were fixed in 4 % neutral buffered formaldehyde and processed 
routinely for light microscopy. Sections were cut at 5 µm and stained with hematoxylin and 
eosin. The pathologist made no observations that would have altered aerobic fitness (except 
from discomfort from injections) or cardiac function. To minimize potentially negative effects 
of the injections on exercise performance, injections were administered after the exercise 
session. 
 
Experimental interventions 
Exercise training program 
To optimize the effect of exercise training, high intensity aerobic interval training was 
performed on rats and mice in paper II and III. Animals were trained 5 days/week for 6 
weeks, running uphill (25˚) on a treadmill. Training sessions consisted of a 10-minute warm 
up at 50-60% of VO2max, whereupon exercise then alternated between 4-minute intervals and 
2-minute active breaks at 85-90% and 50-60% of VO2max, respectively, for 90 minutes in 
paper II and 60 minutes in paper III. VO2max was measured at the beginning of every training 
week to ensure that the desired exercise intensity was obtained and to adjust for exercise-
induced improvements in VO2max and running economy (67,85). Sedentary animals were only 
tested before and after the exercise training period. This model of high intensity aerobic 
interval training was established by Wisløff et al (67), and has been proven efficient for 
inducing cardiovascular adaptations in both clinical and experimental studies 
(22,58,60,69,80,85,104,186,187).  
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Induction of myocardial infarction 
To induce acute MI in paper I, we used ligation of the descending coronary artery through 
thoracotomy. This is a well described and recognised experimental method that provides quite 
reproducible infarct sizes and serves as a rodent simulation of human MI (71,73,188,189). 
Ligation causes an MI in the LV free wall typically characterized by pathological remodelling 
such as increased lumen, dilated LV, thinning of the non-infarcted posterior wall and 
hypertrophy (190). Subsequent depressed contraction, slowed relaxation and impaired Ca2+ 
handling is most pronounced one week after MI is induced, followed by a partial recovery 
towards the fourth week, whereupon it remains unchanged but impaired for several weeks 
(78). Scar formation, as fibroblast proliferation and collagen deposition is completed within 
six weeks, and additional augmentation in ventricular volume will proceed until three months 
even in moderate sized infarctions (20-40% of the LV)(89).  
 
Although the histological evolution and scar formation are comparable in humans and rats 
(71,190), there are some notable limitations to this rat MI model in comparison to human MI. 
Experimental rat MI models and human MI naturally divert in origin (191). MI is usually 
induced in relatively young rats that does not reflect the analogous pathogenesis of coronary 
disease and subsequent MI normally seen in humans, which likely results from symptoms 
evolved over several years due to atherosclerosis, obesity, diabetes or hypertension (189). 
However, rats in paper I were close to one year at MI induction, and LCR rats possessed some 
of the symptoms above, providing a closer association to human MI (39). Moreover, 
variability in induced MI size among rats is inevitable and affects the remodelling process. In 
large MI (>40-50% of LV circumference) symptomatic signs of heart failure will develop 
over time (189,190,192), whereas hypertrophy of surviving myocardium in small MI (<20% 
of LV circumference) may normalize LV wall stress resulting in minimal pathological 
remodelling (192). All experiments were performed after completion of the acute remodelling 
phase. 
 
Experimental protocols  
Testing of maximal oxygen uptake 
Aerobic fitness was measured as VO2max, which represents the upper limit of aerobic exercise 
capacity (28). VO2 increases with power output in dynamic work with large muscle masses up 
 29
to a level where it reaches a plateau despite increasing workloads. VO2max was assessed 
before, during and after the exercise training period in paper II and III. In paper I VO2max was 
tested prior to cardiomyocyte experiments.  
 
      
Figure 5. Illustration of VO2max testing of mice. 
 
We determined VO2max by uphill (25°) treadmill running until exhaustion in a specialized 
metabolic chamber that allows us to register and control the amount of air volume passing 
through the chamber and analyse the fractions of oxygen and carbon dioxide (Figure 5). The 
use of inclination simplifies the assessment of animals’ VO2max and ensures reaching maximal 
work intensity, since performance is not limited by running speed (67,85). Such a full-body 
exercise taxes the cardiovascular system and VO2 maximally. Tests were started at low-
moderate intensity (0.10 m·sec-1 for mice, and 0.12 m·sec-1 for rats), whereupon running speed 
was increased by approximately 0.03 m·sec-1 every second minute until the animals were not 
able to maintain velocity and VO2 levelled off despite increasing work loads. This method has 
been thoroughly tested, and found reliable on rats and mice (67,85,186). To consider 
differences in body weight, VO2max was expressed in relation to body weight raised to the 
power of 0.75 in paper I and III (193). 
 
Familiarization to the treadmill is essential for exercise training and testing outcomes since it 
reduces stress associated with the treadmill and handling procedures. Prior to VO2max tests and 
exercise training rats and mice were allowed a gentle introduction to the treadmills, where 
they were kept on the treadmill at rest and subsequent low speeds. There is an electrical gird 
at the end of the running lanes giving electrical pulses of 0.2 mA causing discomfort but not 
pain. During the familiarization period this gird was turned off and when applied, animals 
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learned quickly to avoid the electrical gird, and thus, exercise intensity could be carefully 
controlled.  
 
Echocardiography in rats and mice 
Global adaptations on cardiac morphology and work was evaluated by echocardiography on 
animals in paper I and III using a single-element mechanical transducer with a center 
frequency of 30 MHz (Vevo 770, VisualSonics, Toronto, Canada) and digital ultrasonic 
system. Echocardiography is considered a feasible method for obtaining good-quality 
measurements of cardiac morphology and physiology in both rats and mice (192,194-199). 
Echocardiography is also validated for characterization of pathological hypertrophy in hearts 
(79,192), whereas the value in determining exercise-induced physiological hypertrophy has 
been questioned and currently measurements of isolated cell dimension are considered more 
accurate. Body composition and anatomical properties might limit echocardiography 
recording quality, and a future high-resolution echocardiography is necessary to obtain better 
quality measurements of exercise-induced hypertrophy comparable to post-mortem and 
isolated cell dimension measures.  
 
Echocardiography in conscious animals has minimal effect on measurements of cardiac 
function (196,199), however it requires substantial training of animals to minimize stress, and 
is also difficult to practice in rats, due to size. To control for potential cardiodepressive effects 
of anesthesia on echocardiography measurements standardizing the anesthetic protocol is 
essential. We performed echocardiography in self-breathing rats and mice exposed to a 
mixture of isoflurane and oxygen. Isoflurane anesthesia lowers breathing rate in a 
concentration-dependent manner, but the effect on cardiac function is considered to be small, 
and isoflurane is preferred over injectable anesthetics (197,200). During echocardiography, 
respiration and heart rate were closely monitored, and the amount of isoflurane (2%) was kept 
stable for all experiments. It is therefore unlikely that anaesthesia would have influenced the 
observed differences between groups. Following echocardiography, animals awoke almost 
immediately, indicating a light anaesthesia.  
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Cardiomyocyte experiments 
Significant correlation between cardiomyocyte contractile function and in vivo cardiac 
function facilitates the use of isolated cardiomyocytes in studies on cellular mechanisms of 
aerobic fitness and CVD (69,77-80). In the present thesis cardiomyocyte experiments were 
performed in paper I, II and III. 
 
Cardiomyocyte isolation 
Animals were anesthetized with isoflurane and heparinised hearts were rapidly removed and 
placed in an ice-cold perfusion buffer. Different perfusion buffers were used when isolating 
cardiomyocytes from rats and mice as described in detail in the respective papers. This is 
because mice cardiomyocytes are more sensitive to Ca2+ concentrations during the isolation 
process than rat cardiomyocytes. In brief, rat cardiomyocytes were isolated as previously 
described with a modified Krebs- Henseleit Ca2+ free buffer (67,80,201), whereas mice 
cardiomyocytes were isolated in a HEPES-based physiological solution, also previously 
described (202,203). Aorta was connected to an aortic cannula on a standardized Langendorff 
retrograde perfusion system and the hearts were cleaned by perfusion of Krebs buffer in paper 
I and II and Hepes buffer containing ethylene glycol tetra acetic acid (EGTA) in paper III. 
When the hearts were clean the perfusion solution was switched to a Krebs (paper I and II) or 
HEPES-based (paper III) solution (zero Ca2+) containing the enzyme collagenase II 
(Worthington, NJ, USA) and bovine serum albumin (Sigma Aldrich, MO, USA). Collagenase 
breaks down the peptide connections in the collagen, enabling separation of the cells. Hearts 
were removed from the perfusion system before the LV was separated and cut into small 
pieces. The tissue was lightly shaken for 10 minutes and the non-digested tissue filtered out 
by a nylon mesh. Cells were centrifuged at 600 rpm (at 37°) for 30 seconds whereupon the 
supernatant was gently removed and new buffer added. This was repeated two times to 
remove dead cells and to subsequently increase the Ca2+ concentration in the HEPES solution 
stepwise to 1.2 or 1.8 mM. In paper I the infarcted area was removed when the heart was cut 
down from the aorta cannula. Cardiomyocytes in paper I was isolated at least 24 hours after 
the VO2max test, and in paper II and III, cardiomyocytes were isolated 24 hours after the last 
exercise training session to measure the chronic adaptation to exercise training. Our research 
group has over several years developed extensive experience in cardiomyocyte isolation. 
However, we had fewer viable cells before centrifugation from mice hearts in paper III than 
expected. This is a limitation to the cardiomyocyte measurements in paper III. In paper I and 
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II we had up to 75% viable cells before centrifugation in line with previous cardiomyocyte 
isolation experiments in our laboratory, and an average of 10 cells from each animal were 
studied. Viable, rod-shaped cells without visible morphological alterations who responded 
adequately to electrical stimulation were used for experiments, and analyses were based on 
these cells.  
 
Cardiomyocyte contractile function and Ca2+ handling 
Cells attached to coverslips rested for 1 hour in HEPES buffer before loading. 
Cardiomyocytes were loaded with 2 µM Fura-2/AM (Molecular Probes, Eugene, OR, USA) 
in order to measure contractile function and Ca2+ cycling simultaneously. The membrane-
permeable derivative of the ratiometric Ca2+ indicator Fura-2/AM has acetoxymethyl (AM) 
ester attached to it (204). Therefore, cardiomyocytes were left in HEPES buffer for 20 
minutes of de-esterfication after the 30 minutes of Fura-2/AM loading in room temperature 
before experiments were started. During de-esterfication nonspecific cellular esterases 
hydrolyze AM which liberates the Ca2+ sensitive indicator and ensures adequate Fura-2 
loading. To avoid incorrect differences between cells a strict loading procedure was used for 
all experiments. This is especially important for fractional shortening, due to the depressive 
effect of Fura-2/AM on cardiomyocyte shortening. In all three papers rod-shaped cells 
without obvious morphological alterations, responding to electrical stimulation were included 
for cardiomyocyte experiments. During the experimental protocol cardiomyocytes in paper I 
were superfused in 1.8 mM Ca2+ HEPES-based solution, in paper II superfused with 1.2 mM 
Ca2+ HEPES-based solution, whereas cardiomyocytes in paper III were field stimulated in 1.8 
mM Ca2+ HEPES-based solution without perfusion. Higher Ca2+ contents in solutions (1.8 
mM vs. 1.2 mM) increase the electrical stimulated Ca2+ transients. To clarify differences in 
cardiomyocyte function between groups in paper I and III we used experimental solutions 
with higher Ca2+ content, since mice cardiomyocytes and failing cardiomyocytes have 
basically lower Ca2+ transients than healthy rats. All perfusion solution was kept at 37˚C 
during experiments. 
 
Electrical field stimulation of isolated cardiomyocytes is a standard and widely used method 
for studies on contractile function and Ca2+ cycling (39,78-80,129). Cardiomyocytes were 
stimulated with increasing frequencies (1-5 Hertz (Hz) in paper I and III and 1-7 Hz in paper 
II) on an inverted epifluorecence microscope (Nikon TE-2000E, Tokyo, Japan). Attached to 
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the side port of the inverted microscope was a video camera, and velocity of shortening and 
relaxation as well as the magnitude of shortening were analyzed during transients (SarcLen™, 
Ionoptix, Milton, USA), using a special designed software (SarcLen Sarcomere Length 
Acqusition Module). Exercise-induced changes in cardiomyocyte function have previously 
been shown to be most marked at physiological frequencies (69,77). However, most 
experiments, including ours, have been performed at stimulation frequencies ranging from 1-5 
Hz (paper II 1-7 Hz) which is below the physiological range in rats (5-10 Hz) and mice (7-12 
Hz). Furthermore, the reliance on CaMKII activity also increases with increasing stimulation 
frequencies (152). Thus, the effects of CaMKII inhibition on i.e. RyR2 Ca2+ release rate (205) 
and cardiac contractility (165) are greater at higher stimulation frequencies compared to 
lower. This reflects a limitation to our studies that may have underestimated the effect of MI, 
exercise training and CaMKII inhibition on cardiomyocyte contractile function and Ca2+ 
handling.  
 
Intracellular Ca2+ transients was collected by rationing the fluorescence intensities detected at 
510 nm emission wavelength using excitation alternating between 340 and 380 nm 
wavelengths (Optoscan, Cairn Research, Kent, UK), which is the largest dynamic range for 
Ca2+ dependent fluorescence signals. Excitation at 340 nm causes fluorescence emission at 
510 nm to increase with increasing Ca2+ concentrations, whereas excitation at 380 nm 
decreases fluorescence emission by increasing Ca2+ concentrations. Collecting excitation 
through band pass filters of 340 and 380 nm by a 500 Hz rotating optical chopper and using 
the ratio of the fluorescence intensities provide more stable Ca2+ measurements and minimize 
factors such as uneven dye distribution, leakage, photo bleaching, different room light, or 
compartments of Fura-2/AM in the cell (204). In addition to measuring systolic and diastolic 
intracellular Ca2+ levels, we examined the time course of the Ca2+ transient by measuring peak 
systolic Ca2+, time to peak Ca2+, time to 50% of peak Ca2+, and time to 50% Ca2+ decay. 
Diastolic Ca2+ cycling was quantified with the use of rate constants of Ca2+ removal during 
twitch-induced stimulation, sustained caffeine stimulation in physiological solution and 
sustained caffeine stimulation in 0Na+/0Ca2+. In paper I we used these measurements to 
quantify SERCA-2a, NCX and PMCA contribution to Ca2+ removal as previously described 
(206). Total SR Ca2+ content was measured by peak caffeine-induced Ca2+ release. Caffeine 
opens RyR2 completely and totally empties SR Ca2+ content. However, since RyR2 sensitivity 
to Ca2+ might increase after caffeine exposure, we stimulated the cardiomyocytes until normal 
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Ca2+ transients were obtained after each caffeine exposure before proceeding the cell 
experiments (164). 
 
When using animal models as in the papers that constitute this thesis, it is important to note 
that the contribution to cellular Ca2+ removal is different in rats and mice compared to 
humans. In humans SERCA-2a removes 70% of the Ca2+ from cytosol into the SR lumen, 
whereas 92% is removed by SERCA-2a in rats and mice. NCX contributes with 28% Ca2+ 
removal out of the cell in human, and 7%  in rats and mice, leaving about 1% for PMCA and 
mitochondrial Ca2+ uniporter in human, rats and mice (110). 
 
SR Ca2+ leak 
To determine whether diastolic SR Ca2+ leak was increased after MI in paper I we used the 
Ca2+ leak protocol established by Shannon et al (207). After measuring contractile function 
and Ca2+ handling during twitch-induced transients in HEPES 1.8 mM buffer, stimulation was 
ceased and quiescent cardiomyocytes were perfused with 0Na+/0Ca2+ while measuring 
diastolic Ca2+ level for 40 seconds immediately followed by a 0Na+/0Ca2+ diluted caffeine-
induced transient. When Ca2+ levels were close to baseline caffeine perfusion was replaced by 
HEPES perfusion and cardiomyocytes were stimulated at 1 Hz until stable Ca2+ transients was 
restored (approximately 20 seconds). Subsequently, perfusion was switched to tetracaine 
solution, whereupon diastolic Ca2+ level were measured for another 40 seconds. This was also 
followed by a 0Na+/0Ca2+ diluted caffeine-induced transient. The quantitative difference in 
diastolic Ca2+ level between the 0Na+/0Ca2+ and tetracaine solution represents the absolute SR 
Ca2+ leak, since 0Na+/0Ca2+ block the NCX Ca2+ influx and efflux and tetracaine blocks Ca2+ 
movement across RyR2 (Figure 6). Diastolic SR Ca2+ leak was presented in relation to total 
SR Ca2+ content.  
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Figure 6. Illustration of Ca2+ transients and the diastolic SR Ca2+ leak protocol. 
 
To examine the impact of PKA and CaMKII on RyR2 diastolic Ca2+ leakage, acute PKA and 
CaMKII inhibition were induced in paper I by pre-incubation of PKA inhibitor (H-89; 3 µM, 
Sigma Aldrich, MO, USA) and the potent and selective CaMKII inhibitor AIP (1 µM, Sigma 
Aldrich, MO, USA) (208). Pre-incubation of cardiomyocytes with either H-89 or AIP was 
started 1 hour prior to experiments. Experiments were conducted within 30 minutes after the 
incubation period, to avoid potential washout of AIP/H-89 by the perfusion system. Like most 
chemical compounds H-89 and AIP have non-specific side effects, which need consideration. 
Murray (209) have observed effects of H-89 on MAPK and Ca2+ signalling, however, we used 
a lower concentration of H-89 to avoid similar off target reactions. A former study has also 
shown effects of H-89 on PLB phosphorylation and SERCA-2a activity, but this cannot be 
attributed simply as a side effect (104). AIP, on the other hand, has been shown to effect 
RyR2 phosphorylation and therefore SR Ca2+ leak (104), however this is in regard with its 
inhibitory effect. Although caution should be made when interpreting data from these 
inhibitors, they provide us with valuable information about the effect of PKA and CaMKII.  
 
T-tubule density and synchrony of Ca2+ release 
Dense and intact T-tubule network throughout the cardiomyocyte is essential for rapid and 
synchronous Ca2+ release. In paper I and II T-tubule density and Ca2+ release synchrony were 
measured on a Pascal (510 LSM, Zeiss, Jena, Germany) confocal microscope with a pinhole 
of 1 airy unit giving a z-resolution < 1 µm. The membrane specific Di-8-ANEPPS (10 µM, 
Molecular Probes, Eugene, OR, USA) was used for T-tubule visualization and Fluo-3/AM (10 
µM, Molecular Probes, Eugene, OR, USA) for Ca2+ release synchrony measurements. Fluo-
3/AM is in comparison to Fura-2/AM more suitable for measuring quick changes of Ca2+, due 
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to faster binding/ dissociation from Ca2+, but is more sensitive to bleaching and 
compartmentalization. Similar to Fura-2/AM, Fluo-3/AM also contains acetoxymethyl ester, 
and likewise requires a 20 minutes de-esterfication after loading prior to experiments.  
 
A                                                                            B 
 
Figure 7. Confocal image of T-tubule structure, membrane specific stained with di-8-ANEPPS (A), and line 
scan image of Ca2+ release, where the yellow line indicate electrical stimuli (B) in ventricular cardiomyocytes. 
 
T-tubules were stained and visualized in LV cardiomyocytes in paper I and II (Figure 7A). T-
tubules density normalized to cell size, captured from the middle of the cell, was obtained 
from 5 images per cell. During analysis the pixels stained with the dye were counted relative 
to the total number of pixels, when pixels associated with the non-T-tubular sarcolemma were 
removed. Analysis of Ca2+ release synchrony in paper I was based on 1-3 Ca2+ transients per 
cell, where line scan of each Ca2+ transient was divided into ~25 equal strips (~4µm) and time 
from stimulation to 50% Ca2+ release was measured for each strip (Figure 7B). Standard 
deviation of these measurements was considered Ca2+ release synchrony across the cell.  
 
Cell dimension 
Measuring cardiomyocyte dimension in isolated cells has been proven sensitive enough to 
establish differences in cellular morphology after exercise training (69). In paper I, II and III 
we measured cardiomyocyte dimension on a Nikon Eclipse E400 Microscope with a DSFil 
camera (Nikon NIS- Elements Basic Research Version 3.00 software, Nikon Instruments Inc., 
New York, USA). Cell length and width were detected by photographing a large number of 
cells, whereupon approximately 100- 150 random cells per rat or mice were included for 
measurements. Cell volume was calculated by cell length · cell width · 0.00759 (210). Only 
viable undamaged rod-shaped cells were selected for measurements of cell dimensions. 
 
  
Time    
(ms) 
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Molecular analysis 
Immunohistology 
Apoptosis and fibrosis were assessed in paraffin-embedded LV tissue sections in paper II to 
investigate possible pathological alterations affecting Ca2+ handling and intrinsic exercise 
responsiveness. Apoptosis was assessed using the CardioTACS™ In Situ Apoptosis Detection 
Kit (Trevigen, Gaithersburg, MD, USA) which detects DNA fragmentation. Evaluation and 
quantification are often prone to error, thus to avoid false results we generated positive 
controls for both LRT and HRT. To enable evaluation of fibrosis we used hematoxylin-
erythrosin-saffron (HES) staining, as saffron stains the connective tissue. In both cases thin 
slices of tissue (4 µm) were cut and mounted on a glass microscope slide to be examined with 
light microscopy. Staining provides contrast to the tissue in addition to highlighting specific 
parts of interest. 
 
Assessment of apoptosis in myocardial tissue by detection of nuclear DNA fragmentation is a 
semi-quantitative and widely accepted method. In contrast to necrosis, apoptosis regulates cell 
death in a controlled process without inflammatory response (70,84). Thus, apoptosis 
generates no or little histological trace making it harder to detect (84). A disadvantage of this 
method is that some necrotic cells might appear as apoptosis positive (211), however this has 
not affected our study as the results were undoubtedly negative. 
 
Western immunoblotting 
To determine expression of selected proteins related to Ca2+ handling in LV tissue 
homogenate we used immunoblotting (Western analysis) in paper I and II. Western 
immunoblotting is a semi-quantitative method that allows detection of specific proteins within 
a tissue homogenate, only limited by availability of the specific antibody (212). We used 
western blot for detection of total and phosphorylated CaMKII (Pierce, Rockford, USA) and 
SERCA-2a expression (Badrilla, Leeds, UK), performed according to previously described 
methodology (213). In brief, gel electrophoresis was applied to separate proteins by their 
molecular weight. The sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis 
(PAGE) disc was loaded with molecular samples and submerged into a buffer where the 
electrical current was provided. The electrical current causes the molecules to migrate through 
the acrylamide mesh of the gel towards the positively charged electrode. Proteins are 
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separated according to size because smaller proteins migrate faster than the larger proteins 
through the mesh. After the electrophoresis separation, proteins were moved from within the 
gel to a nitrocellulose membrane by electro transfer. Ponceau S dye was used to monitor the 
effectiveness and uniformity of the protein transfer. Before probing, the membrane was 
subjected to blocking to avoid interaction between the membrane and the specific antibody. 
This procedure reduces “noise” and provides a more clear result. The membrane was then 
probed with a specific antibody of the desired proteins, washed and exposed to another 
antibody. Several perioxidase-conjugated secondary antibodies bound to one primary 
antibody and enhance the signal detected by autoradiography. ImageJ software (National 
Institutes of Health; USA) performed the quantification analysis of blots. Thus, the protocol 
contains many steps, and good reliable results depend on flawless performance of all steps. 
Limitations of the method include the time consumption in addition to being a mainly 
qualitative assay. 
 
Statistics 
Data are presented as mean ± SD. SPSS version 16 (SPSS Inc., Chicago, Illinois, USA) was 
employed for statistical analysis. Before the analysis all data were checked for normal 
distribution. Data was analysed by one-way ANOVA with LSD or Bonferroni post hoc test, 
independent samples T-test or Mann-Whitney U when appropriate. Determination of absolute 
effect of MI between HCR and LCR in paper I was analysed using mean differences with 
standard errors in a t-test. Pre to post test values in paper II were analysed by repeated 
measures ANOVA. In paper III, we used Paired Samples T-test to identify statistical 
differences from pre to post tests. P<0.05 was considered statistically significant. 
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SUMMARY OF RESULTS 
 
Paper I  High inborn aerobic capacity does not counteract deterioration of cardiac 
function and calcium handling after myocardial infarction  
 
1. There were no significant difference in the deterioration of VO2max between HCR and 
LCR after MI (20% and 36%, respectively). VO2max was similar in HCR-MI and LCR 
sham. 
2. MI depressed in vivo LV fractional shortening by 49% (P<0.01) in HCR and 62% 
(P<0.01) in LCR and ejection fraction measured by echocardiography by 46% 
(P<0.01) and 50% (P<0.01), respectively. Group differences were not statistically 
significant. 
3. MI induced pathological hypertrophy to the same extent in both HCR and LCR rats. 
4. The effect of MI was greater in HCR compared to LCR rats on cardiomyocyte 
fractional shortening (39% vs. 34%, P<0.01), Ca2+ transient amplitude (37% vs. 20%, 
P<0.05) and time to 50% re-lengthening (83% vs. 24%, P<0.05). SR Ca2+ content 
decreased by 20% (P<0.01) in both MI groups (group difference, P<0.01). 
5. Diastolic Ca2+ handling was impaired after MI, reflected by decreased SERCA-2a 
Ca2+ removal (group difference, P<0.05) and increased NCX Ca2+ removal (group 
difference, P<0.05) from cytosol. 
6. HCR-MI was closer to a healthy profile (i.e. HCR sham) than LCR-MI on 
cardiomyocyte contractile measurements, and not significantly different from LCR 
sham. 
7. SR Ca2+ leak increased by 177% (P<0.01) in HCR and 67% (P<0.01) in LCR after MI 
(group difference, P<0.05). Acute CaMKII inhibition abolished the SR Ca2+ leak in 
both MI groups. 
8. Phosphorylated CaMKII relative to total CaMKII assessed by western blot protein 
analysis showed no significant difference between groups. 
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Paper II  Aerobic exercise response is dependent of cardiac plasticity  
 
1. VO2max was similar in HRT and LRT rats at baseline. 
2. High intensity interval training increased VO2max with 39% (P<0.001) in HRT rats 
whereas VO2max was unaltered in LRT rats. 
3. LV weight was 8% (P<0.01) lower and cardiomyocytes 32% (P<0.05) wider and 6% 
(P<0.05) shorter in LRT compared to HRT at baseline, indicating a pathology-like cell 
dimension probably caused by concentric hypertrophy. The morphological difference 
between HRT and LRT at baseline was not reflected by apoptosis or fibrosis detection. 
4. High intensity interval training reduced LV weight (4%, P<0.05), and cell length (5%, 
P<0.05) and cell volume (10%, P<0.05) in LRT, whereas it induced physiological 
hypertrophy associated with increased LV weight (9%, P<0.01), cell length (7%, 
P<0.01), cell width (9%, P<0.05) and cell volume (15%, P<0.001) in HRT. 
5. Before the exercise training intervention there was no difference between HRT and 
LRT rats on cardiomyocyte contractility and Ca2+ handling parameters. 
6. LRT did not improve on any of the measured parameters for cardiomyocyte 
contractility or Ca2+ handling after exercise training. In contrast, exercise training 
induced improvements on all measured parameters for cardiomyocyte contractility and 
Ca2+ handling in HRT. 
7. T-tubule density was lower in LRT compared to HRT (P<0.01) at baseline and after 
exercise training. Exercise training tended to increase T-tubule density in HRT 
(P=0.07). 
8. Total CaMKII and ratio phosphorylated CaMKII in relation to total expression of 
CaMKII was not different between HRT and LRT at baseline.  
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Paper III  Chronic CaMKII inhibition blunts the cardiac contractile response to  
exercise training 
 
1. Chronic CaMKII inhibition with KN-93 treatment did not affect VO2max, cardiac 
function measured with echocardiography or cardiomyocyte size in untrained KN-93 
treated mice. 
2. High intensity interval training increased VO2max with 8% (P<0.05) in sham treated 
mice, whereas KN-93 treated mice increased VO2max with 22% (P<0.01, group 
difference, P<0.01). 
3. In vivo fractional shortening improved by 28% (P=0.02) with exercise training in 
sham mice, whereas no change was observed in KN-93 treated mice. 
4. Exercise training induced physiological hypertrophy that increased cardiomyocyte 
length and width by 13% (P<0.05) and 30% (P<0.05) in sham, and by 8% (P<0.05) 
and 14% (P<0.05) in KN-93 mice, respectively. The physiological hypertrophy in 
cardiomyocyte length and width was significantly greater in sham compared to KN-93 
mice (group difference, P<0.05). 
5. Chronic CaMKII inhibition increased cardiomyocyte time to 50% re-lengthening with 
25% (P<0.05), increased Ca2+ transient decay time with 16% (P<0.05) and reduced 
Ca2+ transient amplitude with 20% (P<0.05) in sedentary mice. These reductions in 
cardiomyocyte function were normalized by exercise training in KN-93 treated mice. 
6. Cardiomyocyte fractional shortening was increased by 63% (P<0.01) in sham mice 
whereas it was increased by 18% (P<0.05) in KN-93 mice.  
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DISCUSSION 
The present thesis shows that 1) inborn VO2max do not provide cardioprotection from the 
deteriorating effects of MI on VO2max and cardiomyocyte function, 2) low training response 
measured as VO2max was associated with lack of cardiomyocyte adaptation to exercise 
training and 3) CaMKII was not required for exercise-induced increase in VO2max in healthy 
mice but seems to be important to obtain optimal exercise response on cardiomyocyte 
function.  
 
Inborn VO2max and cardiac remodelling after MI (paper I) 
Inborn VO2max and cardioprotection 
Several studies report that hearts from exercise-trained individuals are partly protected against 
cardiac injuries such as ischemia-reperfusion and acute MI (214-219). However, the effect of 
inborn exercise capacity on cardiac remodelling after MI has not been investigated. LCR rats 
have an increased risk of ventricular arrhythmias (220) and are predisposed for CVD with 
accumulation of cardiovascular risk factors including hypertension, endothelial dysfunction, 
insulin resistance, impaired glucose tolerance, visceral adiposity, hyperglycemia, 
hypertriglyceridemia, and elevated plasma free fatty acids (39,181). 1 540 cardiac genes are 
differentially expressed between HCR and LCR rats for pathways in cardiac energy substrate, 
growth signalling, contractility and cellular stress potentially triggered by hypoxic conditions 
in LCR rats (221). The LCR rats have decreased expression of inward K+ channels, lower 
energy metabolism and ATP production compared to that observed in the HCR rats, all 
factors associated with failing hearts and CVD (221). It has also been demonstrated that 
higher sensitivity to nitric oxide inhibition in LCR rats is affecting cardiomyocyte function 
(181). Recent reviews indicate that mechanisms for cardioprotection are related to exercise-
dependent induction of heat shock proteins, increase in cardiac antioxidant capacity, 
expression of endoplasmic reticulum stress proteins, anatomical and physiological changes in 
coronary arteries, changes in nitric oxide production, adaptational changes in cardiac 
mitochondria, increased autophagy, and improved function of sarcolemmal and/or 
mitochondrial ATP-sensitive K+ channels (222-224). Based on these previous findings, we 
hypothesized that LCR rats would suffer a greater depression in VO2max after MI than HRT 
rats. However, MI reduced VO2max to the same extent in both HCR and LCR rats. The 
reduced VO2max caused by MI corresponded with changes in cardiac function, cardiomyocyte 
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contractility and Ca2+ handling, in line with other studies demonstrating a relation between 
cardiomyocyte function and VO2max  (32,69,77,80,225).  
 
Although VO2max level is provided to be closely related to health outcome (3,16,26,42,226) 
and aerobic fitness level is considered more important for survival than physical activity level 
(17,19,25) this study (paper I) suggests that high inherited VO2max per se is not sufficient to 
provide cardioprotection against cardiac remodelling and loss of cardiac function in HCR 
compared to LCR rats after MI. This is in consensus with previous studies demonstrating an 
absence of exercise-induced cardioprotection after cessation of exercise training (227,228). 
However, high inborn VO2max appears to serve as a buffer capacity reducing the loss in 
absolute VO2max level after MI (paper I). We did not intend to investigate longevity and 
prognosis, however, previous reports indicate that maintaining a high VO2max after MI 
improves prognosis (3,5,7,226,229), as health risks are highest at low VO2max levels and 
decrease with higher VO2max levels (6,7,40,42). Indeed, a recent paper demonstrated that the 
LCR rats had a 28- 45% shorter lifespan compared to the HCR rats (40). 
 
Echocardiography of cardiac function and dimension 
MI reduced fractional shortening in HCR and LCR rats compared to their sham littermates. 
This is in line with previous MI studies in rats (79,89,192,230,231) and indicates that the 
current MI-model induces systolic dysfunction. Systolic dysfunction caused by the MI was 
confirmed by reduced positive dP/dt and ejection fraction in HCR and LCR rats. The similar 
decline in ejection fraction in HCR and LCR after MI might be explained by similar MI size. 
Decreased ejection fraction after MI can be caused by reduced contractile function due to 
myocardial damage or sustained ischemia and/or be a result of LV dilation due to infarct 
expansion or stretching of the scar (232). MI significantly increased both LV end-systolic 
diameter (LVESD) and LV end-diastolic diameter (LVEDD) in HCR-MI and LVESD in 
LCR-MI, indicating increased chamber dilatation and reduced myocardial contraction both 
consistent with the observed decrease in ejection fraction. LVEDD tended to increase also in 
LCR-MI but did not reach the statistical cut-off (P=0.06). 
 
Despite equal relative effect of MI on cardiac function, the healthier inborn cardiac phenotype 
in HCR rats resulted in better absolute LV function after the MI compared to LCR rats. 
Although the HCR are not protected against pathological remodelling after the MI compared 
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to the LCR, their higher initial cardiac function serve as a buffer capacity reducing the loss in 
cardiac function. Studies with prior exercise training demonstrate smaller MI-induced 
pathological remodelling in exercise-trained individuals (214,215,227,233). Thus, exercise 
training appears to be necessary to obtain cardioprotection from pathological remodelling 
after MI. 
 
Cardiomyocyte pathological hypertrophy  
Cardiomyocyte dimensions were similar in HCR and LCR sham rats at baseline. This is in 
contrast to previous studies in the HCR/LCR model, demonstrating a mild pathological 
concentric hypertrophy in LCR rats compared to HCR rats (39,160,221,234). Following MI, 
HCR and LCR rats underwent similar pathological hypertrophy, shown by increased 
cardiomyocyte length and width. This is in line with the ventricular remodelling previously 
reported to follow MI (89,231).  
 
Echocardiography measurements in HCR-MI and LCR-MI indicated chamber dilatation 
which is normally caused by volume overload due to impaired cardiac pump capacity after 
MI, leading to eccentric hypertrophy (elongation of cardiomyocytes) (235). Moreover, both 
HCR and LCR rats decreased length/width ratio after MI (P<0.05 and P<0.01, respectively, 
Figure 8), indicating that pressure overload may also have occurred. Concentric hypertrophy 
is often associated with pressure overload (74), and is characterized by assembly of 
contractile protein units in parallel (84,93,235,236).  
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Figure 8. Cardiomyocyte length/width ratio (paper I), presented as mean ± SD. * P<0.05, different from HCR 
sham; ** P<0.01 different from HCR sham and LCR sham; ## P<0.01 different from HCR sham. 
 
Ventricular remodelling after MI has been described as a mix of volume and pressure 
overload where stretched and dilated infarcted tissue increases LV volume with a combined 
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volume and pressure load on non-infarcted areas (237). Concentric hypertrophy has also been 
found to progress into eccentric hypertrophy and to promote dilation after long-term pressure 
overload (93). However, experiments in paper I was performed within 3 months after the MI 
and therefore future studies are needed to examine the development of hypertrophy over an 
extended period of time in the HCR and LCR rats. Of the potential mechanisms involved in 
the hypertrophic response, extracellular signal-regulated kinase (ERK1/2) signalling was 
recently found to promote concentric growth and prevent eccentric growth (235), which may 
contribute to explain the decrease in length/width ratio after MI in HCR and LCR rats. 
Moreover, calcineurin and CaMKII is also activated by pressure overload (156) and appears 
to be strictly cardiomyopathic (92,95,98). Inhibition of either calcineurin or CaMKII is 
suggested to reduce pathological hypertrophy and secondary pathological effects after 
pressure overload (92,95,139). However, western blot analysis showed no difference in total 
CaMKII expression or phosphorylation level at baseline or after MI between HCR and LCR. 
 
Cardiomyocyte contractile function 
We found depressed cardiomyocyte fractional shortening and slowed re-lengthening in HCR 
and LCR rats after MI, in line with other MI rat models (75,78,79,217,238). The relative 
effect of MI on contraction and re-lengthening was greater in HCR compared to LCR. 
However, cardiomyocyte contractile function in HCR-MI was not different from LCR sham, 
supporting the beneficial effect of high inborn VO2max as a buffer capacity to reduce the 
deteriorating effects of MI. Similar to our observations in rats, reduced contraction and 
relaxation have been observed in isolated cardiomyocytes from human heart failure (239). 
Whether a high initial VO2max may help preserve the cardiomyocyte function after MI in 
humans as in HCR rats is currently unknown.  
 
A slightly more pronounced concentric than eccentric growth, indicated by the reduced 
length/width ratio, were observed in HCR and LCR cardiomyocytes after MI. This may have 
contributed to reduce the cardiomyocyte function, as concentric growth is known to produce a 
greater depression of cell contractile function than eccentric growth (240). However, the 
cellular basis for these changes in cardiomyocyte contractile function in our study needs 
further investigation, but may be partly linked to changes in intracellular Ca2+ handling as 
discussed below. 
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Cardiomyocyte Ca2+ handling 
The reduction we observed in cardiomyocyte contractile function after MI was associated 
with impaired Ca2+ handling in both HCR and LCR MI rats compared to respective shams. 
However, Ca2+ handling was similar in HCR-MI and LCR sham and better compared to LCR-
MI, indicating a beneficial buffer effect of high initial VO2max also on deterioration of Ca2+ 
handling after MI. The well-known MI-induced defects in Ca2+ handling are attributed to 
alterations in SERCA-2a function, NCX function and PLB expression among other factors 
(93,132,238,241). We observed a reduction in SR Ca2+ content in HCR and LCR after MI 
(paper I), in consensus with previous MI studies (132,238), which was caused by decreased 
SERCA-2a function, reducing Ca2+ reuptake into the SR 108,230. In line with previous studies 
(157,241-243), we also found that NCX activity increased after MI, compensating for the 
reduced SERCA-2a function and contributing to maintain diastolic Ca2+ levels by facilitating 
Ca2+ extrusion over the sarcolemma. These alterations caused an unfavourable situation where 
Ca2+ available for release from SR was reduced resulting in significantly decreased Ca2+ 
transient amplitude in HCR-MI. Such abnormalities in Ca2+ cycling lead to reduction in Ca2+ 
amplitude (150), which we observed in HCR-MI but not in LCR-MI (paper I). Previous 
reports on Ca2+ amplitude after MI have been inconsistent varying from unchanged (244,245), 
increased (79,246) to decreased (78,129,243,247), although the latter is most common. This is 
most likely due to differences in MI-induction methods, MI size, animal model and time after 
MI. The reason for the discrepancy between MI groups in our study is unclear, but may be 
explained by the significantly larger decrease in SERCA-2a function and Ca2+ transient 
amplitude in HCR compared to LCR. However, it is also possible that the pre-existing low 
systolic Ca2+ level in LCR rats blunt further deterioration after MI. The severe reduction in 
fractional cardiomyocyte shortening despite a modest decrease (HCR-MI), or unchanged 
(LCR-MI) systolic Ca2+ level indicate a depression in myofilament Ca2+ sensitivity. This 
hypothesis is supported by other studies showing that depressed myofilament Ca2+ sensitivity 
lead to reduction in contractile function after MI (79,248,249). However, the cellular basis for 
these changes in our study needs further investigation. 
 
Diastolic SR Ca2+ leak 
We observed increased diastolic SR Ca2+ leak in MI rats and LCR sham compared to HCR 
sham (paper I). Acute CaMKII inhibition with AIP in cardiomyocytes reduced the SR Ca2+ 
leak via RyR2 in MI rats and LCR sham towards levels observed in HCR sham (3% SR Ca2+ 
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leak). In contrast, acute PKA inhibition with H-89 did not affect the SR Ca2+ leak in either MI 
rats or LCR sham at all. These data suggest that CaMKII activity, and not PKA, was 
responsible for the increased diastolic SR Ca2+ leak in MI rats and LCR sham in our study. 
Although PKA has been suggested  as a therapeutic target to reduce SR Ca2+ leak (250,251), 
it is controversial  and most studies have observed CaMKII-dependent SR Ca2+ leak in failing 
cardiomyocytes (94,95,143,148,152,164,252). Cellular evidence that CaMKII is involved in 
SR Ca2+ leak is based on observations of enhanced SR Ca2+ leak in CaMKII over-expressing 
myocytes (155,253), enhanced SR Ca2+ leak by CaMKII-dependent phosphorylation of RyR2 
in heart failure (143) and reduced SR Ca2+ leak with CaMKII inhibition (96,97,140,165). 
About 50% of heart failure patients die of sudden cardiac death caused by ventricular 
arrhythmias (254,255) and a large fraction of these arrhythmias are attributed to spontaneous 
Ca2+ release (96,110,157,172). Therefore, prevention of diastolic SR Ca2+ leak with CaMKII 
inhibition is a potentially life-saving treatment hindering Ca2+ waves and lethal arrhythmias as 
well as facilitating SR Ca2+ load to maintain force of contractions (155,165,175,256).  
 
Adaptations to exercise training in high and low responder rats and chronic 
CaMKII inhibited mice  
Exercise training is a useful and important tool to prevent and mend CVD and other life-style 
related diseases (6,7,11,22,60). However, inborn characteristics, environmental factors and 
pharmacological treatment may influence the nature of exercise response and must therefore 
be considered. We found that inborn exercise response determined VO2max after exercise 
training in paper II and that chronic CaMKII inhibition with KN-93 treatment in paper III 
surprisingly improved VO2max exercise response compared to sham mice that performed the 
same training regimen. The difference in VO2max did not occur until after the exercise training 
period in either the HRT/LRT rat model or the CaMKII inhibited/sham mice model. Hence, 
baseline VO2max was not associated with VO2max exercise response in paper II and III, as 
supported by others (43,46,54). The potential mechanisms for differences in VO2max exercise 
response in our studies are discussed below. 
 
High intensity interval training did not improve VO2max in LRT rats 
Despite being proven effective in providing robust cardiovascular adaptations by numerous 
studies (22,58,59,63,69,257), high intensity interval training did not increase VO2max in LRT 
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rats (paper II). In contrast, HRT rats increased VO2max significantly by 39% (paper II). Thus, 
the HRT/LRT model reflects the higher and lower ends in the reported range of VO2max 
exercise response (-5% to +50%) observed in humans (43,45-47,52,53,258), although 
comparing exercise load in rats and humans are complicated. The exercise-induced VO2max 
improvements in HRT rats in paper II were explained by physiological hypertrophy and 
improved cardiomyocyte contractility and Ca2+ handling, as described in previous studies 
(67,77,80,181). In addition, peripheral factors, not measured in the present study, may further 
have contributed to the discrepancy in VO2max exercise response between HRT and LRT rats. 
However, the lack of VO2max exercise response in LRT rats was at least partly explained by 
the lack of cardiac adaptations to exercise training.  
 
Although LRT rats did not improve VO2max in response to exercise training we cannot 
exclude that they improved other physiological parameters. However, this was beyond the 
scope of the current study, as there are thousands of biochemical adaptations to exercise 
training (259). Indeed, low responders to VO2max have been reported to improve other health 
related variables (47) and to increase VO2max by use of other methods than endurance training, 
e.g. resistance training (260), supporting the idea that complete “non-responders” to exercise 
training do not exist. Therefore, exercise training for health purposes should be encouraged 
also in low responders to VO2max.  
 
Chronic CaMKII inhibition enhanced VO2max exercise response 
KN-93 treated mice increased VO2max significantly more than sham mice (22% vs. 8%, 
respectively) after high intensity interval training (paper III). This finding was in contrast to 
our hypothesis based on previous reports of exercise-induced up-regulation of CaMKII 
activity in healthy individuals (103,127). The greater VO2max improvement in KN-93 treated 
mice compared to sham mice was reflected by similar results on maximal running speed. 
There is a lack of studies investigating the effects of CaMKII on continued exercise training. 
However, acute studies of CaMKII inhibition on skeletal muscles have reported that KN-93 or 
KN-62 (another specific CaMKII inhibitor) injections do not impair exercise performance or 
decrease skeletal muscle contractile force (261,262). However, further investigation is needed 
to determine the effects of chronic CaMKII inhibition on peripheral factors such as skeletal 
muscles and their contribution to alterations in VO2max after exercise training. The observed 
VO2max level in our study is slightly lower than previous studies on female mice (85,186). The 
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reason for this is unclear, although it might be due to mice strain or possible abdominal 
discomfort from daily injections of KN-93 and DMSO.  
 
Echocardiography of cardiac function in CaMKII inhibited mice 
CaMKII inhibition with KN-93 did not alter cardiac function compared to sham littermates, 
which is in line with a study on genetic CaMKII inhibition (97). However, exercise training 
increased fractional shortening in sham mice, but not in KN-93 treated mice. Stroke volume 
was not significantly increased in either exercise group, but the absolute improvement after 
exercise was greater in KN-93 treated mice. This may presumably be due to a slightly higher 
LVEDD and LV mass. However, these indications were not supported by cardiomyocyte size 
or function measurements. 
 
We found no echocardiography indices of physiological hypertrophy in contrast to 
measurements of isolated cardiomyocyte size. However, absolute change in size associated 
with physiological hypertrophy in rodents are rather small, and echocardiography is 
considered less sensitive in measuring physiological hypertrophy compared to measuring 
cardiomyocyte size or LV weight (69,79,85). 
 
Pathological-like hypertrophy in LRT cardiomyocytes 
Characterization of cardiac function in untrained HRT and LRT (paper II) revealed a 
pathological-like hypertrophy of cardiomyocytes in LRT, paradoxically with reduced LV 
weight. Interestingly, cardiomyocytes were shorter (6%) but wider (32%) in the LRT 
compared to HRT, as previously observed in the LCR and HCR (160), respectively, which is 
typical for concentric hypertrophy (93). Concentric hypertrophy is usually accompanied by 
apoptosis and increased fibrosis (84,93), which is mostly prominent at the detrimental late-
phase remodelling associated with pathological hypertrophy (131,236). Although apoptosis 
would be suitable to explain the reduced LV weight in LRT, neither apoptosis nor fibrosis 
were present in LRT LV tissue at the time of sacrificing, suggesting a congenital nature of the 
hypertrophy possibly without other signs of pathology.  
 
Although the underlying molecular mechanisms responsible for pathological hypertrophy are 
not completely clear, several signalling pathways have been suggested to influence on the 
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continuum of states in cardiac plasticity (70,263). Consistent with our observations in LRT 
rats, ERK1/2 activation may occur without signs of pathology and favour concentric 
hypertrophy (263). Moreover, we observed a trend for higher ratio of phosphorylated CaMKII 
in untrained LRT compared to HRT. Increased CaMKII phosphorylation affects calcineurin 
(264), activates hypertrophic pathways including MEF2 and NFAT (139,140) and is 
considered a central molecule in the pathological response mechanisms of the heart (156). 
CaMKII over-expression contribute to development of cardiac hypertrophy (156) whereas 
CaMKII inhibition reduces pathological hypertrophy (97,156,265). However, whether the 
CaMKII phosphorylation level contributed to the observed hypertrophy in LRT rats warrants 
further investigation. 
 
Cardiomyocyte hypertrophy with exercise training 
Exercise training increased LV cardiomyocyte dimensions in HRT rats (paper II) and sham 
mice (paper III) which corresponds with previous exercise studies in female rats (67,69,80) 
and mice (85), respectively. The increased dimensions are most likely a result of the 
hypertrophic stimuli induced by high intensity interval training (67,69,77,80,85). In contrast, 
LRT rats (paper II) experienced a further decrease in LV weight, probably due to the 
reduction in cell length. Distinct signalling pathways mediate physiological and pathological 
hypertrophy (266), and whether the response to exercise training in LRT is compensatory or a 
result of negative response to exercise is currently unknown. CaMKII inhibition with KN-93 
(paper III) blunted the exercise-induced physiological hypertrophy, and exercise-trained KN-
93 treated mice gained only half the increase in cardiomyocyte size compared to exercise-
trained sham mice. This is quite paradoxical considering the close association between 
cardiomyocyte dimension and VO2max reported in previous studies (77,181). Thus, our results 
indicate that CaMKII is necessary to yield optimal exercise response on physiological 
hypertrophy even though its exact role in physiological hypertrophy is still unknown. 
 
Although not studied in the current thesis, IGF-1 is involved in most biological processes 
promoting physiological hypertrophy (267), and the IGF-1/Akt1 pathway is considered the 
main signalling pathway for physiological hypertrophy (86,87,268,269). The necessity of 
IGF-1/Akt1 activation in physiological hypertrophy is evidenced in experimental models 
where disruption of the IGF-1/Akt1 pathway leads to virtually no sign of physiological 
hypertrophy in response to exercise training (86,87). Disruption or deficiency in the IGF-
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1/Akt1 pathway is a potential mechanism sufficient to explain the lack of cardiac exercise 
response in the LRT rats. Moreover, CaMKII inhibition with KN-93 has been shown to cause 
withdrawal of Akt (270), making it a potential mechanism to explain the blunted exercise 
response on physiological hypertrophy in KN-93 treated cardiomyocytes.  
 
Cardiomyocyte contractile function  
Cardiomyocyte contraction and relaxation was similar in sedentary HRT and LRT rats (paper 
II), and cardiomyocyte relaxation was reduced in mice receiving daily KN-93 injections 
(paper III). Exercise training is known to increase cardiomyocyte contractility measured as 
fractional shortening in both rats (77,79,80) and mice (33,69,80,85,103,106) as we observed 
in exercise-trained HRT rats, sham mice and KN-93 treated mice. However, KN-93 
administration in mice during the exercise intervention blunted the improvement on fractional 
shortening compared to sham treated mice (18% vs. 63% improvement, respectively). This is 
in consensus with a previous study by Kemi et al (103), which reported that acute CaMKII 
inhibition substantially blunted the exercise-induced improvements in cardiomyocyte 
contractility. These results and ours (paper III) indicate that CaMKII activity is important in 
maintaining normal cardiomyocyte function and achieving full benefits of exercise training. 
However, the more the merrier does not apply to CaMKII activity level as mice with elevated 
CaMKII activity may possess heart failure (104).  
 
Exercise-induced improvement on relaxation rates is a consistent finding following high 
intensity interval training (33,69,79,80). We observed that high intensity interval training 
shortened time to re-lengthening in HRT rats, sham mice and KN-93 treated mice. The 
prolonged time to re-lengthening in mice treated with KN-93 was normalized by exercise 
training. The relative effect of exercise training on time to re-lengthening was similar in both 
exercise-trained sham and KN-93 treated mice. Previous reports on contraction rates are not 
as consistent as relaxation rates and faster contraction rates have been reported in some 
(69,77) but not all studies (79,80). In paper II we observed faster contraction rates in HRT 
after exercise training. Cardiomyocyte contractile function is largely dependent on Ca2+ 
handling properties, and exercise training is known to increase speed of Ca2+ cycling, leading 
to a more rapid contraction and relaxation of the cardiomyocyte (80). This will be discussed 
in detail in the section below. 
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LRT rats did not improve on either of the contractile properties after exercise training. The 
underlying molecular mechanisms for lack of cardiac exercise response in LRT rats are 
currently unknown. However, Akt1 deficient mice also lack exercise response on cardiac 
function (86,271), as seen in LRT cardiomyocytes. Furthermore, Akt is found to enhance 
contractile function and modulate protein levels of several major Ca2+ regulatory proteins 
including SERCA-2a, PLB, NCX and RyR2 (268), making Akt an intriguing target for future 
studies of cardiac exercise response in the HRT/LRT model.  
 
Cardiomyocyte Ca2+ handling 
High intensity exercise training is known to improve cardiomyocyte Ca2+ handling 
(67,79,103,122), which is consistent with observations in HRT rats in paper II and mice in 
paper III. In contrast, LRT rats (paper II) did not improve any of the measured parameters of 
Ca2+ handling after exercise training.  
 
There is a discrepancy among studies on alterations in Ca2+ transient amplitude after exercise 
training in healthy individuals (79,80,225). However, exercise-trained HRT rats, sham and 
KN-93 treated mice increased Ca2+ transient amplitude significantly. This has been observed 
in studies with exercise training in cardiomyocytes with pre-existing low Ca2+ transient 
amplitude due to CaMKII over-expression (unpublished work), heart failure (unpublished 
work) or diabetic cardiomyopathy (104). The increased Ca2+ transient amplitude in HRT rats 
may be explained by the increased SR Ca2+ load, providing more Ca2+ available for Ca2+ 
release, and in part provide the increased fractional shortening of the cardiomyocyte. In paper 
III sham treated mice improved Ca2+ transient amplitude significantly more than KN-93 
treated mice. The difference in exercise-induced improvements in Ca2+ transient amplitude 
between sham and KN-93 treated mice may in part be explained by the pre-elevated systolic 
and diastolic Ca2+ levels in KN-93 treated mice. This increased systolic and diastolic Ca2+ 
levels caused by KN-93 administration suggest increased Ca2+ influx and/or decreased Ca2+ 
efflux, that may explain the blunted improvement in Ca2+ transient amplitude and fractional 
shortening in KN-93 treated mice (70).  
 
For cardiomyocyte relaxation, Ca2+ must be removed from the cytosol. In line with other 
studies (79,80), exercise training decreased time to 50% Ca2+ decay in HRT rats and both 
sham and KN-93 treated mice. KN-93 treatment prolonged Ca2+ decay time in sedentary 
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mice, but as with cardiomyocyte re-lengthening, this was normalized with exercise training. 
The faster Ca2+ decay in exercise-trained HRT rats, KN-93 treated and sham treated mice 
might at least partly be explained by increased levels of SERCA-2a and NCX. This would 
facilitate diastolic Ca2+ reuptake into SR and Ca2+ removal over the sarcolemma, respectively, 
which has previously been shown in exercise studies (33,79,80,103). This is supported by the 
increased SR Ca2+ load in HRT rats and decreased diastolic Ca2+ level in sham treated mice. 
In KN-93 treated mice diastolic Ca2+ level was unaltered. However, the faster Ca2+ decay in 
exercise-trained KN-93 treated mice did not increase the Ca2+ amplitude as much as in the 
sham treated mice, indicating that SERCA-2a activity is blunted by CaMKII inhibition, as 
shown by others (205,272).  
 
Changes in Ca2+ handling, but unaltered fractional shortening, in the sedentary KN-93 might 
indicate altered myofilament Ca2+ sensitivity through reduced myosin binding protein C, 
which may lead to decreased rate of force development regardless of intracellular Ca2+ levels 
(273). Ca2+ sensitivity is known to adapt to exercise training with a leftward shift in the 
tension-pCa2+ relationship, indicating faster shortening, greater contraction and higher force 
output at every contraction (102). In fact, improvement in Ca2+ sensitivity is considered a 
major cause of exercise-induced improvements in cardiomyocyte contractility (33,79,162).  
 
The observed reduction in Ca2+ handling caused by CaMKII inhibition in our study were 
probably due to the combined actions of several CaMKII phosphorylated targets of the ECC 
(111). Whether these negative alterations in Ca2+ handling after chronic CaMKII inhibition 
would have developed into dysfunctional Ca2+ handling over an extended period of time is 
currently unknown and needs further investigation. Depressed cardiac function that may lead 
to pathological hypertrophy and heart failure due to sustained CaMKII inhibition have been 
shown by others (272,274), whereas some report stable cardiac phenotypes in transgenic 
CaMKII inhibited mice (97). Why there is a discrepancy between studies with sustained 
CaMKII inhibition is not known, but it may in part be explained by differences in CaMKII 
inhibition methods, sites and specificity. 
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CONCLUSIONS 
1. High intrinsic (inborn) VO2max do not provide cardioprotection from the detrimental 
effects of MI as relative cardiac remodelling and reduction in cardiomyocyte function 
was similar among HCR and LCR rats. 
2. High inborn VO2max may serve as a buffer capacity, maintaining higher absolute 
values on VO2max and cardiac function measurements after ischemic remodelling when 
compared to rats with low intrinsic VO2max. 
3. Baseline VO2max and cardiomyocyte function was not associated with inborn exercise 
response in the HRT/LRT rats. 
4. High intensity interval training increased VO2max in HRT rats, sham and KN-93 
treated mice, but not in LRT rats. 
5. Cardiomyocyte function failed to adapt to exercise training in LRT rats, indicating that 
the lack of cardiac plasticity attenuates VO2max exercise response.  
6. CaMKII seems important for maintenance of Ca2+ homeostasis as KN-93 treatment 
negatively affected Ca2+ removal evidenced by elevated intracellular Ca2+ levels and 
prolonged time to re-lengthening and time to Ca2+ decay. 
7. Exercise-trained KN-93 treated mice increased VO2max more than twice as much as 
sham mice, indicating that CaMKII is not necessary for VO2max improvement with 
exercise training. 
8. Exercise-induced improvements on cardiomyocyte size and contractile function were 
blunted by KN-93 treatment, suggesting that CaMKII is essential for optimal exercise 
adaptations in cardiomyocytes. 
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Abstract Activation of the multifunctional Ca2?/cal-
modulin-dependent protein kinase II (CaMKII) plays a
critical role modulating cardiac function in both health and
disease. Here, we determined the effect of chronic CaMKII
inhibition during an exercise training program in healthy
mice. CaMKII was inhibited by KN-93 injections. Mice
were randomized to the following groups: sham sedentary,
sham exercise, KN-93 sedentary, and KN-93 exercise.
Cardiorespiratory function was evaluated by ergospirome-
try during treadmill running, echocardiography, and car-
diomyocyte fractional shortening and calcium handling.
The results revealed that KN-93 alone had no effect on
exercise capacity or fractional shortening. In sham animals,
exercise training increased maximal oxygen uptake by 8%
(p \ 0.05) compared to a 22% (p \ 0.05) increase after
exercise in KN-93 treated mice (group difference
p \ 0.01). In contrast, in vivo fractional shortening eval-
uated by echocardiography improved after exercise in
sham animals only: from 25 to 32% (p \ 0.02). In inactive
mice, KN-93 reduced rates of diastolic cardiomyocyte re-
lengthening (by 25%, p \ 0.05) as well as Ca2? transient
decay (by 16%, p \ 0.05), whereas no such effect was
observed after exercise training. KN-93 blunted exercise
training response on cardiomyocyte fractional shortening
(63% sham vs. 18% KN-93; p \ 0.01 and p \ 0.05,
respectively). These effects could not be solely explained
by the Ca2? transient amplitude, as KN-93 reduced it by
20% (p \ 0.05) and response to exercise training was equal
(64% sham and 47% KN-93; both p \ 0.01). We con-
cluded that chronic CaMKII inhibition increased time to
50% re-lengthening which were recovered by exercise
training, but paradoxically led to a greater increase in
maximal oxygen uptake compared to sham mice. Thus, the
effect of chronic CaMKII inhibition is multifaceted and of
a complex nature.
Keywords Aerobic interval training  KN-93  Exercise
training and cardiac function  CaMKII inhibition in
healthy mice
Introduction
The ubiquitous and multifunctional Ca2?/calmodulin-
dependent protein kinase II (CaMKII) regulates a number
of intracellular processes related to cellular contractility
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and nuclear gene expression, thereby controlling the pump
function and growth of the heart. Some of the specific
targets include the L-type Ca2? channel, the sarcoplasmic
reticulum (SR) Ca2? release channel (ryanodine receptor 2,
RyR2), phospholamban (PLB), Na? and K? channels
making CaMKII a prominent regulator of excitation–con-
traction coupling (Couchonnal and Anderson 2008; Hash-
ambhoy et al. 2010; Maier et al. 2007; Maier and Bers
2002). Furthermore, CaMKII can regulate nuclear gene
expression on class II histone deacetylase (HDAC), which
increases myocyte-enhanced factor 2 (Mef2)-regulated
transcription (Erickson and Anderson 2008; Maier and
Bers 2002, 2007; Maier et al. 2007; Sag et al. 2009).
However, the functional consequences of CaMKII activa-
tion are still unclear, since heart failure is associated with
increased CaMKII (Anderson 2005; Anderson et al. 1998;
Couchonnal and Anderson 2008; Khoo et al. 2006; Vila-
Petroff et al. 2007; Zhang et al. 2005); in fact, CaMKII
may constitute a molecular switch between cardiac
hypertrophy and failure (Zhang et al. 2005), and CaMKII
activation may also precede arrhythmic events and con-
tractile dysfunction, mainly because of its effect on the
RyR2 (Anderson 2005; Ling et al. 2009; van Oort et al.
2010). On the other hand, improved contractile function
after aerobic interval exercise training also associates with
activated CaMKII, but in this scenario, the main effect is
on the SR Ca2? uptake due to phosphorylation of PLB.
Interestingly, in mice with type-2 diabetes with chronically
increased cardiac CaMKII and reduced cardiomyocyte
contractile function and Ca2? handling, aerobic interval
exercise training resulted in reduced levels of CaMKII and
improved cardiomyocyte contractile function and Ca2?
handling (Stolen et al. 2009). Recent studies have shown
that CaMKII negatively regulates calcineurin activity
(Khoo et al. 2006; MacDonnell et al. 2009), which in turn
regulates mitochondrial respiration, and further compli-
cates the role of CaMKII (Jiang et al. 2010; Wang et al.
2011).
The exact role of CaMKII activation in the heart
remains unclear, as it associates with dysfunction, failure,
and propensity for arrhythmias, but also with increased
function under different circumstances such as exercise
training. Based on the potential clinical value of chronic
CaMKII inhibition (Khoo et al. 2006; Sag et al. 2009;
Zhang et al. 2005) and the beneficial effect of exercise
training on delaying cardiac dysfunction and correcting
function after onset of heart disease (Stolen et al. 2009;
Wisloff et al. 2002, 2007; Adams et al. 2005; Erbs et al.
2010; Mezzani et al. 2008; Hambrecht et al. 2000;
Anderson et al. 1998; Kemi et al. 2007; Zhang et al. 2005)
two scenarios that may mutually oppose each other,
determining the effect of chronic CaMKII inhibition on the
response to exercise training would be of considerable
interest. Therefore, we aimed to study the effect of chronic
CaMKII inhibition during the course of an exercise training
program in healthy mice. We hypothesized that chronic
CaMKII inhibition would abolish the normal exercise
training response in the hearts.
Materials and methods
Mice and CaMKII inhibition
Eighteen female C57 BL/6J mice (Møllegaard Breeding
Center, Lille Skensved, Denmark) 18–20 g, 8 weeks of age
at inclusion were randomized into four groups: (1) sham
control sedentary, (2) sham control exercise training, (3)
KN-93 sedentary, and (4) KN-93 exercise training. KN-93
(2-[N-(2-hydroxyethyl)-N-(4 methoxybenzenesulfonyl)]
amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; Alexis-
Biochemical, Enzo Life Science, PA, USA) diluted in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO,
USA, 2 mg KN-93/1 mL DMSO, 10 lmol/kg (Zhang et al.
2005)) was intraperitoneally injected daily after the exer-
cise training session (for those that exercise trained),
throughout the experimental period. In a previous study,
Zhang et al. (2005) observed dose-dependent CaMKII
inhibition by KN-93, in which daily injections of 10 lmol/
kg KN-93 produced similar effect on left ventricular con-
traction measurements as the genetically CaMKII-inhibited
AC3:I mice (Zhang et al. 2005; Khoo et al. 2006). Sham
control mice received similar amounts of DMSO daily. The
Norwegian council for Animal Research approved the
study, which was in accordance with the Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health Publications No. 85–23, revised 1996).
Exercise training
Exercise training was performed as aerobic interval train-
ing for 6 weeks, 5 days/week, on an inclined (25) tread-
mill, each session starting with a 10-min warm-up at
50–60% of maximal oxygen uptake (VO2max), whereupon
exercise then alternated between 4- and 2-min intervals at
85–90 and 50–60% of VO2max, respectively for 60 min.
VO2max was assessed during a treadmill running test to
exhaustion in a metabolic chamber. After a warm-up period
of about 10 min, treadmill band velocity was increased by
0.03 m/s for every second minute until mice were not able
to maintain the treadmill velocity (Hoydal et al. 2007;
Kemi et al. 2002). To maintain the exercise intensity
throughout the experimental period, VO2max was tested at
the beginning of each week in addition to pre- and post-
tests. This exercise protocol has previously been proven
efficient for inducing exercise and cardiovascular
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adaptations in both the clinical and experimental studies
(Tjonna et al. 2008; Hoydal et al. 2007; Kemi et al. 2002,
2005; Wisloff et al. 2001; Stolen et al. 2009).
Echocardiography
High-resolution echocardiography (Vevo 770, VisualSon-
ics, Toronto, Canada) using a single-element mechanical
transducer with a center frequency of 30 MHz was per-
formed on self-breathing mice exposed to a mixture of 2%
isoflurane and 98% oxygen. A two-dimensional long-axis
view was used to visualize both ventricles, the ascending
aorta, and the right ventricular outflow tract by placing the
ultrasound transducer on the left parasternal position,
whereas a short-axis view was used to visualize systolic and
diastolic movement of both ventricles by placing the trans-
ducer horizontally above the heart. Left ventricular end-
diastolic diameter (LVEDD), left ventricular end-systolic
diameter (LVESD), interventricular septum (IVST) and
posterior wall thickness (PWT) were recorded with M-mode
echocardiography, which allowed calculation of the frac-
tional shortening (% = [(LVEDD - LVESD)/LVEDD] 9
[100]) as an index of systolic left ventricular function.
The following equation was used to calculate LV
mass (mg) = [(LVEDD ? IVST ? PWT)3 - LVEDD3] 9
1.055, where 1.055 (mg/mm3) is the density of myocardium.
IVST and PWT were measured at end diastole.
Cardiomyocyte isolation, contractile function, Ca2?
measurements and cell size
Left ventricular cardiomyocytes were isolated as previ-
ously described using a Hepes-based solution (Mitra and
Morad 1981; Guatimosim et al. 2001). Exercised hearts
were excised 24 h after the last exercise session. A mixture
of 3–4% isoflurane and 96–97% oxygen were used to
anesthetize the mice, whereupon the heart was heparinized
and removed. Until it was connected to the aortic cannula
on a standard Langendorff retrograde perfusion system, the
hearts were kept on ice cold Hepes solution. The hearts
were cleaned with a Hepes solution containing EGTA
(Sigma-Aldrich Corp., Missouri, USA) before the perfu-
sion was switched to Hepes solution with collagenase
(Worthington, Lakewood, USA), and perfusion was con-
tinued for approximately 10 min (3.5 ml/min). After the
hearts were taken down, left ventricles were carefully cut
off and gently shaken for 2 min before the non-digested
tissue was filtered out (nylon mesh, 250 lm). Further, cells
were stepwise exposed to increasing Ca2? levels (initially
0.05 mM). The isolated cells were centrifuged (30 s,
600 rpm) before solution was switched to 1.2 mM Hepes-
based solution. Fura-2/AM-loaded (2 lmol/l, Molecular
Probes, Eugene, OR, USA) cardiomyocytes were field
stimulated by bipolar electrical pulse at 1 Hz, on an
inverted epifluorescence microscope (Nikon TE-2000E,
Tokyo, Japan), whereupon cell shortening was recorded by
video-based myocyte sarcomere spacing (SarcLenTM,
IonOptix, Milton, MA, USA) and intracellular Ca2? con-
centration was measured by fluorescence after excitation
by alternating 340 and 380 nm wavelengths (F340/380 ratio)
(Optoscan, Cairn Research, Kent, UK). Cells with a clear
visual intracellular structure that were able to follow
stimulation frequency were included for the experiment.
The total number of cardiomyocytes included for all
analysis in the different groups was: sham sedentary 8,
sham exercise 20, KN-93 sedentary 5, and in KN-93
exercise 9. During the stimulation protocol, cells were kept
in 1.2 mM Ca2? HEPES-based solution at 37C. Cell size
was measured with Nikon Eclipse E400 Microscope with a
DSFil camera (Nikon NIS-Elements Basic Research Ver-
sion 3.00 software, Nikon Instruments Inc., Melville, NY,
USA). Cardiomyocyte size was measured on 80–120
cardiomyocytes per group.
Statistics
A one-way ANOVA with LSD post hoc test was used to
detect significant differences between groups. For within-
group differences from pre- to post-test, a paired sample
T test was used. Statistical significance level was set to
p \ 0.05.
Results
VO2max and exercise capacity
In sedentary mice, daily intraperitoneal injections of the
CaMKII-selective inhibitor KN-93 did not affect VO2max,
running speed at VO2max, or body mass (Fig. 1). However,
while chronic CaMKII inhibition had no effect in sedentary
mice, it did affect the response to exercise training. Whereas
exercise training increased VO2max by 8% (p \ 0.05) in
sham, the effect was 22% (p \ 0.01) in KN-93 mice after
the exercise training period (magnitude of response differ-
ence p \ 0.01, Fig. 1a). KN-93 tended to suppress the
growth in body mass (Fig. 1c), which made it necessary to
normalize VO2max according to correct scaling procedures,
which involves the correct normalization of a physiological
variable (here VO2max) to a body dimension (here body
mass). It is well established that cardiorespiratory capacity
in lighter individuals will be overestimated compared to
heavier ones when VO2max is expressed in direct relation to
body mass (i.e., ml/kg/min) and that VO2max should be
expressed with body mass raised to the power of 0.75 (i.e.,
ml/kg0.75/min) when comparing individuals that differ in
Eur J Appl Physiol (2012) 112:579–588 581
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body mass (Taylor et al. 1981). Hence, VO2max was divided
by body mass raised to the power of 0.75 as an exponent in
the present study in order not to overestimate the effect of
KN-93 on VO2max. In line with a larger increase in VO2max
after exercise training in KN-93 mice, we observed that
running speed at VO2max also increased twice as much
compared to that observed in sham mice 32% (p \ 0.01),
and 61% (p \ 0.01) in KN-93 mice.
Cardiac remodeling
KN-93 injections did not significantly change LVEDD,
LVESD, PWT, or IVST (Table 1). However, there was a
trend for decreased LV mass, and LVEDD in sedentary
KN-93 treated mice compared to sham sedentary.
Also, CaMKII inhibition by KN-93 injections did not
affect cardiomyocyte size in sedentary mice, measured as
cell length and width in isolated cardiomyocytes, but it did
blunt the exercise training-induced hypertrophy of the
cardiomyocytes. Exercise-induced cardiomyocyte hyper-
trophy was observed in both sham and KN-93 mice, but the
effect was larger in sham mice. Exercise training increased
cardiomyocyte length and width by 13% (p \ 0.05) and
30% (p \ 0.05) in sham mice, and by 8% (p \ 0.05) and
14% (p \ 0.05) in KN-93 mice, respectively (group dif-
ferences p \ 0.05, Fig. 2a, b). Thus, the cardiomyocyte
hypertrophy response to exercise in KN-93 mice was
approximately half of that in sham mice.
Fig. 1 Values of VO2max (a),
maximal aerobic running speed
(b), and body mass (c), before
and after the exercise training
intervention (pre- and post-
tests), presented as mean
values ± SD. *p \ 0.05 versus
sedentary; **p \ 0.01 versus
sedentary; ##p \ 0.01 versus
sham exercise; §p \ 0.05 versus
pre-test
Table 1 Two-dimensional echocardiography measurements
Sham KN-93
Sedentary Exercise Sedentary Exercise
n 6 4 4 4
Echocardiography
HR
(beats/min)
441 ± 21.3 450 ± 36.2 478 ± 18.0 447 ± 36.4
SV
(ll/min)
23.7 ± 4.0 25.2 ± 1.4 20.2 ± 5.7 25.4 ± 6.0
CO
(ml/min)
10.4 ± 1.8 11.3 ± 1.4 9.7 ± 2.7 11.3 ± 2.3
LVEDD
(mm)
3.7 ± 0.2 3.7 ± 0.2 3.5 ± 0.3 3.8 ± 0.2
LVESD
(mm)
2.8 ± 0.3 2.5 ± 0.3 2.6 ± 0.2 2.7 ± 0.1
LV mass
(mg)
96 ± 11.7 94 ± 8.7 85 ± 23.5 99 ± 23.0
FS (%) 25 ± 4.5 32 ± 5.2* 28 ± 3.2 30 ± 1.6
PWT
(mm)
0.69 ± 0.07 0.7 ± 0.09 0.75 ± 0.09 0.7 ± 0.11
IVST
(mm)
0.74 ± 0.06 0.66 ± 0.14 0.7 ± 0.12 0.68 ± 0.06
Data are presented as mean values ± SD
HR heart rate, SV stroke volume, CO cardiac output, LVEDD left ven-
tricular end-diastolic dimension, LVESD left ventricular end-systolic
dimension, FS fractional shortening, PWT posterior wall thickness, IVST
intraventricular septal thickness
* p \ 0.05 versus sedentary
582 Eur J Appl Physiol (2012) 112:579–588
123
Cardiac contractile function
According to the measurements of in vivo cardiac function
with echocardiography, KN-93 injections did not signifi-
cantly affect heart rate, stroke volume (SV), cardiac output
or fractional shortening (Table 1; Fig. 3). In contrast to
VO2max and exercise capacity, left ventricular fractional
shortening improved from 25 to 32% after exercise training
in sham mice (28% training response, p \ 0.02). Cardiac
contractile function is largely dependent on Ca2? handling
properties. Systolic Ca2? and diastolic Ca2? level were
significantly increased by KN-93 injections (Fig. 4a, b,
p \ 0.01). Only sham exercise increased systolic Ca2?
levels (Fig. 4a, p \ 0.05), and decreased diastolic Ca2?
level (Fig. 4b, p \ 0.01).
Chronic CaMKII inhibition by KN-93 injections
induced a reduction of the cardiomyocyte ability to re-
lengthen (25% increased time to 50% re-lengthening;
Fig. 4c, p \ 0.05) after twitch contractions. This was at
least partly explained by the 16% increase in the Ca2?
transient decay time (Fig. 4d, p \ 0.05). Exercise training
normalized cardiomyocyte re-lengthening and Ca2? tran-
sient decay times to levels comparable to sedentary sham
mice, and the response to exercise training was not dif-
ferent between sham and KN-93 mice. In particular,
exercise training decreased the re-lengthening time by 12%
(p \ 0.05) and 16% (p \ 0.05) in sham and KN-93 mice,
respectively, which was linked to comparable exercise
training-induced changes in the Ca2? transient decay times
(Fig. 4c, d).
In contrast to the above, the observed effects of KN-93
and exercise training on cardiomyocyte fractional short-
ening (amplitude of the contraction) and the associated
Ca2? transient amplitude showed a more complex nature.
First, KN-93 reduced the Ca2? transient amplitude by 20%
(Fig. 4e, p \ 0.05), but this did not translate into a com-
parable reduction in the fractional shortening, as no effect
was observed. Second, fractional shortening improved by
exercise training, but the response was blunted in KN-93
mice compared to sham mice. Exercise training in sham
mice increased fractional shortening by 63% (p \ 0.01),
but only by 18% (p \ 0.05) in KN-93 mice (magnitude of
response difference p \ 0.05, Fig. 4f). This could not be
solely explained by changes to the Ca2? transient ampli-
tude, as the exercise training response did not differ
between sham and KN-93 mice; sham increased by 64%
(p \ 0.01), and KN-93 by 47% (p \ 0.01) in response to
exercise training (Fig. 4e). Table 2 provides an overview
of the effects of CaMKII inhibition on whole-body and
cardiac, and cardiomyocyte exercise training response.
Discussion
Given that (1) experimental trials (Anderson 2005; Zhang
et al. 2005; Grimm and Brown 2010) have raised the
possibility that systemic CaMKII inhibition may be a via-
ble and effective strategy for the treatment of heart disease,
and (2) exercise training in both experimental (Rose et al.
2007; Wisloff et al. 2002; Stolen et al. 2009) and clinical
Fig. 2 Isolated cardiomyocyte dimension; cell length (a), and cell width (b), presented as mean values ± SD. *p \ 0.05 versus sedentary;
#p \ 0.05 versus KN-93 exercise
Fig. 3 In vivo LV fractional shortening, presented as mean val-
ues ± SD. *p \ 0.05 versus sedentary
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(Adams et al. 2005; Erbs et al. 2010; Hambrecht et al.
2000; Mezzani et al. 2008; Wisloff et al. 2007) trials show
improved heart function in similar scenarios of heart dis-
ease, we aimed to test the potential value of combining
those strategies; first in normal healthy mice. The reasoning
for the latter is that exercise training and CaMKII also
interact in the heart, as the inotropic effects of exercise
training are at least partly modulated by an exercise
training-induced increase in CaMKII activity (Kemi et al.
2007). This complicates the combination scenario as
CaMKII seems to act as a two edged sword. In fact,
CaMKII contributes to decompensate pathologic hyper-
trophy to heart failure, mainly by its action on the RyR2 to
increase SR Ca2? leak (Sag et al. 2009; Ling et al. 2009).
Thus, the possibility arises that chronic CaMKII inhibition
and exercise training may oppose each other, though it
remains to be studied.
As such, this is the first study to introduce the combi-
nation of chronic CaMKII inhibition by daily KN-93
injections and aerobic interval exercise training. The main
finding was that chronic CaMKII inhibition blunted several
Fig. 4 Cardiomyocyte systolic
Ca2? level (a), diastolic Ca2?
level (b), time to 50% diastolic
re-lengthening (c), Ca2?
transient decay time (d),
intracellular Ca2? transient
amplitude (e), and fractional
shortening (f), presented as
mean values ± SD. *p \ 0.05
versus sedentary; **p \ 0.01
versus sedentary; #p \ 0.05
versus KN-93 exercise;
##p \ 0.01 versus KN-93
exercise; §p \ 0.05 versus sham
sedentary; §§p \ 0.01 versus
sham sedentary
Table 2 Comparison of effects of CaMKII inhibition on exercise
training response
Variable Sham
exercise
KN-93
exercise
Aerobic exercise capacity
VO2max : ::
Echocardiography
LV fractional shortening : $
Cardiomyocyte Ca2? handling
Systolic Ca2? : :
Diastolic Ca2? ; $
Fractional shortening :: :
Ca2? transient amplitude : :
Time to 50% re-lengthening ; ;
Time to 50% Ca2? decay ; ;
Cardiomyocyte dimension
Cell length :: :
Cell width :: :
:, indicates value increase; ;, value decrease; $, value remain
unchanged; 1 or 2 arrows, indicate size of exercise-induced response
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aspects of the response patterns of cardiomyocyte contrac-
tility, and intracellular Ca2? handling to exercise training,
but it did not fully prevent such adaptations. Moreover,
CaMKII inhibition also enhanced exercise training-induced
improvements on VO2max and aerobic exercise capacity,
whereas it did not affect either of them in sedentary mice.
Mechanisms of exercise training-induced adaptation
The present study provides several mechanistic clues as to
the response to exercise training. First, it shows that while
CaMKII activation contributes to the cardiac improve-
ments after exercise training (Kemi et al. 2007), other
mechanisms must also contribute, as CaMKII inhibition
only partly blunted the exercise response. Whether those
mechanisms naturally co-exist or occur to compensate for
the loss of CaMKII activation remains unknown.
Second, the finding that VO2max and exercise capacity
responded more to exercise training in the presence of the
chronic CaMKII inhibition compared to the absence
thereof indicates that CaMKII also may negatively regulate
exercise adaptation in peripheral organs. While this
requires further investigation, it is plausible all the while it
is ubiquitous and exists in most, if not all, cellular systems
(Hudmon and Schulman 2002; Chin 2004).
Third, the opposite effects of exercise training on VO2max
and exercise capacity on the one side, and cardiac inotropy
and hypertrophy on the other side in the face of CaMKII
inhibition highlights that other organs are important in
determining VO2max (Bassett and Howley 2000; Coffey and
Hawley 2007). In particular, chronic exercise training
elicits resistance to muscle fatigue through metabolic
responses including mitochondrial biogenesis, increased
oxidative capacity, and alterations in gene and protein
expression that ultimately leads to phenotype changes that
support endurance-type activity (Rose et al. 2007; Benziane
et al. 2008; Chin 2004; Coffey and Hawley 2007; Bassett
and Howley 2000). The exact mechanism of this rather
surprising observation is not known; however, the interac-
tion between CaMKII and calcineurin is a possible candi-
date. CaMKII modulation of calcineurin signaling is
released by CaMKII inhibition. Calcineruin modulates
exercise-induced skeletal muscle phenotypes and enhances
exercise capacity through increase in mitochondrial oxida-
tive function and energy substrate storage in skeletal mus-
cles (Wang et al. 2011; Jiang et al. 2010). This should be
elucidated in future studies.
Cardiac contractile capacity, Ca2? handling,
and CaMKII
Both in vivo and cellular fractional shortening were unaf-
fected by KN-93-induced inhibition of CaMKII in
sedentary mice, whereas the expected training-induced
increase in both whole-heart and cellular fractional short-
ening was blunted by the chronic KN-93 treatment. How-
ever, chronic CaMKII inhibition did reduce the rate of
diastolic cellular relaxation in sedentary mice, which was
explained by slower intracellular Ca2? removal (longer
time to 50% Ca2? transient decay) and higher systolic
Ca2? levels. Exercise training normalized Ca2? removal
times, and in contrast to fractional shortening, the effect
was not blunted by CaMKII inhibition. These results are in
accordance with Kemi et al. (2007), who found that acute
pre-incubation, with AIP (comparable CaMKII inhibitor)
in isolated cardiomyocytes also blunted the exercise
training-induced improvements in cellular contractility.
Together, these results suggest that CaMKII at least partly
modulates the exercise training-induced improvements in
cardiac contractility, excitation–contraction coupling, and
intracellular Ca2? handling (Kemi et al. 2007; Stolen et al.
2009). The accumulated evidence also suggests that this
modulation occurs via targeting of several loci of excita-
tion–contraction coupling and Ca2? handling (Stolen et al.
2009). Indeed, fractional shortening is dependent on both
SR Ca2? release and myofilaments Ca2? sensitivity, where
the latter may explain the dissociation between fractional
shortening and the intracellular Ca2? transient amplitude in
the present study, as shown directly by others after exercise
training (de Waard et al. 2007; Diffee et al. 2001). How-
ever, in our experiments we used unloaded myocytes where
tension development and basal sarcomere length were not
considered.
Current results together with the previous studies
(Anderson 2005; Anderson et al. 1998; Couchonnal and
Anderson 2008; Erickson and Anderson 2008; Kemi et al.
2007; Khoo et al. 2006; Maier and Bers 2002; Maier et al.
2007; Sag et al. 2009; Vila-Petroff et al. 2007; Zhang
et al. 2005) suggest that CaMKII is a versatile kinase that
may shift cardiac function into different and also opposite
phenotypes. In healthy mice, it appears that a controlled
increase in the CaMKII activity increases cardiac con-
traction (Kemi et al. 2007); that CaMKII inhibition reduces
cardiac contraction, and that these effects mainly occur
because CaMKII inhibition reduces SR Ca2? uptake via
SERCA2a. Therefore, it is also possible that the depression
of cardiomyocyte contractile parameters by chronic
CaMKII inhibition observed here might have progressed to
a global dysfunction and a failure if CaMKII inhibition was
continued. As such, maintained CaMKII seems to be
important for normal cardiomyocyte function in healthy
mice. In contrast, the cardiac dysfunction that also has been
linked to increased CaMKII activity (Ai et al. 2005;
Couchonnal and Anderson 2008; Maier et al. 2007; Zhang
and Brown 2004) has mainly been attributed to hypersen-
sitization of the RyR2 to luminal Ca2? with subsequent
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diastolic SR Ca2? leak and a shift of Ca2? out of the cell; a
scenario that may lead to contractile dysfunction and
increased propensity for arrhythmic events (Sag et al. 2009;
Ai et al. 2005; Grimm and Brown 2010; Khoo et al. 2006;
Ling et al. 2009; Stolen et al. 2009; Wu et al. 2002), in
which CaMKII inhibition or reduction would become
particularly beneficial (Kemi et al. 2007; Laurita and
Rosenbaum 2008; Li et al. 2006; Vila-Petroff et al. 2007;
Yang et al. 2006; Zhang et al. 2005). In a recent modula-
tion study, Hashambhoy et al. (2010) report that inhibition
of CaMKII phosphorylation of the L-type Ca2? channel
rather than the RyR2 is more effective in modulating dia-
stolic RyR2 flux. Thus, a pharmacological approach of
CaMKII inhibition in the heart should also target the
L-type Ca2? channel in order to prevent or treat cardiac
dysfunction and disease. Whether this will be feasible
remains to be investigated. KN-93 inhibits CaMKII by
competing for the calmodulin binding site, and has been
widely used to implicate roles of CaMKII in Ca2? handling
(Sumi et al. 1991). KN-93 is not heart-specific and is
known to have other actions than CaMKII inhibition
(Anderson et al. 1998; Gao et al. 2006). Previous studies
have observed that KN-93 might inhibit L-type Ca2? cur-
rent independent of CaMKII (Anderson et al. 1998; Gao
et al. 2006). This negative effect of KN-93 on intracellular
Ca2? levels are balanced by inhibition of voltage-depen-
dent potassium currents which enhance Ca2? entry via
L-type Ca2? channel (Anderson et al. 1998; Rezazadeh
et al. 2006; Ledoux et al. 1999). The lack of organ speci-
ficity of KN-93 is a limitation of this study, and interpre-
tations should be considered with caution. We did,
however, control for non-cardiac side effects of chronic
KN-93 injections by the pathological examinations of the
vital organs after euthanasia in mice.
Physiological hypertrophy
Echocardiography measurements observed a trend for
decreased LV mass in sedentary KN-93 treated mice,
which was normalized by exercise-induced hypertrophy,
and cardiomyocyte length and width increased significantly
less in KN-93-treated mice compared to sham-treated mice.
These results are somewhat similar to the observations of
Zhang et al. (2005), with myocardial infarction as the
physiological stressor, who reported that cardiomyocyte
transverse cross-sectional area and heart weight were
comparably smaller after genetic inhibition of CaMKII
than in control cardiomyocytes. Furthermore, Ramirez
et al. (1997) reported that pre-treatment with KN-93
blocked hypertrophic responses to the hypertrophy devel-
oped by pressure overload or endothelin-1 (Zhang et al.
2004; Zhu et al. 2000). Our observation suggests that
CaMKII may also modulate cardiomyocyte growth in
response to exercise training (physiological hypertrophy)
and not only in response to the pathologic conditions.
Conclusion
This study indicates the importance of maintaining normal
CaMKII activity in cardiomyocytes of healthy individuals,
also because it positively modulates inotropic/lusitropic
responses to exercise training. However, targeting CaMKII
by selective inhibitors has recently been suggested to cor-
rect cardiac dysfunction and prevent decompensation and
progression of heart disease; a clinical scenario that also is
targeted by exercise training. This study indicates that a
combination strategy of CaMKII inhibition and exercise
training may be feasible for the purpose of attenuating
heart disease, although this does present a complex sce-
nario that may also reduce some of the beneficial effects of
exercise training, especially if CaMKII inhibitors cannot be
closely tuned into localized subcellular targets that mainly
cause the cardiac dysfunction.
Limitations
The small molecule inhibitor KN-93 has potential non-
specific effects other than CaMKII inhibition which were
not controlled for; this is a limitation of the present study.
The pathological examinations were done to rule out
effects on the results from any of the other vital organs due
to KN-93 or DMSO injections.
Acknowledgments We thank Trine Skoglund for excellent labora-
tory assistance. The study was supported by grants from the K.G.
Jebsen Foundation; the Blix Foundation for the Promotion of Medical
Science (GK), and the Norwegian Research Council Funding for
Outstanding Young Investigators (UW), and the British Heart Foun-
dation (OJK).
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Adams V, Linke A, Krankel N, Erbs S, Gielen S, Mobius-Winkler S,
Gummert JF, Mohr FW, Schuler G, Hambrecht R (2005) Impact of
regular physical activity on the NAD(P)H oxidase and angiotensin
receptor system in patients with coronary artery disease. Circula-
tion 111(5):555–562. doi:10.1161/01.CIR.0000154560.88933.7E
Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM (2005) Ca2?/
calmodulin-dependent protein kinase modulates cardiac ryano-
dine receptor phosphorylation and sarcoplasmic reticulum Ca2?
586 Eur J Appl Physiol (2012) 112:579–588
123
leak in heart failure. Circ Res 97(12):1314–1322. doi:10.1161/
01.RES.0000194329.41863.89
Anderson ME (2005) Calmodulin kinase signaling in heart: an
intriguing candidate target for therapy of myocardial dysfunction
and arrhythmias. Pharmacol Ther 106(1):39–55. doi:10.1016/
j.pharmthera.2004.11.002
Anderson ME, Braun AP, Wu Y, Lu T, Schulman H, Sung RJ (1998)
KN-93, an inhibitor of multifunctional Ca??/calmodulin-
dependent protein kinase, decreases early after depolarizations
in rabbit heart. J Pharmacol Exp Ther 287(3):996–1006
Bassett DR Jr, Howley ET (2000) Limiting factors for maximum
oxygen uptake and determinants of endurance performance. Med
Sci Sports Exerc 32(1):70–84
Benziane B, Burton TJ, Scanlan B, Galuska D, Canny BJ, Chibalin
AV, Zierath JR, Stepto NK (2008) Divergent cell signaling after
short-term intensified endurance training in human skeletal
muscle. Am J Physiol Endocrinol Metab 295(6):E1427–E1438.
doi:10.1152/ajpendo.90428.2008
Chin ER (2004) The role of calcium and calcium/calmodulin-
dependent kinases in skeletal muscle plasticity and mitochon-
drial biogenesis. Proc Nutr Soc 63(2):279–286. pii:10.1079/
PNS2004335S0029665104000370
Coffey VG, Hawley JA (2007) The molecular bases of training
adaptation. Sports Med 37(9):737–763
Couchonnal LF, Anderson ME (2008) The role of calmodulin kinase
II in myocardial physiology and disease. Physiology
23:151–159. doi:10.1152/physiol.00043.2007
de Waard MC, van der Velden J, Bito V, Ozdemir S, Biesmans L,
Boontje NM, Dekkers DHW, Schoonderwoerd K, Schuurbiers
HCH, de Crom R, Stienen GJM, Sipido KR, Lamers JMJ,
Duncker DJ (2007) Early exercise training normalizes myofil-
ament function and attenuates left ventricular pump dysfunction
in mice with a large myocardial infarction. Circ Res 100(7):
1079–1088. doi:10.1161/01.Res.0000262655.16373.37
Diffee GM, Seversen EA, Titus MM (2001) Exercise training
increases the Ca2? sensitivity of tension in rat cardiac myocytes.
J Appl Physiol 91:309–315
Erbs S, Hollriegel R, Linke A, Beck EB, Adams V, Gielen S, Mobius-
Winkler S, Sandri M, Krankel N, Hambrecht R, Schuler G
(2010) Exercise training in patients with advanced chronic heart
failure (NYHA IIIb) promotes restoration of peripheral vasomo-
tor function, induction of endogenous regeneration, and
improvement of left ventricular function. Circ Heart Fail
3(4):486–494. doi:10.1161/CIRCHEARTFAILURE.109.868992
Erickson JR, Anderson ME (2008) CaMKII and its role in cardiac
arrhythmia. J Cardiovasc Electrophysiol 19(12):1332–1336. doi:
10.1111/j.1540-8167.2008.01295.x
Gao L, Blair LAC, Marshall J (2006) CaMKII-independent effects of
KN93 and its inactive analog KN92: reversible inhibition of
L-type calcium channels. Biochem Biophys Res Commun
345:1606–1610
Grimm M, Brown JH (2010) Beta-adrenergic receptor signaling in the
heart: role of CaMKII. J Mol Cell Cardiol 48(2):322–330. doi:
10.1016/j.yjmcc.2009.10.016
Guatimosim S, Sobie EA, Cruz JDS, Martin LA, Lederer WJ (2001)
Molecular identification of a TTX-sensitive Ca2? current. Am J
Physiol Cell Physiol 280:1327–1339
Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene
N, Schuler G (2000) Effect of exercise on coronary endothelial
function in patients with coronary artery disease. N Engl J Med
342(7):454–460. doi:10.1056/NEJM200002173420702
Hashambhoy YL, Greenstein JL, Winslow RL (2010) Role of
CaMKII in RyR leak, EC coupling and action potential duration:
a computational model. J Mol Cell Cardiol. doi:10.1016/
j.yjmcc.2010.1007.1011
Hoydal MA, Wisloff U, Kemi OJ, Ellingsen O (2007) Running speed
and maximal oxygen uptake in rats and mice: practical
implications for exercise training. Eur J Cardiovasc Prev Rehabil
14(6):753–760. doi:10.1097/HJR.0b013e3281eacef1
Hudmon A, Schulman H (2002) Structure-function of the multifunc-
tional Ca2?/calmodulin-dependent protein kinase II. Biochem J
364:593–611
Jiang LQ, Garcia-Roves PM, de Castro Barbosa T, Zierath JR (2010)
Constitutively active calcineurin in skeletal muscle increases
endurance performance and mitochondrial respiratory capacity.
Am J Physiol Endocrinol Metab 298(1):E8–E16. doi:10.1152/
ajpendo.00403.2009
Kemi OJ, Loennechen JP, Wisloff U, Ellingsen O (2002) Intensity-
controlled treadmill running in mice: cardiac and skeletal muscle
hypertrophy. J Appl Physiol 93(4):1301–1309. doi:10.1152/
japplphysiol.00231.2002
Kemi OJ, Haram PM, Loennechen JP, Osnes JB, Skomedal T, Wisloff
U, Ellingsen O (2005) Moderate vs. high exercise intensity:
differential effects on aerobic fitness, cardiomyocyte contractil-
ity, and endothelial function. Cardiovasc Res 67 (1):161–172.
doi:10.1016/j.cardiores.2005.03.010
Kemi OJ, Ellingsen O, Ceci M, Grimaldi S, Smith GL, Condorelli G,
Wisloff U (2007) Aerobic interval training enhances cardiomy-
ocyte contractility and Ca2? cycling by phosphorylation of
CaMKII and Thr-17 of phospholamban. J Mol Cell Cardiol
43(3):354–361. doi:10.1016/j.yjmcc.2007.06.013
Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, Grueter
CE, Guan X, Oddis CV, Zhang R, Mendes L, Ni G, Madu EC,
Yang J, Bass M, Gomez RJ, Wadzinski BE, Olson EN, Colbran
RJ, Anderson ME (2006) Death, cardiac dysfunction, and
arrhythmias are increased by calmodulin kinase II in calcineurin
cardiomyopathy. Circulation 114(13):1352–1359. doi:10.1161/
CIRCULATIONAHA.106.644583
Laurita KR, Rosenbaum DS (2008) Mechanisms and potential
therapeutic targets for ventricular arrhythmias associated with
impaired cardiac calcium cycling. J Mol Cell Cardiol 44(1):
31–43. doi:10.1016/j.yjmcc.2007.10.012
Ledoux J, Chartier D, Leblanc N (1999) Inhibitors of calmodulin-
dependent protein kinase are nonspecific blockers of voltage-
dependent K? channels in vascular myocytes. J Pharmacol Exp
Ther 290(3):1165–1174
Li J, Marionneau C, Zhang R, Shah V, Hell JW, Nerbonne JM, Anderson
ME (2006) Calmodulin kinase II inhibition shortens action
potential duration by upregulation of K? currents. Circ Res
99(10):1092–1099. doi:10.1161/01.RES.0000249369.71709.5c
Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND,
Peteron KL, Chen J, Bers D, Brown JH (2009) Requirement for
Ca2?/calmodulin-dependent kinase II in the transition from
pressure overload-induced cardiac hypertrophy to heart failure in
mice. J Clin Invest 119:1230–1240
MacDonnell SM, Weisser-Thomas J, Kubo H, Hanscome M, Liu Q,
Jaleel N, Berretta R, Chen X, Brown JH, Sabri AK, Molkentin
JD, Houser SR (2009) CaMKII negatively regulates calcineurin-
NFAT signaling in cardiac myocytes. Circ Res 105(4):316–325.
doi:10.1161/CIRCRESAHA.109.194035
Maier LS, Bers DM (2002) Calcium, calmodulin, and calcium-
calmodulin kinase II: heartbeat to heartbeat and beyond. J Mol
Cell Cardiol 34(8):919–939. pii:S0022282802920389
Maier LS, Bers DM (2007) Role of Ca2?/calmodulin-dependent
protein kinase (CaMK) in excitation–contraction coupling in the
heart. Cardiovasc Res 73:631–640
Maier LS, Bers DM, Brown JH (2007) Calmodulin and Ca2?/
calmodulin kinases in the heart—physiology and pathophysiol-
ogy. Cardiovasc Res 73(4):629–630. doi:10.1016/j.cardiores.
2007.01.005
Eur J Appl Physiol (2012) 112:579–588 587
123
Mezzani A, Corra U, Giannuzzi P (2008) Central adaptations to
exercise training in patients with chronic heart failure. Heart Fail
Rev 13(1):13–20. doi:10.1007/s10741-007-9053-y
Mitra R, Morad M (1981) A uniform enzymatic method for
dissociation of myocytes from hearts and stomachs of verte-
brates. Pflugers Arch 391:85–100
Ramirez MT, Zhao X, Schulman H, Brown JH (1997) The nuclear
deltaB isoform of Ca2?/Calmodulin-dependent protein kinase II
regulated atrial natriuretic factor gene expression in ventricular
myocytes. J Biol Chem 272:31203–31208
Rezazadeh S, Claydon TW, Fedida D (2006) KN-93 (2-[N-(2-hydro-
xyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinn
amyl)-N-methylbenzylamine), a calcium/calmodulin-dependent
protein kinase II inhibitor, is a direct extracellular blocker of
voltage-gated potassium channels. J Pharmacol Exp Ther
317(1):292–299. doi:10.1124/jpet.105.097618
Rose AJ, Frosig C, Kiens B, Wojtaszewski JF, Richter EA (2007)
Effect of endurance exercise training on Ca2? calmodulin-
dependent protein kinase II expression and signalling in skeletal
muscle of humans. J Physiol 583(Pt 2):785–795. doi:10.1113/
jphysiol.2007.138529
Sag CM, Wadsack DP, Khabbazzadeh S, Abesser M, Grefe C,
Neumann K, Opiela MK, Backs J, Olson EN, Brown JH, Neef S,
Maier SK, Maier LS (2009) Calcium/calmodulin-dependent
protein kinase II contributes to cardiac arrhythmogenesis in
heart failure. Circ Heart Fail 2(6):664–675. doi:10.1161/
CIRCHEARTFAILURE.109.865279
Stolen TO, Hoydal MA, Kemi OJ, Catalucci D, Ceci M, Aasum E,
Larsen T, Rolim N, Condorelli G, Smith GL, Wisloff U (2009)
Interval training normalizes cardiomyocyte function, diastolic
Ca2? control, and SR Ca2? release synchronicity in a mouse
model of diabetic cardiomyopathy. Circ Res 105(6):527–536.
doi:10.1161/CIRCRESAHA.109.199810
Sumi MKK, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H
(1991) The newly synthesized selective Ca2?/calmodulin
dependent protein kinase II inhibitor KN-93 reduces dopamine
contents in PC12h cells. Biochem Biophys Res Commun
181:968–975
Taylor CR, Maloiy GM, Weibel ER, Langman VA, Kamau JM,
Seeherman HJ, Heglund NC (1981) Design of the mammalian
respiratory system. III Scaling maximum aerobic capacity to
body mass: wild and domestic mammals. Respir Physiol 44
(1):25–37
Tjonna AE, Lee SJ, Rognmo O, Stolen TO, Bye A, Haram PM,
Loennechen JP, Al-Share QY, Skogvoll E, Slordahl SA, Kemi
OJ, Najjar SM, Wisloff U (2008) Aerobic interval training versus
continuous moderate exercise as a treatment for the metabolic
syndrome: a pilot study. Circulation 118(4):346–354. doi:
10.1161/CIRCULATIONAHA.108.772822
van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress
JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, Bers
DM, Wehrens XH (2010) Ryanodine receptor phosphorylation
by calcium/calmodulin-dependent protein kinase II promotes
life-threatening ventricular arrhythmias in mice with heart
failure. Circulation 122(25):2669–2679. doi:
10.1161/CIRCULATIONAHA.110.982298
Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L, Portiansky
E, Hajjar RJ, Kranias EG, Mundina-Weilenmann C, Mattiazzi A
(2007) CaMKII inhibition protects against necrosis and apopto-
sis in irreversible ischemia-reperfusion injury. Cardiovasc Res
73(4):689–698. doi:10.1016/j.cardiores.2006.12.003
Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, Li YR, Li PF
(2011) miR-499 regulates mitochondrial dynamics by targeting
calcineurin and dynamin-related protein-1. Nat Med 17(1):
71–78. doi:10.1038/nm.2282
Wisloff U, Helgerud J, Kemi OJ, Ellingsen O (2001) Intensity-
controlled treadmill running in rats: VO(2 max) and cardiac
hypertrophy. Am J Physiol Heart Circ Physiol 280(3):H1301–
H1310
Wisloff U, Loennechen JP, Currie S, Smith GL, Ellingsen O (2002)
Aerobic exercise reduces cardiomyocyte hypertrophy and
increases contractility, Ca2? sensitivity and SERCA-2 in rat
after myocardial infarction. Cardiovasc Res 54(1):162–174. pii:
S000863630100565X
Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram
PM, Tjonna AE, Helgerud J, Slordahl SA, Lee SJ, Videm V, Bye
A, Smith GL, Najjar SM, Ellingsen O, Skjaerpe T (2007)
Superior cardiovascular effect of aerobic interval training versus
moderate continuous training in heart failure patients: a
randomized study. Circulation 115(24):3086–3094. doi:10.1161/
CIRCULATIONAHA.106.675041
Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, Trimble R, Roden
DM, Passier R, Olson EN, Colbran RJ, Anderson ME (2002)
Calmodulin kinase II and arrhythmias in a mouse model of
cardiac hypertrophy. Circulation 106(10):1288–1293
Yang Y, Zhu WZ, Joiner ML, Zhang R, Oddis CV, Hou Y, Yang J, Price
EE, Gleaves L, Eren M, Ni G, Vaughan DE, Xiao RP, Anderson
ME (2006) Calmodulin kinase II inhibition protects against
myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol
291(6):H3065–H3075. doi:10.1152/ajpheart.00353.2006
Zhang T, Brown JH (2004) Role of Ca2?/calmodulin-dependent protein
kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res
63(3):476–486. doi:10.1016/j.cardiores.2004.04.026
Zhang T, Miyamoto S, Brown JH (2004) Cardiomyocyte calcium and
calcium/calmodulin-dependent protein kinase II: friends or foes?
Recent Prog Horm Res 59:141–168
Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr,
Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN,
Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G,
Lederer WJ, Colbran RJ, Anderson ME (2005) Calmodulin
kinase II inhibition protects against structural heart disease. Nat
Med 11(4):409–417. doi:10.1038/nm1215
Zhu WZ, Zou Y, Shiojima I, Kudoh S, Aikawa R, Hayashi D,
Mizukami M, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro
I (2000) Ca2?/Calmodulin-dependent Kinase II and Calcineurin
play critical roles in endothelin-1-induced cardiomyocyte hyper-
trophy. J Biol Chem 275(19):15239–15245
588 Eur J Appl Physiol (2012) 112:579–588
123
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertations at the Faculty of Medicine, NTNU 
 
1977 
1. Knut Joachim Berg: EFFECT OF ACETYLSALICYLIC ACID ON RENAL FUNCTION 
2. Karl Erik Viken and Arne Ødegaard: STUDIES ON HUMAN MONOCYTES CULTURED IN  
VITRO 
1978 
3. Karel Bjørn Cyvin: CONGENITAL DISLOCATION OF THE HIP JOINT. 
4. Alf O. Brubakk: METHODS FOR STUDYING FLOW DYNAMICS IN THE LEFT 
VENTRICLE  AND THE AORTA IN MAN. 
1979 
5. Geirmund Unsgaard: CYTOSTATIC AND IMMUNOREGULATORY ABILITIES OF 
HUMAN    BLOOD MONOCYTES CULTURED IN VITRO 
1980 
6. Størker Jørstad: URAEMIC TOXINS 
7. Arne Olav Jenssen: SOME RHEOLOGICAL, CHEMICAL AND STRUCTURAL 
PROPERTIES    OF MUCOID SPUTUM FROM PATIENTS WITH CHRONIC 
OBSTRUCTIVE BRONCHITIS 
1981 
8. Jens Hammerstrøm: CYTOSTATIC AND CYTOLYTIC ACTIVITY OF HUMAN 
MONOCYTES AND EFFUSION MACROPHAGES AGAINST TUMOR CELLS IN VITRO 
1983 
9. Tore Syversen: EFFECTS OF METHYLMERCURY ON RAT BRAIN PROTEIN. 
10. Torbjørn Iversen: SQUAMOUS CELL CARCINOMA OF THE VULVA. 
1984 
11. Tor-Erik Widerøe: ASPECTS OF CONTINUOUS AMBULATORY PERITONEAL 
DIALYSIS. 
12. Anton Hole: ALTERATIONS OF MONOCYTE AND LYMPHOCYTE FUNCTIONS IN 
REALTION TO SURGERY UNDER EPIDURAL OR GENERAL ANAESTHESIA. 
13. Terje Terjesen: FRACTURE HEALING AND STRESS-PROTECTION AFTER METAL 
PLATE FIXATION AND EXTERNAL FIXATION. 
14. Carsten Saunte: CLUSTER HEADACHE SYNDROME. 
15. Inggard Lereim: TRAFFIC ACCIDENTS AND THEIR CONSEQUENCES. 
16. Bjørn Magne Eggen: STUDIES IN CYTOTOXICITY IN HUMAN ADHERENT 
MONONUCLEAR BLOOD CELLS. 
17. Trond Haug: FACTORS REGULATING BEHAVIORAL EFFECTS OG DRUGS. 
1985 
18. Sven Erik Gisvold: RESUSCITATION AFTER COMPLETE GLOBAL BRAIN ISCHEMIA. 
19. Terje Espevik: THE CYTOSKELETON OF HUMAN MONOCYTES. 
20. Lars Bevanger: STUDIES OF THE Ibc (c) PROTEIN ANTIGENS OF GROUP B 
STREPTOCOCCI. 
21. Ole-Jan Iversen: RETROVIRUS-LIKE PARTICLES IN THE PATHOGENESIS OF 
PSORIASIS. 
22. Lasse Eriksen: EVALUATION AND TREATMENT OF ALCOHOL DEPENDENT 
BEHAVIOUR. 
23. Per I. Lundmo: ANDROGEN METABOLISM IN THE PROSTATE. 
1986 
24. Dagfinn Berntzen: ANALYSIS AND MANAGEMENT OF EXPERIMENTAL AND 
CLINICAL PAIN. 
25. Odd Arnold Kildahl-Andersen: PRODUCTION AND CHARACTERIZATION OF 
MONOCYTE-DERIVED CYTOTOXIN AND ITS ROLE IN MONOCYTE-MEDIATED 
CYTOTOXICITY. 
26. Ola Dale: VOLATILE ANAESTHETICS. 
1987 
27. Per Martin Kleveland: STUDIES ON GASTRIN. 
28. Audun N. Øksendal: THE CALCIUM PARADOX AND THE HEART. 
29. Vilhjalmur R. Finsen: HIP FRACTURES 
 
1988 
30. Rigmor Austgulen: TUMOR NECROSIS FACTOR: A MONOCYTE-DERIVED 
REGULATOR OF CELLULAR GROWTH. 
31. Tom-Harald Edna: HEAD INJURIES ADMITTED TO HOSPITAL. 
32. Joseph D. Borsi: NEW ASPECTS OF THE CLINICAL PHARMACOKINETICS OF 
METHOTREXATE. 
33. Olav F. M. Sellevold: GLUCOCORTICOIDS IN MYOCARDIAL PROTECTION. 
34. Terje Skjærpe: NONINVASIVE QUANTITATION OF GLOBAL PARAMETERS ON LEFT 
VENTRICULAR FUNCTION: THE SYSTOLIC PULMONARY ARTERY PRESSURE AND 
CARDIAC OUTPUT. 
35. Eyvind Rødahl: STUDIES OF IMMUNE COMPLEXES AND RETROVIRUS-LIKE 
ANTIGENS IN PATIENTS WITH ANKYLOSING SPONDYLITIS. 
36. Ketil Thorstensen: STUDIES ON THE MECHANISMS OF CELLULAR UPTAKE OF IRON 
FROM TRANSFERRIN. 
37. Anna Midelfart: STUDIES OF THE MECHANISMS OF ION AND FLUID TRANSPORT IN 
THE BOVINE CORNEA. 
38. Eirik Helseth: GROWTH AND PLASMINOGEN ACTIVATOR ACTIVITY OF HUMAN 
GLIOMAS AND BRAIN METASTASES - WITH SPECIAL REFERENCE TO 
TRANSFORMING GROWTH FACTOR BETA AND THE EPIDERMAL GROWTH 
FACTOR RECEPTOR. 
39. Petter C. Borchgrevink: MAGNESIUM AND THE ISCHEMIC HEART. 
40. Kjell-Arne Rein: THE EFFECT OF EXTRACORPOREAL CIRCULATION ON 
SUBCUTANEOUS TRANSCAPILLARY FLUID BALANCE. 
41. Arne Kristian Sandvik: RAT GASTRIC HISTAMINE. 
42. Carl Bredo Dahl: ANIMAL MODELS IN PSYCHIATRY. 
1989 
43. Torbjørn A. Fredriksen: CERVICOGENIC HEADACHE. 
44. Rolf A. Walstad: CEFTAZIDIME. 
45. Rolf Salvesen: THE PUPIL IN CLUSTER HEADACHE. 
46. Nils Petter Jørgensen: DRUG EXPOSURE IN EARLY PREGNANCY. 
47. Johan C. Ræder: PREMEDICATION AND GENERAL ANAESTHESIA IN OUTPATIENT 
GYNECOLOGICAL SURGERY. 
48. M. R. Shalaby: IMMUNOREGULATORY PROPERTIES OF TNF-α AND THE RELATED 
CYTOKINES. 
49. Anders Waage: THE COMPLEX PATTERN OF CYTOKINES IN SEPTIC SHOCK. 
50. Bjarne Christian Eriksen: ELECTROSTIMULATION OF THE PELVIC FLOOR IN FEMALE 
URINARY INCONTINENCE. 
51. Tore B. Halvorsen: PROGNOSTIC FACTORS IN COLORECTAL CANCER. 
1990 
52. Asbjørn Nordby: CELLULAR TOXICITY OF ROENTGEN CONTRAST MEDIA. 
53. Kåre E. Tvedt: X-RAY MICROANALYSIS OF BIOLOGICAL MATERIAL. 
54. Tore C. Stiles: COGNITIVE VULNERABILITY FACTORS IN THE DEVELOPMENT AND 
MAINTENANCE OF DEPRESSION. 
55. Eva Hofsli: TUMOR NECROSIS FACTOR AND MULTIDRUG RESISTANCE. 
56. Helge S. Haarstad: TROPHIC EFFECTS OF CHOLECYSTOKININ AND SECRETIN ON 
THE RAT PANCREAS. 
57. Lars Engebretsen: TREATMENT OF ACUTE ANTERIOR CRUCIATE LIGAMENT 
INJURIES. 
58. Tarjei Rygnestad: DELIBERATE SELF-POISONING IN TRONDHEIM. 
59. Arne Z. Henriksen: STUDIES ON CONSERVED ANTIGENIC DOMAINS ON MAJOR 
OUTER MEMBRANE PROTEINS FROM ENTEROBACTERIA. 
60. Steinar Westin: UNEMPLOYMENT AND HEALTH: Medical and social consequences of a 
factory closure in a ten-year controlled follow-up study. 
61. Ylva Sahlin: INJURY REGISTRATION, a tool for accident preventive work. 
62. Helge Bjørnstad Pettersen: BIOSYNTHESIS OF COMPLEMENT BY HUMAN ALVEOLAR 
MACROPHAGES WITH SPECIAL REFERENCE TO SARCOIDOSIS. 
63. Berit Schei: TRAPPED IN PAINFUL LOVE. 
64. Lars J. Vatten: PROSPECTIVE STUDIES OF THE RISK OF BREAST CANCER IN A 
COHORT OF NORWEGIAN WOMAN. 
 
1991 
65. Kåre Bergh: APPLICATIONS OF ANTI-C5a SPECIFIC MONOCLONAL ANTIBODIES FOR 
THE ASSESSMENT OF COMPLEMENT ACTIVATION. 
66. Svein Svenningsen: THE CLINICAL SIGNIFICANCE OF INCREASED FEMORAL 
ANTEVERSION. 
67. Olbjørn Klepp: NONSEMINOMATOUS GERM CELL TESTIS CANCER: THERAPEUTIC 
OUTCOME AND PROGNOSTIC FACTORS. 
68. Trond Sand: THE EFFECTS OF CLICK POLARITY ON BRAINSTEM AUDITORY 
EVOKED POTENTIALS AMPLITUDE, DISPERSION, AND LATENCY VARIABLES. 
69. Kjetil B. Åsbakk: STUDIES OF A PROTEIN FROM PSORIATIC SCALE, PSO P27, WITH 
RESPECT TO ITS POTENTIAL ROLE IN IMMUNE REACTIONS IN PSORIASIS. 
70. Arnulf Hestnes: STUDIES ON DOWN´S SYNDROME. 
71. Randi Nygaard: LONG-TERM SURVIVAL IN CHILDHOOD LEUKEMIA. 
72. Bjørn Hagen: THIO-TEPA. 
73. Svein Anda: EVALUATION OF THE HIP JOINT BY COMPUTED TOMOGRAMPHY AND 
ULTRASONOGRAPHY. 
1992 
74. Martin Svartberg: AN INVESTIGATION OF PROCESS AND OUTCOME OF SHORT-TERM 
PSYCHODYNAMIC PSYCHOTHERAPY. 
75. Stig Arild Slørdahl: AORTIC REGURGITATION. 
76. Harold C Sexton: STUDIES RELATING TO THE TREATMENT OF SYMPTOMATIC NON-
PSYCHOTIC PATIENTS. 
77. Maurice B. Vincent: VASOACTIVE PEPTIDES IN THE OCULAR/FOREHEAD AREA. 
78. Terje Johannessen: CONTROLLED TRIALS IN SINGLE SUBJECTS. 
79. Turid Nilsen: PYROPHOSPHATE IN HEPATOCYTE IRON METABOLISM. 
80. Olav Haraldseth: NMR SPECTROSCOPY OF CEREBRAL ISCHEMIA AND REPERFUSION 
IN RAT. 
81. Eiliv Brenna: REGULATION OF FUNCTION AND GROWTH OF THE OXYNTIC 
MUCOSA. 
1993 
82. Gunnar Bovim: CERVICOGENIC HEADACHE. 
83. Jarl Arne Kahn: ASSISTED PROCREATION. 
84. Bjørn Naume: IMMUNOREGULATORY EFFECTS OF CYTOKINES ON NK CELLS. 
85. Rune Wiseth: AORTIC VALVE REPLACEMENT. 
86. Jie Ming Shen: BLOOD FLOW VELOCITY AND RESPIRATORY STUDIES. 
87. Piotr Kruszewski: SUNCT SYNDROME WITH SPECIAL REFERENCE TO THE 
AUTONOMIC NERVOUS SYSTEM. 
88. Mette Haase Moen: ENDOMETRIOSIS. 
89. Anne Vik: VASCULAR GAS EMBOLISM DURING AIR INFUSION AND AFTER 
DECOMPRESSION IN PIGS. 
90. Lars Jacob Stovner: THE CHIARI TYPE I MALFORMATION. 
91. Kjell Å. Salvesen: ROUTINE ULTRASONOGRAPHY IN UTERO AND DEVELOPMENT IN 
CHILDHOOD. 
1994 
92. Nina-Beate Liabakk: DEVELOPMENT OF IMMUNOASSAYS FOR TNF AND ITS 
SOLUBLE RECEPTORS. 
93. Sverre Helge Torp: erbB ONCOGENES IN HUMAN GLIOMAS AND MENINGIOMAS. 
94. Olav M. Linaker: MENTAL RETARDATION AND PSYCHIATRY. Past and present. 
95. Per Oscar Feet: INCREASED ANTIDEPRESSANT AND ANTIPANIC EFFECT IN 
COMBINED TREATMENT WITH DIXYRAZINE AND TRICYCLIC ANTIDEPRESSANTS. 
96. Stein Olav Samstad: CROSS SECTIONAL FLOW VELOCITY PROFILES FROM TWO-
DIMENSIONAL DOPPLER ULTRASOUND: Studies on early mitral blood flow. 
97. Bjørn Backe: STUDIES IN ANTENATAL CARE. 
98. Gerd Inger Ringdal: QUALITY OF LIFE IN CANCER PATIENTS. 
99. Torvid Kiserud: THE DUCTUS VENOSUS IN THE HUMAN FETUS. 
100. Hans E. Fjøsne: HORMONAL REGULATION OF PROSTATIC METABOLISM. 
101. Eylert Brodtkorb: CLINICAL ASPECTS OF EPILEPSY IN THE MENTALLY RETARDED. 
102. Roar Juul: PEPTIDERGIC MECHANISMS IN HUMAN SUBARACHNOID HEMORRHAGE. 
103. Unni Syversen: CHROMOGRANIN A. Phsysiological and Clinical Role. 
 
1995 
104. Odd Gunnar Brakstad: THERMOSTABLE NUCLEASE AND THE nuc GENE IN THE 
DIAGNOSIS OF Staphylococcus aureus INFECTIONS. 
105. Terje Engan: NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY OF PLASMA 
IN MALIGNANT DISEASE. 
106. Kirsten Rasmussen: VIOLENCE IN THE MENTALLY DISORDERED. 
107. Finn Egil Skjeldestad: INDUCED ABORTION: Timetrends and Determinants. 
108. Roar Stenseth: THORACIC EPIDURAL ANALGESIA IN AORTOCORONARY BYPASS 
SURGERY. 
109. Arild Faxvaag: STUDIES OF IMMUNE CELL FUNCTION in mice infected with MURINE 
RETROVIRUS. 
1996 
110. Svend Aakhus: NONINVASIVE COMPUTERIZED ASSESSMENT OF LEFT 
VENTRICULAR FUNCTION AND SYSTEMIC ARTERIAL PROPERTIES. Methodology and 
some clinical applications. 
111. Klaus-Dieter Bolz: INTRAVASCULAR ULTRASONOGRAPHY. 
112. Petter Aadahl: CARDIOVASCULAR EFFECTS OF THORACIC AORTIC CROSS-
CLAMPING. 
113. Sigurd Steinshamn: CYTOKINE MEDIATORS DURING GRANULOCYTOPENIC 
INFECTIONS. 
114. Hans Stifoss-Hanssen: SEEKING MEANING OR HAPPINESS? 
115. Anne Kvikstad: LIFE CHANGE EVENTS AND MARITAL STATUS IN RELATION TO 
RISK AND PROGNOSIS OF CANCER. 
116. Torbjørn Grøntvedt: TREATMENT OF ACUTE AND CHRONIC ANTERIOR CRUCIATE 
LIGAMENT INJURIES. A clinical and biomechanical study. 
117. Sigrid Hørven Wigers: CLINICAL STUDIES OF FIBROMYALGIA WITH FOCUS ON 
ETIOLOGY, TREATMENT AND OUTCOME. 
118. Jan Schjøtt: MYOCARDIAL PROTECTION: Functional and Metabolic Characteristics of Two 
Endogenous Protective Principles. 
119. Marit Martinussen: STUDIES OF INTESTINAL BLOOD FLOW AND ITS RELATION TO 
TRANSITIONAL CIRCULATORY ADAPATION IN NEWBORN INFANTS. 
120. Tomm B. Müller: MAGNETIC RESONANCE IMAGING IN FOCAL CEREBRAL 
ISCHEMIA. 
121. Rune Haaverstad: OEDEMA FORMATION OF THE LOWER EXTREMITIES. 
122. Magne Børset: THE ROLE OF CYTOKINES IN MULTIPLE MYELOMA, WITH SPECIAL 
REFERENCE TO HEPATOCYTE GROWTH FACTOR. 
123. Geir Smedslund: A THEORETICAL AND EMPIRICAL INVESTIGATION OF SMOKING, 
STRESS AND DISEASE: RESULTS FROM A POPULATION SURVEY. 
1997 
124. Torstein Vik: GROWTH, MORBIDITY, AND PSYCHOMOTOR DEVELOPMENT IN 
INFANTS WHO WERE GROWTH RETARDED IN UTERO. 
125. Siri Forsmo: ASPECTS AND CONSEQUENCES OF OPPORTUNISTIC SCREENING FOR 
CERVICAL CANCER. Results based on data from three Norwegian counties. 
126. Jon S. Skranes: CEREBRAL MRI AND NEURODEVELOPMENTAL OUTCOME IN VERY 
LOW BIRTH WEIGHT (VLBW) CHILDREN. A follow-up study of a geographically based 
year cohort of VLBW children at ages one and six years. 
127. Knut Bjørnstad: COMPUTERIZED ECHOCARDIOGRAPHY FOR EVALUTION OF 
CORONARY ARTERY DISEASE. 
128. Grethe Elisabeth Borchgrevink: DIAGNOSIS AND TREATMENT OF WHIPLASH/NECK 
SPRAIN INJURIES CAUSED BY CAR ACCIDENTS. 
129. Tor Elsås: NEUROPEPTIDES AND NITRIC OXIDE SYNTHASE IN OCULAR 
AUTONOMIC AND SENSORY NERVES. 
130. Rolf W. Gråwe: EPIDEMIOLOGICAL AND NEUROPSYCHOLOGICAL PERSPECTIVES 
ON SCHIZOPHRENIA. 
131. Tonje Strømholm: CEREBRAL HAEMODYNAMICS DURING THORACIC AORTIC 
CROSSCLAMPING. An experimental study in pigs 
1998 
132. Martinus Bråten: STUDIES ON SOME PROBLEMS REALTED TO INTRAMEDULLARY 
NAILING OF FEMORAL FRACTURES. 
133. Ståle Nordgård: PROLIFERATIVE ACTIVITY AND DNA CONTENT AS PROGNOSTIC 
INDICATORS IN ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK. 
134. Egil Lien: SOLUBLE RECEPTORS FOR TNF AND LPS: RELEASE PATTERN AND 
POSSIBLE SIGNIFICANCE IN DISEASE. 
135. Marit Bjørgaas: HYPOGLYCAEMIA IN CHILDREN WITH DIABETES MELLITUS 
136. Frank Skorpen: GENETIC AND FUNCTIONAL ANALYSES OF DNA REPAIR IN HUMAN 
CELLS. 
137. Juan A. Pareja: SUNCT SYNDROME. ON THE CLINICAL PICTURE. ITS DISTINCTION 
FROM OTHER, SIMILAR HEADACHES. 
138. Anders Angelsen: NEUROENDOCRINE CELLS IN HUMAN PROSTATIC CARCINOMAS 
AND THE PROSTATIC COMPLEX OF RAT, GUINEA PIG, CAT AND DOG. 
139. Fabio Antonaci: CHRONIC  PAROXYSMAL HEMICRANIA AND HEMICRANIA 
CONTINUA: TWO DIFFERENT ENTITIES? 
140. Sven M. Carlsen: ENDOCRINE AND METABOLIC EFFECTS OF METFORMIN WITH 
SPECIAL EMPHASIS ON CARDIOVASCULAR RISK FACTORES. 
1999 
141. Terje A. Murberg: DEPRESSIVE SYMPTOMS AND COPING AMONG PATIENTS WITH 
CONGESTIVE HEART FAILURE. 
142. Harm-Gerd Karl Blaas: THE EMBRYONIC EXAMINATION. Ultrasound studies on the 
development of the human embryo. 
143. Noèmi Becser Andersen:THE CEPHALIC SENSORY NERVES IN UNILATERAL 
HEADACHES. Anatomical background and neurophysiological evaluation. 
144. Eli-Janne Fiskerstrand: LASER TREATMENT OF PORT WINE STAINS. A study of the 
efficacy and limitations of the pulsed dye laser. Clinical and morfological analyses aimed at 
improving the therapeutic outcome. 
145. Bård Kulseng: A STUDY OF ALGINATE CAPSULE PROPERTIES AND CYTOKINES IN 
RELATION TO INSULIN DEPENDENT DIABETES MELLITUS. 
146. Terje Haug: STRUCTURE AND REGULATION OF THE HUMAN UNG GENE ENCODING 
URACIL-DNA GLYCOSYLASE. 
147. Heidi Brurok: MANGANESE AND THE HEART. A Magic Metal with Diagnostic and 
Therapeutic Possibilites. 
148. Agnes Kathrine Lie: DIAGNOSIS AND PREVALENCE OF HUMAN PAPILLOMAVIRUS 
INFECTION IN CERVICAL INTRAEPITELIAL NEOPLASIA. Relationship to Cell Cycle 
Regulatory Proteins and HLA DQBI Genes. 
149. Ronald Mårvik: PHARMACOLOGICAL, PHYSIOLOGICAL AND 
PATHOPHYSIOLOGICAL STUDIES ON ISOLATED STOMACS. 
150. Ketil Jarl Holen: THE ROLE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND 
TREATMENT OF HIP DYSPLASIA IN NEWBORNS. 
151. Irene Hetlevik:  THE ROLE OF CLINICAL GUIDELINES IN CARDIOVASCULAR RISK 
INTERVENTION IN GENERAL PRACTICE. 
152. Katarina Tunòn: ULTRASOUND AND PREDICTION OF GESTATIONAL AGE. 
153. Johannes Soma: INTERACTION BETWEEN THE LEFT VENTRICLE AND THE SYSTEMIC 
ARTERIES. 
154. Arild Aamodt: DEVELOPMENT AND PRE-CLINICAL EVALUATION OF A CUSTOM-
MADE FEMORAL STEM. 
155. Agnar Tegnander: DIAGNOSIS AND FOLLOW-UP OF CHILDREN WITH SUSPECTED OR 
KNOWN HIP DYSPLASIA. 
156. Bent Indredavik: STROKE UNIT TREATMENT: SHORT AND LONG-TERM EFFECTS 
157. Jolanta Vanagaite Vingen: PHOTOPHOBIA AND PHONOPHOBIA IN PRIMARY 
HEADACHES 
2000 
158. Ola Dalsegg Sæther: PATHOPHYSIOLOGY DURING PROXIMAL AORTIC CROSS-
CLAMPING CLINICAL AND EXPERIMENTAL STUDIES 
159. xxxxxxxxx (blind number) 
160. Christina Vogt Isaksen: PRENATAL ULTRASOUND AND POSTMORTEM FINDINGS – A 
TEN YEAR CORRELATIVE STUDY OF FETUSES AND INFANTS WITH 
DEVELOPMENTAL ANOMALIES. 
161. Holger Seidel: HIGH-DOSE METHOTREXATE THERAPY IN CHILDREN WITH ACUTE 
LYMPHOCYTIC LEUKEMIA: DOSE, CONCENTRATION, AND EFFECT 
CONSIDERATIONS. 
162. Stein Hallan: IMPLEMENTATION OF MODERN MEDICAL DECISION ANALYSIS INTO 
CLINICAL DIAGNOSIS AND TREATMENT. 
163. Malcolm Sue-Chu: INVASIVE AND NON-INVASIVE STUDIES IN CROSS-COUNTRY 
SKIERS WITH ASTHMA-LIKE SYMPTOMS. 
164. Ole-Lars Brekke: EFFECTS OF ANTIOXIDANTS AND FATTY ACIDS ON TUMOR 
NECROSIS FACTOR-INDUCED CYTOTOXICITY. 
165. Jan Lundbom: AORTOCORONARY BYPASS SURGERY: CLINICAL ASPECTS, COST 
CONSIDERATIONS AND WORKING ABILITY. 
166. John-Anker Zwart: LUMBAR NERVE ROOT COMPRESSION, BIOCHEMICAL AND 
NEUROPHYSIOLOGICAL ASPECTS. 
167. Geir Falck: HYPEROSMOLALITY AND THE HEART. 
168. Eirik Skogvoll: CARDIAC ARREST Incidence, Intervention and Outcome. 
169. Dalius Bansevicius: SHOULDER-NECK REGION IN CERTAIN HEADACHES AND 
CHRONIC PAIN SYNDROMES. 
170. Bettina Kinge: REFRACTIVE ERRORS AND BIOMETRIC CHANGES AMONG 
UNIVERSITY STUDENTS IN NORWAY. 
171. Gunnar Qvigstad: CONSEQUENCES OF HYPERGASTRINEMIA IN MAN 
172. Hanne Ellekjær: EPIDEMIOLOGICAL STUDIES OF STROKE IN A NORWEGIAN 
POPULATION. INCIDENCE, RISK FACTORS AND PROGNOSIS 
173. Hilde Grimstad: VIOLENCE AGAINST WOMEN AND PREGNANCY OUTCOME. 
174. Astrid Hjelde: SURFACE TENSION AND COMPLEMENT ACTIVATION: Factors 
influencing bubble formation and bubble effects after decompression. 
175. Kjell A. Kvistad: MR IN BREAST CANCER – A CLINICAL STUDY. 
176. Ivar Rossvoll: ELECTIVE ORTHOPAEDIC SURGERY IN A DEFINED POPULATION. 
Studies on demand, waiting time for treatment and incapacity for work. 
177. Carina Seidel: PROGNOSTIC VALUE AND BIOLOGICAL EFFECTS OF HEPATOCYTE 
GROWTH FACTOR AND SYNDECAN-1 IN MULTIPLE MYELOMA. 
2001 
178. Alexander Wahba: THE INFLUENCE OF CARDIOPULMONARY BYPASS ON PLATELET 
FUNCTION AND BLOOD COAGULATION – DETERMINANTS AND CLINICAL 
CONSEQUENSES 
179. Marcus Schmitt-Egenolf: THE RELEVANCE OF THE MAJOR hISTOCOMPATIBILITY 
COMPLEX FOR THE GENETICS OF PSORIASIS 
180. Odrun Arna Gederaas: BIOLOGICAL MECHANISMS INVOLVED IN 5-AMINOLEVULINIC 
ACID BASED PHOTODYNAMIC THERAPY 
181. Pål Richard Romundstad: CANCER INCIDENCE AMONG NORWEGIAN ALUMINIUM 
WORKERS 
182. Henrik Hjorth-Hansen: NOVEL CYTOKINES IN GROWTH CONTROL AND BONE 
DISEASE OF MULTIPLE MYELOMA 
183. Gunnar Morken: SEASONAL VARIATION OF HUMAN MOOD AND BEHAVIOUR 
184. Bjørn Olav Haugen: MEASUREMENT OF CARDIAC OUTPUT AND STUDIES OF 
VELOCITY PROFILES IN AORTIC AND MITRAL FLOW USING TWO- AND THREE-
DIMENSIONAL COLOUR FLOW IMAGING 
185. Geir Bråthen: THE CLASSIFICATION AND CLINICAL DIAGNOSIS OF ALCOHOL-
RELATED SEIZURES 
186. Knut Ivar Aasarød: RENAL INVOLVEMENT IN INFLAMMATORY RHEUMATIC 
DISEASE. A Study of Renal Disease in Wegener’s Granulomatosis and in Primary Sjögren’s 
Syndrome  
187. Trude Helen Flo: RESEPTORS INVOLVED IN CELL ACTIVATION BY DEFINED URONIC 
ACID POLYMERS AND BACTERIAL COMPONENTS 
188. Bodil Kavli: HUMAN URACIL-DNA GLYCOSYLASES FROM THE UNG GENE: 
STRUCTRUAL BASIS FOR SUBSTRATE SPECIFICITY AND REPAIR 
189. Liv Thommesen: MOLECULAR MECHANISMS INVOLVED IN TNF- AND GASTRIN-
MEDIATED GENE REGULATION 
190. Turid Lingaas Holmen: SMOKING AND HEALTH IN ADOLESCENCE; THE NORD-
TRØNDELAG HEALTH STUDY, 1995-97 
191. Øyvind Hjertner: MULTIPLE MYELOMA: INTERACTIONS BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MICROENVIRONMENT 
192. Asbjørn Støylen: STRAIN RATE IMAGING OF THE LEFT VENTRICLE BY 
ULTRASOUND. FEASIBILITY, CLINICAL VALIDATION AND PHYSIOLOGICAL 
ASPECTS 
193. Kristian Midthjell: DIABETES IN ADULTS IN NORD-TRØNDELAG. PUBLIC HEALTH 
ASPECTS OF DIABETES MELLITUS IN A LARGE, NON-SELECTED NORWEGIAN 
POPULATION. 
194. Guanglin Cui: FUNCTIONAL ASPECTS OF THE ECL CELL IN RODENTS 
195. Ulrik Wisløff: CARDIAC EFFECTS OF AEROBIC ENDURANCE TRAINING: 
HYPERTROPHY, CONTRACTILITY AND CALCUIM HANDLING IN NORMAL AND 
FAILING HEART 
196. Øyvind Halaas: MECHANISMS OF IMMUNOMODULATION AND CELL-MEDIATED 
CYTOTOXICITY INDUCED BY BACTERIAL PRODUCTS 
197. Tore Amundsen: PERFUSION MR IMAGING IN THE DIAGNOSIS OF PULMONARY 
EMBOLISM 
198. Nanna Kurtze: THE SIGNIFICANCE OF ANXIETY AND DEPRESSION IN FATIQUE AND 
PATTERNS OF PAIN AMONG INDIVIDUALS DIAGNOSED WITH FIBROMYALGIA: 
RELATIONS WITH QUALITY OF LIFE, FUNCTIONAL DISABILITY, LIFESTYLE, 
EMPLOYMENT STATUS, CO-MORBIDITY AND GENDER 
199. Tom Ivar Lund Nilsen: PROSPECTIVE STUDIES OF CANCER RISK IN NORD-
TRØNDELAG: THE HUNT STUDY. Associations with anthropometric, socioeconomic, and 
lifestyle risk factors 
200. Asta Kristine Håberg: A NEW APPROACH TO THE STUDY OF MIDDLE CEREBRAL 
ARTERY OCCLUSION IN THE RAT USING MAGNETIC RESONANCE TECHNIQUES 
2002 
201. Knut Jørgen Arntzen: PREGNANCY AND CYTOKINES 
202. Henrik Døllner: INFLAMMATORY MEDIATORS IN PERINATAL INFECTIONS 
203. Asta Bye: LOW FAT, LOW LACTOSE DIET USED AS PROPHYLACTIC TREATMENT OF 
ACUTE INTESTINAL REACTIONS DURING PELVIC RADIOTHERAPY. A 
PROSPECTIVE RANDOMISED STUDY. 
204. Sylvester Moyo: STUDIES ON STREPTOCOCCUS AGALACTIAE  (GROUP B 
STREPTOCOCCUS) SURFACE-ANCHORED MARKERS WITH EMPHASIS ON STRAINS 
AND HUMAN SERA FROM ZIMBABWE. 
205. Knut Hagen: HEAD-HUNT: THE EPIDEMIOLOGY OF HEADACHE IN NORD-
TRØNDELAG 
206. Li Lixin: ON THE REGULATION AND ROLE OF UNCOUPLING PROTEIN-2 IN INSULIN 
PRODUCING ß-CELLS 
207. Anne Hildur Henriksen: SYMPTOMS OF ALLERGY AND ASTHMA VERSUS MARKERS 
OF LOWER AIRWAY INFLAMMATION AMONG ADOLESCENTS 
208. Egil Andreas Fors: NON-MALIGNANT PAIN IN RELATION TO PSYCHOLOGICAL AND 
ENVIRONTENTAL FACTORS. EXPERIENTAL AND CLINICAL STUDES OF PAIN WITH 
FOCUS ON FIBROMYALGIA 
209. Pål Klepstad:  MORPHINE FOR CANCER PAIN 
210. Ingunn Bakke: MECHANISMS AND CONSEQUENCES OF PEROXISOME 
PROLIFERATOR-INDUCED HYPERFUNCTION OF THE RAT GASTRIN PRODUCING 
CELL 
211. Ingrid Susann Gribbestad: MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY OF 
BREAST CANCER 
212. Rønnaug Astri Ødegård: PREECLAMPSIA – MATERNAL RISK FACTORS AND FETAL 
GROWTH 
213. Johan Haux: STUDIES ON CYTOTOXICITY INDUCED BY HUMAN NATURAL KILLER 
CELLS AND DIGITOXIN 
214. Turid Suzanne Berg-Nielsen: PARENTING PRACTICES AND MENTALLY DISORDERED 
ADOLESCENTS 
215. Astrid Rydning: BLOOD FLOW AS A PROTECTIVE FACTOR FOR THE STOMACH 
MUCOSA. AN EXPERIMENTAL STUDY ON THE ROLE OF MAST CELLS AND 
SENSORY AFFERENT NEURONS 
2003 
216. Jan Pål Loennechen: HEART FAILURE AFTER MYOCARDIAL INFARCTION. Regional 
Differences, Myocyte Function, Gene Expression, and Response to Cariporide, Losartan, and 
Exercise Training. 
217. Elisabeth Qvigstad: EFFECTS OF FATTY ACIDS AND OVER-STIMULATION ON 
INSULIN SECRETION IN MAN 
218. Arne Åsberg: EPIDEMIOLOGICAL STUDIES IN HEREDITARY HEMOCHROMATOSIS: 
PREVALENCE, MORBIDITY AND BENEFIT OF SCREENING. 
219. Johan Fredrik Skomsvoll: REPRODUCTIVE OUTCOME IN WOMEN WITH RHEUMATIC 
DISEASE. A population registry based study of the effects of inflammatory rheumatic disease 
and connective tissue disease on reproductive outcome in Norwegian women in 1967-1995. 
220. Siv Mørkved: URINARY INCONTINENCE DURING PREGNANCY AND AFTER  
DELIVERY: EFFECT OF PELVIC FLOOR MUSCLE TRAINING IN PREVENTION AND 
TREATMENT 
221. Marit S. Jordhøy: THE IMPACT OF COMPREHENSIVE PALLIATIVE CARE 
222. Tom Christian Martinsen: HYPERGASTRINEMIA AND HYPOACIDITY IN RODENTS – 
CAUSES AND CONSEQUENCES  
223. Solveig Tingulstad: CENTRALIZATION OF PRIMARY SURGERY FOR OVARAIN 
CANCER. FEASIBILITY AND IMPACT ON SURVIVAL  
224. Haytham Eloqayli: METABOLIC CHANGES IN THE BRAIN CAUSED BY EPILEPTIC 
SEIZURES 
225. Torunn Bruland: STUDIES OF EARLY RETROVIRUS-HOST INTERACTIONS – VIRAL 
DETERMINANTS FOR PATHOGENESIS AND THE INFLUENCE OF SEX ON THE 
SUSCEPTIBILITY TO FRIEND MURINE LEUKAEMIA VIRUS INFECTION 
226. Torstein Hole: DOPPLER ECHOCARDIOGRAPHIC EVALUATION OF LEFT 
VENTRICULAR FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
227. Vibeke Nossum: THE EFFECT OF VASCULAR BUBBLES ON ENDOTHELIAL FUNCTION 
228. Sigurd Fasting: ROUTINE BASED RECORDING OF ADVERSE EVENTS DURING 
ANAESTHESIA – APPLICATION IN QUALITY IMPROVEMENT AND SAFETY 
229. Solfrid Romundstad: EPIDEMIOLOGICAL STUDIES OF MICROALBUMINURIA. THE 
NORD-TRØNDELAG HEALTH STUDY 1995-97 (HUNT 2) 
230. Geir Torheim: PROCESSING OF DYNAMIC DATA SETS IN MAGNETIC RESONANCE 
IMAGING 
231. Catrine Ahlén: SKIN INFECTIONS IN OCCUPATIONAL SATURATION DIVERS IN THE 
NORTH SEA AND THE IMPACT OF THE ENVIRONMENT 
232. Arnulf Langhammer: RESPIRATORY SYMPTOMS, LUNG FUNCTION AND BONE 
MINERAL DENSITY IN A COMPREHENSIVE POPULATION SURVEY. THE NORD-
TRØNDELAG HEALTH STUDY 1995-97. THE BRONCHIAL OBSTRUCTION IN NORD-
TRØNDELAG STUDY 
233. Einar Kjelsås: EATING DISORDERS AND PHYSICAL ACTIVITY IN NON-CLINICAL 
SAMPLES 
234. Arne Wibe: RECTAL CANCER TREATMENT IN NORWAY – STANDARDISATION OF 
SURGERY AND QUALITY ASSURANCE 
2004 
235. Eivind Witsø: BONE GRAFT AS AN ANTIBIOTIC CARRIER 
236. Anne Mari Sund: DEVELOPMENT OF DEPRESSIVE SYMPTOMS IN EARLY 
ADOLESCENCE   
237. Hallvard Lærum: EVALUATION OF ELECTRONIC MEDICAL RECORDS – A CLINICAL 
TASK PERSPECTIVE  
238. Gustav Mikkelsen: ACCESSIBILITY OF INFORMATION IN ELECTRONIC PATIENT 
RECORDS; AN EVALUATION OF THE ROLE OF DATA QUALITY 
239. Steinar Krokstad: SOCIOECONOMIC INEQUALITIES IN HEALTH AND DISABILITY. 
SOCIAL EPIDEMIOLOGY IN THE NORD-TRØNDELAG HEALTH STUDY (HUNT), 
NORWAY 
240. Arne Kristian Myhre: NORMAL VARIATION IN ANOGENITAL ANATOMY AND 
MICROBIOLOGY IN NON-ABUSED PRESCHOOL CHILDREN 
241. Ingunn Dybedal: NEGATIVE REGULATORS OF HEMATOPOIETEC STEM AND 
PROGENITOR CELLS 
242. Beate Sitter: TISSUE CHARACTERIZATION BY HIGH RESOLUTION MAGIC ANGLE 
SPINNING MR SPECTROSCOPY 
243. Per Arne Aas: MACROMOLECULAR MAINTENANCE IN HUMAN CELLS – REPAIR OF 
URACIL IN DNA AND METHYLATIONS IN DNA AND RNA 
244. Anna Bofin:  FINE NEEDLE ASPIRATION CYTOLOGY IN THE PRIMARY 
INVESTIGATION OF BREAST TUMOURS AND IN THE DETERMINATION OF 
TREATMENT STRATEGIES 
245. Jim Aage Nøttestad: DEINSTITUTIONALIZATION AND MENTAL HEALTH CHANGES 
AMONG PEOPLE WITH MENTAL RETARDATION 
246. Reidar Fossmark:  GASTRIC CANCER IN JAPANESE COTTON RATS 
247. Wibeke Nordhøy:  MANGANESE AND THE HEART, INTRACELLULAR MR 
RELAXATION AND WATER EXCHANGE ACROSS THE CARDIAC CELL MEMBRANE 
2005 
248. Sturla Molden:  QUANTITATIVE ANALYSES OF SINGLE UNITS RECORDED FROM THE 
HIPPOCAMPUS AND ENTORHINAL CORTEX OF BEHAVING RATS 
249. Wenche Brenne Drøyvold:  EPIDEMIOLOGICAL STUDIES ON WEIGHT CHANGE AND 
HEALTH IN A LARGE POPULATION.  THE NORD-TRØNDELAG HEALTH STUDY 
(HUNT) 
250. Ragnhild Støen:  ENDOTHELIUM-DEPENDENT VASODILATION IN THE FEMORAL 
ARTERY OF DEVELOPING PIGLETS 
251. Aslak Steinsbekk:  HOMEOPATHY IN THE PREVENTION OF UPPER RESPIRATORY 
TRACT INFECTIONS IN CHILDREN 
252. Hill-Aina Steffenach:  MEMORY IN HIPPOCAMPAL AND CORTICO-HIPPOCAMPAL 
CIRCUITS 
253. Eystein Stordal:  ASPECTS OF THE EPIDEMIOLOGY OF DEPRESSIONS BASED ON 
SELF-RATING IN A LARGE GENERAL HEALTH STUDY (THE HUNT-2 STUDY) 
254. Viggo Pettersen:  FROM MUSCLES TO SINGING:  THE ACTIVITY OF ACCESSORY 
BREATHING MUSCLES AND THORAX  MOVEMENT IN CLASSICAL SINGING 
255. Marianne Fyhn:  SPATIAL MAPS IN THE HIPPOCAMPUS AND ENTORHINAL CORTEX 
256. Robert Valderhaug:  OBSESSIVE-COMPULSIVE DISORDER AMONG CHILDREN AND 
ADOLESCENTS:  CHARACTERISTICS AND PSYCHOLOGICAL MANAGEMENT OF 
PATIENTS IN OUTPATIENT PSYCHIATRIC CLINICS 
257. Erik Skaaheim Haug:  INFRARENAL ABDOMINAL  AORTIC ANEURYSMS – 
COMORBIDITY AND RESULTS FOLLOWING OPEN SURGERY 
258. Daniel Kondziella: GLIAL-NEURONAL INTERACTIONS IN EXPERIMENTAL BRAIN 
DISORDERS 
259. Vegard Heimly Brun:  ROUTES TO SPATIAL MEMORY IN HIPPOCAMPAL PLACE 
CELLS 
260. Kenneth McMillan:  PHYSIOLOGICAL ASSESSMENT AND TRAINING OF ENDURANCE 
AND STRENGTH IN PROFESSIONAL YOUTH SOCCER PLAYERS 
261. Marit Sæbø Indredavik:  MENTAL HEALTH AND CEREBRAL MAGNETIC RESONANCE 
IMAGING IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
262. Ole Johan Kemi:  ON THE CELLULAR BASIS OF AEROBIC FITNESS, INTENSITY-
DEPENDENCE AND TIME-COURSE OF CARDIOMYOCYTE AND ENDOTHELIAL 
ADAPTATIONS TO EXERCISE TRAINING 
263. Eszter Vanky: POLYCYSTIC OVARY SYNDROME – METFORMIN TREATMENT IN 
PREGNANCY 
264. Hild Fjærtoft:  EXTENDED STROKE UNIT SERVICE AND EARLY SUPPORTED 
DISCHARGE.  SHORT AND LONG-TERM EFFECTS   
265. Grete Dyb:  POSTTRAUMATIC STRESS REACTIONS IN CHILDREN AND 
ADOLESCENTS 
266. Vidar Fykse: SOMATOSTATIN AND THE STOMACH 
267. Kirsti Berg: OXIDATIVE STRESS AND THE ISCHEMIC HEART:  A STUDY IN PATIENTS 
UNDERGOING CORONARY REVASCULARIZATION  
268. Björn Inge Gustafsson:  THE SEROTONIN PRODUCING ENTEROCHROMAFFIN CELL, 
AND EFFECTS OF HYPERSEROTONINEMIA ON HEART AND BONE 
2006 
269. Torstein Baade Rø:  EFFECTS OF BONE MORPHOGENETIC PROTEINS, HEPATOCYTE 
GROWTH FACTOR AND INTERLEUKIN-21 IN MULTIPLE MYELOMA 
270. May-Britt Tessem:  METABOLIC EFFECTS OF ULTRAVIOLET RADIATION ON THE 
ANTERIOR PART OF THE EYE 
271. Anne-Sofie Helvik:  COPING AND EVERYDAY LIFE IN A POPULATION OF ADULTS 
WITH HEARING IMPAIRMENT 
272. Therese Standal:  MULTIPLE MYELOMA:  THE INTERPLAY BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MARROW MICROENVIRONMENT 
273. Ingvild Saltvedt:  TREATMENT OF ACUTELY SICK, FRAIL ELDERLY PATIENTS IN A 
GERIATRIC EVALUATION AND MANAGEMENT UNIT – RESULTS FROM A 
PROSPECTIVE RANDOMISED TRIAL 
274. Birger Henning Endreseth:  STRATEGIES IN RECTAL CANCER TREATMENT – FOCUS 
ON EARLY RECTAL CANCER AND THE INFLUENCE OF AGE ON PROGNOSIS 
275. Anne Mari Aukan Rokstad:  ALGINATE CAPSULES AS BIOREACTORS FOR CELL 
THERAPY 
276. Mansour Akbari: HUMAN BASE EXCISION REPAIR FOR PRESERVATION OF GENOMIC 
STABILITY 
277. Stein Sundstrøm:  IMPROVING TREATMENT IN PATIENTS WITH LUNG CANCER – 
RESULTS FROM TWO MULITCENTRE RANDOMISED STUDIES 
278. Hilde Pleym: BLEEDING AFTER CORONARY ARTERY BYPASS SURGERY -  STUDIES 
ON HEMOSTATIC MECHANISMS, PROPHYLACTIC DRUG TREATMENT AND 
EFFECTS OF AUTOTRANSFUSION 
279. Line Merethe Oldervoll:  PHYSICAL ACTIVITY AND EXERCISE INTERVENTIONS IN 
CANCER PATIENTS 
280. Boye Welde:  THE SIGNIFICANCE OF ENDURANCE TRAINING, RESISTANCE 
TRAINING AND MOTIVATIONAL STYLES IN ATHLETIC PERFORMANCE AMONG 
ELITE JUNIOR CROSS-COUNTRY SKIERS 
281. Per Olav Vandvik:  IRRITABLE BOWEL SYNDROME IN NORWAY,  STUDIES OF 
PREVALENCE, DIAGNOSIS AND CHARACTERISTICS IN GENERAL PRACTICE AND 
IN THE POPULATION 
282. Idar Kirkeby-Garstad:  CLINICAL PHYSIOLOGY OF EARLY MOBILIZATION AFTER 
CARDIAC SURGERY 
283. Linn Getz: SUSTAINABLE AND RESPONSIBLE PREVENTIVE MEDICINE.  
CONCEPTUALISING ETHICAL DILEMMAS ARISING FROM CLINICAL 
IMPLEMENTATION OF ADVANCING MEDICAL TECHNOLOGY  
284. Eva Tegnander: DETECTION OF CONGENITAL HEART DEFECTS  IN A NON-SELECTED 
POPULATION OF 42,381 FETUSES 
285. Kristin Gabestad Nørsett:  GENE EXPRESSION STUDIES IN GASTROINTESTINAL 
PATHOPHYSIOLOGY AND NEOPLASIA 
286. Per Magnus Haram:  GENETIC VS. AQUIRED FITNESS:  METABOLIC, VASCULAR AND 
CARDIOMYOCYTE  ADAPTATIONS 
287. Agneta Johansson:  GENERAL RISK FACTORS FOR GAMBLING PROBLEMS AND THE 
PREVALENCE OF PATHOLOGICAL GAMBLING IN NORWAY  
288. Svein Artur Jensen:  THE PREVALENCE OF SYMPTOMATIC ARTERIAL DISEASE OF 
THE LOWER LIMB 
289. Charlotte Björk Ingul:  QUANITIFICATION OF REGIONAL MYOCARDIAL FUNCTION 
BY STRAIN RATE AND STRAIN FOR EVALUATION OF CORONARY ARTERY 
DISEASE.  AUTOMATED VERSUS MANUAL ANALYSIS DURING ACUTE 
MYOCARDIAL INFARCTION AND DOBUTAMINE STRESS ECHOCARDIOGRAPHY 
290. Jakob Nakling:  RESULTS AND CONSEQUENCES OF ROUTINE ULTRASOUND 
SCREENING IN PREGNANCY – A GEOGRAPHIC BASED POPULATION STUDY 
291. Anne Engum:  DEPRESSION AND ANXIETY – THEIR RELATIONS TO THYROID 
DYSFUNCTION AND DIABETES IN A LARGE EPIDEMIOLOGICAL STUDY 
292. Ottar Bjerkeset: ANXIETY AND DEPRESSION IN THE GENERAL POPULATION:  RISK 
FACTORS, INTERVENTION AND OUTCOME – THE NORD-TRØNDELAG HEALTH 
STUDY (HUNT) 
293. Jon Olav Drogset:  RESULTS AFTER SURGICAL TREATMENT OF ANTERIOR 
CRUCIATE LIGAMENT INJURIES – A CLINICAL STUDY  
294. Lars Fosse: MECHANICAL BEHAVIOUR OF COMPACTED MORSELLISED BONE – AN 
EXPERIMENTAL IN VITRO STUDY 
295. Gunilla Klensmeden Fosse: MENTAL HEALTH OF PSYCHIATRIC OUTPATIENTS 
BULLIED IN CHILDHOOD 
296. Paul Jarle Mork:  MUSCLE ACTIVITY IN WORK  AND LEISURE AND ITS ASSOCIATION 
TO MUSCULOSKELETAL PAIN 
297. Björn Stenström:  LESSONS FROM RODENTS:  I: MECHANISMS OF OBESITY SURGERY 
– ROLE OF STOMACH.  II: CARCINOGENIC EFFECTS OF HELICOBACTER PYLORI 
AND SNUS IN THE STOMACH 
2007 
298. Haakon R. Skogseth:  INVASIVE PROPERTIES OF CANCER – A TREATMENT TARGET ?  
IN VITRO STUDIES IN HUMAN PROSTATE CANCER CELL LINES 
299. Janniche Hammer:  GLUTAMATE METABOLISM AND CYCLING IN MESIAL 
TEMPORAL LOBE EPILEPSY 
300. May Britt Drugli:  YOUNG CHILDREN TREATED BECAUSE OF ODD/CD:  CONDUCT 
PROBLEMS AND SOCIAL COMPETENCIES IN DAY-CARE AND SCHOOL SETTINGS 
301. Arne Skjold:  MAGNETIC RESONANCE KINETICS OF MANGANESE DIPYRIDOXYL 
DIPHOSPHATE (MnDPDP) IN HUMAN MYOCARDIUM.  STUDIES IN HEALTHY 
VOLUNTEERS AND IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION 
302. Siri Malm:  LEFT VENTRICULAR SYSTOLIC FUNCTION AND MYOCARDIAL 
PERFUSION ASSESSED BY CONTRAST ECHOCARDIOGRAPHY 
303. Valentina Maria do Rosario Cabral Iversen:  MENTAL HEALTH AND PSYCHOLOGICAL 
ADAPTATION OF CLINICAL AND NON-CLINICAL MIGRANT GROUPS 
304. Lasse Løvstakken:  SIGNAL PROCESSING IN DIAGNOSTIC ULTRASOUND:  
ALGORITHMS FOR REAL-TIME ESTIMATION AND VISUALIZATION OF BLOOD 
FLOW VELOCITY 
305. Elisabeth Olstad:  GLUTAMATE AND GABA:  MAJOR PLAYERS IN NEURONAL 
METABOLISM  
306. Lilian Leistad:  THE ROLE OF CYTOKINES AND PHOSPHOLIPASE A2s  IN ARTICULAR 
CARTILAGE CHONDROCYTES IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS 
307. Arne Vaaler:  EFFECTS OF PSYCHIATRIC INTENSIVE CARE UNIT IN AN ACUTE 
PSYCIATHRIC WARD 
308. Mathias Toft:  GENETIC STUDIES OF LRRK2 AND PINK1 IN PARKINSON’S DISEASE 
309. Ingrid Løvold Mostad:  IMPACT OF DIETARY FAT QUANTITY AND QUALITY IN TYPE 
2 DIABETES WITH EMPHASIS ON MARINE N-3 FATTY ACIDS 
310. Torill Eidhammer Sjøbakk:  MR DETERMINED BRAIN METABOLIC PATTERN IN 
PATIENTS WITH BRAIN METASTASES AND ADOLESCENTS WITH LOW BIRTH 
WEIGHT 
311. Vidar Beisvåg:  PHYSIOLOGICAL GENOMICS OF HEART FAILURE:  FROM 
TECHNOLOGY TO PHYSIOLOGY 
312. Olav Magnus Søndenå Fredheim:  HEALTH RELATED QUALITY OF LIFE ASSESSMENT 
AND ASPECTS OF THE CLINICAL PHARMACOLOGY OF METHADONE IN PATIENTS 
WITH CHRONIC NON-MALIGNANT PAIN 
313. Anne Brantberg: FETAL AND PERINATAL IMPLICATIONS OF ANOMALIES IN THE 
GASTROINTESTINAL TRACT AND THE ABDOMINAL WALL 
314. Erik Solligård: GUT LUMINAL MICRODIALYSIS 
315. Elin Tollefsen: RESPIRATORY SYMPTOMS IN A COMPREHENSIVE POPULATION 
BASED STUDY AMONG ADOLESCENTS 13-19 YEARS. YOUNG-HUNT 1995-97 AND 
2000-01; THE NORD-TRØNDELAG HEALTH STUDIES (HUNT) 
316. Anne-Tove Brenne:  GROWTH REGULATION OF MYELOMA CELLS 
317. Heidi Knobel:  FATIGUE IN CANCER TREATMENT – ASSESSMENT, COURSE AND 
ETIOLOGY 
318. Torbjørn Dahl:  CAROTID ARTERY STENOSIS.  DIAGNOSTIC AND THERAPEUTIC 
ASPECTS 
319. Inge-Andre Rasmussen jr.:  FUNCTIONAL AND DIFFUSION TENSOR MAGNETIC 
RESONANCE IMAGING IN NEUROSURGICAL PATIENTS 
320. Grete Helen Bratberg:  PUBERTAL TIMING – ANTECEDENT TO RISK OR RESILIENCE ?  
EPIDEMIOLOGICAL STUDIES ON GROWTH, MATURATION AND HEALTH RISK 
BEHAVIOURS; THE YOUNG HUNT STUDY, NORD-TRØNDELAG, NORWAY 
321. Sveinung Sørhaug:  THE PULMONARY NEUROENDOCRINE SYSTEM.  
PHYSIOLOGICAL, PATHOLOGICAL AND TUMOURIGENIC ASPECTS 
322. Olav Sande Eftedal:  ULTRASONIC DETECTION OF DECOMPRESSION INDUCED 
VASCULAR MICROBUBBLES 
323. Rune Bang Leistad:  PAIN, AUTONOMIC ACTIVATION AND MUSCULAR ACTIVITY 
RELATED TO EXPERIMENTALLY-INDUCED COGNITIVE STRESS IN HEADACHE 
PATIENTS 
324. Svein Brekke:  TECHNIQUES FOR ENHANCEMENT OF TEMPORAL RESOLUTION IN 
THREE-DIMENSIONAL ECHOCARDIOGRAPHY 
325. Kristian Bernhard Nilsen:  AUTONOMIC ACTIVATION AND MUSCLE ACTIVITY IN 
RELATION TO MUSCULOSKELETAL PAIN 
326. Anne Irene Hagen:  HEREDITARY BREAST CANCER IN NORWAY.  DETECTION AND 
PROGNOSIS OF BREAST CANCER IN FAMILIES WITH BRCA1GENE MUTATION 
327. Ingebjørg S. Juel :  INTESTINAL INJURY AND RECOVERY AFTER ISCHEMIA.  AN 
EXPERIMENTAL STUDY ON RESTITUTION OF THE SURFACE EPITHELIUM, 
INTESTINAL PERMEABILITY, AND RELEASE OF BIOMARKERS FROM THE MUCOSA 
328. Runa Heimstad:  POST-TERM PREGNANCY 
329. Jan Egil Afset:  ROLE OF ENTEROPATHOGENIC ESCHERICHIA COLI  IN CHILDHOOD 
DIARRHOEA IN NORWAY 
330. Bent Håvard Hellum:  IN VITRO INTERACTIONS BETWEEN MEDICINAL DRUGS AND 
HERBS ON CYTOCHROME P-450 METABOLISM AND P-GLYCOPROTEIN TRANSPORT 
331. Morten André Høydal:  CARDIAC DYSFUNCTION AND MAXIMAL OXYGEN UPTAKE 
MYOCARDIAL ADAPTATION TO ENDURANCE TRAINING 
2008 
332. Andreas Møllerløkken:  REDUCTION OF VASCULAR BUBBLES:  METHODS TO 
PREVENT THE ADVERSE EFFECTS OF DECOMPRESSION 
333. Anne Hege Aamodt:  COMORBIDITY OF HEADACHE AND MIGRAINE IN THE NORD-
TRØNDELAG HEALTH STUDY 1995-97 
334. Brage Høyem Amundsen:  MYOCARDIAL FUNCTION QUANTIFIED BY SPECKLE 
TRACKING AND TISSUE DOPPLER ECHOCARDIOGRAPHY – VALIDATION AND 
APPLICATION IN EXERCISE TESTING AND TRAINING 
335. Inger Anne Næss:  INCIDENCE, MORTALITY AND RISK FACTORS OF FIRST VENOUS 
THROMBOSIS IN A GENERAL POPULATION.  RESULTS FROM THE SECOND NORD-
TRØNDELAG HEALTH STUDY (HUNT2) 
336. Vegard Bugten:  EFFECTS OF POSTOPERATIVE MEASURES AFTER FUNCTIONAL 
ENDOSCOPIC SINUS  SURGERY 
337. Morten Bruvold:  MANGANESE AND WATER IN CARDIAC MAGNETIC RESONANCE 
IMAGING  
338. Miroslav Fris:  THE EFFECT OF SINGLE AND REPEATED ULTRAVIOLET RADIATION 
ON THE ANTERIOR SEGMENT OF THE RABBIT EYE 
339. Svein Arne Aase:  METHODS FOR IMPROVING QUALITY AND EFFICIENCY IN 
QUANTITATIVE ECHOCARDIOGRAPHY – ASPECTS OF USING HIGH FRAME RATE 
340. Roger Almvik:  ASSESSING THE RISK OF VIOLENCE:  DEVELOPMENT AND 
VALIDATION OF THE BRØSET VIOLENCE CHECKLIST 
341. Ottar Sundheim:  STRUCTURE-FUNCTION ANALYSIS OF HUMAN ENZYMES 
INITIATING NUCLEOBASE REPAIR IN DNA AND RNA 
342. Anne Mari Undheim:  SHORT AND LONG-TERM OUTCOME OF EMOTIONAL AND 
BEHAVIOURAL PROBLEMS IN YOUNG ADOLESCENTS WITH AND WITHOUT 
READING DIFFICULTIES 
343. Helge Garåsen:  THE TRONDHEIM MODEL.  IMPROVING THE PROFESSIONAL 
COMMUNICATION BETWEEN THE VARIOUS LEVELS OF HEALTH CARE SERVICES 
AND IMPLEMENTATION OF INTERMEDIATE CARE AT A COMMUNITY HOSPITAL 
COULD PROVIDE BETTER CARE FOR OLDER PATIENTS.  SHORT AND LONG TERM 
EFFECTS  
344. Olav A. Foss:  “THE ROTATION RATIOS METHOD”.  A METHOD TO DESCRIBE 
ALTERED SPATIAL ORIENTATION IN SEQUENTIAL RADIOGRAPHS FROM ONE 
PELVIS 
345. Bjørn Olav Åsvold:  THYROID FUNCTION AND CARDIOVASCULAR HEALTH 
346. Torun Margareta Melø: NEURONAL GLIAL INTERACTIONS IN EPILEPSY 
347. Irina Poliakova Eide:  FETAL GROWTH RESTRICTION AND PRE-ECLAMPSIA:   SOME 
CHARACTERISTICS OF FETO-MATERNAL INTERACTIONS IN DECIDUA BASALIS 
348. Torunn Askim:  RECOVERY AFTER STROKE.  ASSESSMENT AND TREATMENT;  WITH 
FOCUS ON MOTOR FUNCTION 
349. Ann Elisabeth Åsberg:  NEUTROPHIL ACTIVATION IN A ROLLER PUMP MODEL OF 
CARDIOPULMONARY BYPASS.  INFLUENCE ON BIOMATERIAL, PLATELETS AND 
COMPLEMENT 
350. Lars Hagen:  REGULATION OF DNA BASE EXCISION REPAIR BY PROTEIN 
INTERACTIONS AND POST TRANSLATIONAL MODIFICATIONS 
351. Sigrun Beate Kjøtrød:  POLYCYSTIC OVARY SYNDROME – METFORMIN TREATMENT 
IN ASSISTED REPRODUCTION 
352. Steven Keita Nishiyama:  PERSPECTIVES ON LIMB-VASCULAR HETEROGENEITY:  
IMPLICATIONS FOR HUMAN AGING, SEX, AND EXERCISE 
353. Sven Peter Näsholm:  ULTRASOUND BEAMS FOR ENHANCED IMAGE QUALITY 
354. Jon Ståle Ritland:  PRIMARY OPEN-ANGLE GLAUCOMA & EXFOLIATIVE GLAUCOMA. 
SURVIVAL, COMORBIDITY AND GENETICS 
355. Sigrid Botne Sando:  ALZHEIMER’S DISEASE IN CENTRAL NORWAY.  GENETIC AND 
EDUCATIONAL ASPECTS 
356. Parvinder Kaur: CELLULAR AND MOLECULAR MECHANISMS BEHIND 
METHYLMERCURY-INDUCED NEUROTOXICITY 
357. Ismail Cüneyt Güzey:  DOPAMINE AND SEROTONIN RECEPTOR AND TRANSPORTER 
GENE POLYMORPHISMS AND EXTRAPYRAMIDAL SYMPTOMS. STUDIES IN 
PARKINSON’S DISEASE AND IN PATIENTS TREATED WITH ANTIPSYCHOTIC OR 
ANTIDEPRESSANT DRUGS 
358. Brit Dybdahl:  EXTRA-CELLULAR INDUCIBLE HEAT-SHOCK PROTEIN 70 (Hsp70) – A 
ROLE IN THE INFLAMMATORY RESPONSE ? 
359. Kristoffer Haugarvoll:  IDENTIFYING GENETIC CAUSES OF PARKINSON’S DISEASE IN 
NORWAY 
360. Nadra Nilsen: TOLL-LIKE RECEPTOR 2 –EXPRESSION, REGULATION AND SIGNALING 
361. Johan Håkon Bjørngaard: PATIENT SATISFACTION WITH OUTPATIENT MENTAL 
HEALTH SERVICES – THE INFLUENCE OF ORGANIZATIONAL FACTORS. 
362. Kjetil Høydal : EFFECTS OF HIGH INTENSITY AEROBIC TRAINING IN HEALTHY 
SUBJECTS AND CORONARY ARTERY DISEASE PATIENTS; THE IMPORTANCE OF 
INTENSITY,, DURATION AND FREQUENCY OF TRAINING. 
363. Trine Karlsen: TRAINING IS MEDICINE: ENDURANCE AND STRENGTH TRAINING IN 
CORONARY ARTERY DISEASE AND HEALTH. 
364. Marte Thuen: MANGANASE-ENHANCED AND DIFFUSION TENSOR MR IMAGING OF 
THE NORMAL, INJURED AND REGENERATING RAT VISUAL PATHWAY 
365. Cathrine Broberg Vågbø:  DIRECT REPAIR OF ALKYLATION DAMAGE IN DNA AND 
RNA BY 2-OXOGLUTARATE- AND IRON-DEPENDENT DIOXYGENASES 
366. Arnt Erik Tjønna:  AEROBIC EXERCISE AND CARDIOVASCULAR RISK FACTORS IN 
OVERWEIGHT AND OBESE ADOLESCENTS AND ADULTS 
367. Marianne W. Furnes:  FEEDING BEHAVIOR AND BODY WEIGHT DEVELOPMENT:  
LESSONS FROM RATS  
368. Lene N. Johannessen:  FUNGAL PRODUCTS AND INFLAMMATORY RESPONSES IN 
HUMAN MONOCYTES AND EPITHELIAL CELLS  
369. Anja Bye:  GENE EXPRESSION PROFILING OF INHERITED AND ACQUIRED MAXIMAL 
OXYGEN UPTAKE – RELATIONS TO THE METABOLIC SYNDROME. 
370. Oluf Dimitri Røe:  MALIGNANT MESOTHELIOMA:  VIRUS, BIOMARKERS AND GENES.  
A TRANSLATIONAL APPROACH 
371. Ane Cecilie Dale:  DIABETES MELLITUS AND FATAL ISCHEMIC HEART DISEASE. 
ANALYSES FROM THE HUNT1 AND 2 STUDIES 
372. Jacob Christian Hølen:  PAIN ASSESSMENT IN PALLIATIVE CARE:  VALIDATION OF 
METHODS FOR SELF-REPORT AND BEHAVIOURAL ASSESSMENT 
373. Erming Tian:  THE GENETIC IMPACTS IN THE ONCOGENESIS OF MULTIPLE 
MYELOMA 
374. Ole Bosnes:  KLINISK UTPRØVING AV NORSKE VERSJONER AV NOEN SENTRALE 
TESTER PÅ KOGNITIV FUNKSJON 
375. Ola M. Rygh:  3D ULTRASOUND BASED NEURONAVIGATION IN NEUROSURGERY.  A 
CLINICAL EVALUATION 
376. Astrid Kamilla Stunes:  ADIPOKINES, PEROXISOME PROFILERATOR ACTIVATED 
RECEPTOR (PPAR) AGONISTS AND SEROTONIN.  COMMON REGULATORS OF BONE 
AND FAT METABOLISM 
377. Silje Engdal:  HERBAL REMEDIES USED BY NORWEGIAN CANCER PATIENTS AND 
THEIR ROLE IN HERB-DRUG INTERACTIONS 
378. Kristin Offerdal:  IMPROVED ULTRASOUND IMAGING OF THE FETUS AND ITS 
CONSEQUENCES FOR SEVERE AND LESS SEVERE ANOMALIES 
379. Øivind Rognmo:  HIGH-INTENSITY AEROBIC EXERCISE AND CARDIOVASCULAR 
HEALTH 
380. Jo-Åsmund Lund:  RADIOTHERAPY IN ANAL CARCINOMA AND PROSTATE CANCER 
2009 
381. Tore Grüner Bjåstad:  HIGH FRAME RATE ULTRASOUND IMAGING USING PARALLEL 
BEAMFORMING 
382. Erik Søndenaa:  INTELLECTUAL DISABILITIES IN THE CRIMINAL JUSTICE SYSTEM 
383. Berit Rostad:  SOCIAL INEQUALITIES IN WOMEN’S HEALTH, HUNT 1984-86 AND 
1995-97, THE NORD-TRØNDELAG HEALTH STUDY (HUNT) 
384. Jonas Crosby:  ULTRASOUND-BASED QUANTIFICATION OF MYOCARDIAL 
DEFORMATION AND ROTATION 
385. Erling Tronvik:  MIGRAINE, BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN 
SYSTEM 
386. Tom Christensen:  BRINGING THE GP TO THE FOREFRONT OF EPR DEVELOPMENT 
387. Håkon Bergseng:  ASPECTS OF GROUP B STREPTOCOCCUS (GBS) DISEASE IN THE 
NEWBORN.  EPIDEMIOLOGY, CHARACTERISATION OF INVASIVE STRAINS AND 
EVALUATION OF INTRAPARTUM SCREENING  
388. Ronny Myhre: GENETIC STUDIES OF CANDIDATE TENE3S IN PARKINSON’S  
DISEASE 
389. Torbjørn Moe Eggebø:  ULTRASOUND AND LABOUR 
390. Eivind Wang:  TRAINING IS MEDICINE FOR PATIENTS WITH PERIPHERAL ARTERIAL 
DISEASE 
391. Thea Kristin Våtsveen: GENETIC ABERRATIONS IN MYELOMA CELLS 
392. Thomas Jozefiak:  QUALITY OF LIFE AND MENTAL HEALTH IN CHILDREN AND 
ADOLESCENTS:  CHILD AND PARENT PERSPECTIVES 
393. Jens Erik Slagsvold:  N-3 POLYUNSATURATED FATTY ACIDS IN HEALTH AND 
DISEASE – CLINICAL AND MOLECULAR ASPECTS 
394. Kristine Misund:  A STUDY OF THE TRANSCRIPTIONAL REPRESSOR ICER.  
REGULATORY NETWORKS IN GASTRIN-INDUCED GENE EXPRESSION 
395. Franco M. Impellizzeri:  HIGH-INTENSITY TRAINING IN FOOTBALL PLAYERS.  
EFFECTS ON PHYSICAL AND TECHNICAL PERFORMANCE 
396. Kari Hanne Gjeilo:  HEALTH-RELATED QUALITY OF LIFE AND CHRONIC PAIN IN 
PATIENTS UNDERGOING CARDIAC SURGERY 
397. Øyvind Hauso:  NEUROENDOCRINE ASPECTS OF PHYSIOLOGY AND DISEASE 
398. Ingvild Bjellmo Johnsen:  INTRACELLULAR SIGNALING MECHANISMS IN THE INNATE 
IMMUNE RESPONSE TO VIRAL INFECTIONS 
399. Linda Tømmerdal Roten:  GENETIC PREDISPOSITION FOR DEVELOPMENT OF 
PREEMCLAMPSIA – CANDIDATE GENE STUDIES IN THE HUNT (NORD-TRØNDELAG 
HEALTH STUDY) POPULATION 
400. Trude Teoline Nausthaug Rakvåg:  PHARMACOGENETICS OF MORPHINE IN CANCER 
PAIN 
401. Hanne Lehn:  MEMORY FUNCTIONS OF THE HUMAN MEDIAL TEMPORAL LOBE 
STUDIED WITH fMRI 
402. Randi Utne Holt:  ADHESION AND MIGRATION OF MYELOMA CELLS – IN VITRO 
STUDIES – 
403. Trygve Solstad: NEURAL REPRESENTATIONS OF EUCLIDEAN SPACE 
404. Unn-Merete Fagerli:  MULTIPLE MYELOMA CELLS AND CYTOKINES FROM THE 
BONE MARROW ENVIRONMENT; ASPECTS OF GROWTH REGULATION AND 
MIGRATION 
405. Sigrid Bjørnelv:  EATING– AND WEIGHT PROBLEMS IN ADOLESCENTS, THE YOUNG 
HUNT-STUDY 
406. Mari Hoff:  CORTICAL HAND BONE LOSS IN RHEUMATOID ARTHRITIS.  
EVALUATING DIGITAL X-RAY RADIOGRAMMETRY AS OUTCOME MEASURE OF 
DISEASE ACTIVITY, RESPONSE VARIABLE TO TREATMENT AND PREDICTOR OF 
BONE DAMAGE  
407. Siri Bjørgen:  AEROBIC HIGH INTENSITY INTERVAL TRAINING IS AN EFFECTIVE 
TREATMENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
408. Susanne Lindqvist:  VISION AND BRAIN IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
409. Torbjørn Hergum:  3D ULTRASOUND FOR QUANTITATIVE ECHOCARDIOGRAPHY 
410. Jørgen Urnes:  PATIENT EDUCATION IN GASTRO-OESOPHAGEAL REFLUX DISEASE. 
VALIDATION OF A DIGESTIVE SYMPTOMS AND IMPACT QUESTIONNAIRE AND A 
RANDOMISED CONTROLLED TRIAL OF PATIENT EDUCATION 
411. Elvar Eyjolfsson:  13C NMRS OF ANIMAL MODELS OF SCHIZOPHRENIA 
412. Marius Steiro Fimland: CHRONIC AND ACUTE NEURAL ADAPTATIONS TO STRENGTH 
TRAINING 
413. Øyvind Støren: RUNNING AND CYCLING ECONOMY IN ATHLETES; DETERMINING 
FACTORS, TRAINING INTERVENTIONS AND TESTING 
414. Håkon Hov:  HEPATOCYTE GROWTH FACTOR AND ITS RECEPTOR C-MET.  
AUTOCRINE GROWTH AND SIGNALING IN MULTIPLE MYELOMA CELLS 
415. Maria Radtke: ROLE OF AUTOIMMUNITY AND OVERSTIMULATION FOR BETA-CELL 
DEFICIENCY. EPIDEMIOLOGICAL AND THERAPEUTIC PERSPECTIVES 
416. Liv Bente Romundstad:  ASSISTED FERTILIZATION IN NORWAY:  SAFETY OF THE 
REPRODUCTIVE TECHNOLOGY 
417. Erik Magnus Berntsen: PREOPERATIV PLANNING AND FUNCTIONAL 
NEURONAVIGATION – WITH FUNCTIONAL MRI AND DIFFUSION TENSOR 
TRACTOGRAPHY IN PATIENTS WITH BRAIN LESIONS 
418. Tonje Strømmen Steigedal:  MOLECULAR MECHANISMS OF THE PROLIFERATIVE 
RESPONSE TO THE HORMONE GASTRIN 
419. Vidar Rao:  EXTRACORPOREAL PHOTOCHEMOTHERAPY IN PATIENTS WITH 
CUTANEOUS T CELL LYMPHOMA OR GRAFT-vs-HOST DISEASE 
420. Torkild Visnes:  DNA EXCISION REPAIR OF URACIL AND 5-FLUOROURACIL IN 
HUMAN CANCER CELL LINES 
2010 
421. John Munkhaugen:  BLOOD PRESSURE, BODY WEIGHT, AND KIDNEY FUNCTION IN 
THE NEAR-NORMAL RANGE: NORMALITY, RISK FACTOR OR MORBIDITY ? 
422. Ingrid Castberg:  PHARMACOKINETICS, DRUG INTERACTIONS AND ADHERENCE TO 
TREATMENT WITH ANTIPSYCHOTICS: STUDIES IN A NATURALISTIC SETTING 
423. Jian Xu: BLOOD-OXYGEN-LEVEL-DEPENDENT-FUNCTIONAL MAGNETIC 
RESONANCE IMAGING AND DIFFUSION TENSOR IMAGING IN TRAUMATIC BRAIN 
INJURY RESEARCH 
424. Sigmund Simonsen: ACCEPTABLE RISK AND THE REQUIREMENT OF 
PROPORTIONALITY IN EUROPEAN BIOMEDICAL RESEARCH LAW. WHAT DOES 
THE REQUIREMENT THAT BIOMEDICAL RESEARCH SHALL NOT INVOLVE RISKS 
AND BURDENS DISPROPORTIONATE TO ITS POTENTIAL BENEFITS MEAN?  
425. Astrid Woodhouse:  MOTOR CONTROL IN WHIPLASH AND CHRONIC NON-
TRAUMATIC NECK PAIN 
426. Line Rørstad Jensen:  EVALUATION OF TREATMENT EFFECTS IN CANCER BY MR 
IMAGING AND SPECTROSCOPY 
427. Trine Moholdt:  AEROBIC EXERCISE IN CORONARY HEART DISEASE 
428. Øystein Olsen:  ANALYSIS OF MANGANESE ENHANCED MRI OF THE NORMAL AND 
INJURED RAT CENTRAL NERVOUS SYSTEM 
429. Bjørn H. Grønberg:   PEMETREXED IN THE TREATMENT OF ADVANCED LUNG 
CANCER 
430. Vigdis Schnell Husby:  REHABILITATION OF PATIENTS UNDERGOING TOTAL HIP 
ARTHROPLASTY  WITH FOCUS ON MUSCLE STRENGTH, WALKING AND AEROBIC 
ENDURANCE PERFORMANCE 
431. Torbjørn Øien:  CHALLENGES IN PRIMARY PREVENTION OF ALLERGY.  THE 
PREVENTION OF ALLERGY AMONG CHILDREN IN TRONDHEIM (PACT) STUDY. 
432. Kari Anne Indredavik Evensen:  BORN TOO SOON OR TOO SMALL:  MOTOR PROBLEMS 
IN ADOLESCENCE 
433. Lars Adde:  PREDICTION OF CEREBRAL PALSY IN YOUNG INFANTS.  COMPUTER 
BASED ASSESSMENT OF GENERAL MOVEMENTS 
434. Magnus Fasting:  PRE- AND POSTNATAL RISK FACTORS FOR CHILDHOOD 
ADIPOSITY 
435. Vivi Talstad Monsen:  MECHANISMS OF ALKYLATION DAMAGE REPAIR BY HUMAN 
AlkB HOMOLOGUES 
436. Toril Skandsen:  MODERATE AND SEVERE TRAUMATIC BRAIN INJURY.  MAGNETIC 
RESONANCE IMAGING FINDINGS, COGNITION AND RISK FACTORS FOR 
DISABILITY 
437. Ingeborg Smidesang:  ALLERGY RELATED DISORDERS AMONG 2-YEAR OLDS AND 
ADOLESCENTS IN MID-NORWAY – PREVALENCE, SEVERITY AND IMPACT.  THE 
PACT STUDY 2005, THE YOUNG HUNT STUDY 1995-97 
438. Vidar Halsteinli:  MEASURING EFFICIENCY IN MENTAL HEALTH  SERVICE 
DELIVERY:  A STUDY OF OUTPATIENT UNITS IN NORWAY 
439. Karen Lehrmann Ægidius: THE PREVALENCE OF HEADACHE AND MIGRAINE IN 
RELATION TO SEX HORMONE STATUS IN WOMEN. THE HUNT 2 STUDY 
440. Madelene Ericsson:  EXERCISE TRAINING IN GENETIC MODELS OF HEART FAILURE 
441. Marianne Klokk:  THE ASSOCIATION BETWEEN SELF-REPORTED ECZEMA AND 
COMMON MENTAL DISORDERS IN THE GENERAL POPULATION.  THE 
HORDALAND HEALTH STUDY (HUSK) 
442. Tomas Ottemo Stølen: IMPAIRED CALCIUM HANDLING IN ANIMAL AND HUMAN 
CARDIOMYOCYTES REDUCE CONTRACTILITY AND INCREASE ARRHYTHMIA 
POTENTIAL – EFFECTS OF AEROBIC EXERCISE TRAINING  
443. Bjarne Hansen:  ENHANCING TREATMENT OUTCOME IN COGNITIVE BEHAVIOURAL 
THERAPY FOR OBSESSIVE COMPULSIVE DISORDER: THE IMPORTANCE OF 
COGNITIVE FACTORS 
444. Mona Løvlien: WHEN EVERY MINUTE COUNTS. FROM SYMPTOMS TO ADMISSION 
FOR ACUTE MYOCARDIAL INFARCTION WITH SPECIAL EMPHASIS ON GENDER 
DIFFERECES 
445. Karin Margaretha Gilljam:  DNA REPAIR PROTEIN COMPLEXES, FUNCTIONALITY AND 
SIGNIFICANCE FOR REPAIR EFFICIENCY AND CELL SURVIVAL 
446. Anne Byriel Walls:  NEURONAL GLIAL INTERACTIONS IN CEREBRAL ENERGY – AND 
AMINO ACID HOMEOSTASIS – IMPLICATIONS OF GLUTAMATE AND GABA 
447. Cathrine Fallang Knetter:  MECHANISMS OF TOLL-LIKE RECEPTOR 9 ACTIVATION 
448. Marit Følsvik Svindseth:  A STUDY OF HUMILIATION, NARCISSISM AND TREATMENT 
OUTCOME IN PATIENTS ADMITTED TO PSYCHIATRIC EMERGENCY UNITS 
449. Karin Elvenes Bakkelund:  GASTRIC NEUROENDOCRINE CELLS – ROLE IN GASTRIC 
NEOPLASIA IN MAN AND RODENTS 
450. Kirsten Brun Kjelstrup:  DORSOVENTRAL DIFFERENCES IN THE SPATIAL 
REPRESENTATION AREAS OF THE RAT BRAIN 
451. Roar Johansen:  MR EVALUATION OF BREAST CANCER PATIENTS WITH POOR 
PROGNOSIS 
452. Rigmor Myran:  POST TRAUMATIC NECK PAIN.  EPIDEMIOLOGICAL, 
NEURORADIOLOGICAL AND CLINICAL ASPECTS 
453. Krisztina Kunszt Johansen:  GENEALOGICAL, CLINICAL AND BIOCHEMICAL STUDIES 
IN LRRK2 – ASSOCIATED PARKINSON’S DISEASE 
454. Pål Gjerden:  THE USE OF ANTICHOLINERGIC ANTIPARKINSON AGENTS IN 
NORWAY.  EPIDEMIOLOGY, TOXICOLOGY AND CLINICAL IMPLICATIONS 
455. Else Marie Huuse:  ASSESSMENT OF TUMOR MICROENVIRONMENT AND 
TREATMENT EFFECTS IN HUMAN BREAST CANCER XENOGRAFTS USING MR 
IMAGING AND SPECTROSCOPY 
456. Khalid S. Ibrahim:  INTRAOPERATIVE ULTRASOUND ASSESSMENT IN CORONARY 
ARTERY BYPASS SURGERY – WITH SPECIAL REFERENCE TO CORONARY 
ANASTOMOSES AND THE ASCENDING AORTA  
457. Bjørn Øglænd:  ANTHROPOMETRY, BLOOD PRESSURE AND REPRODUCTIVE 
DEVELOPMENT IN ADOLESCENCE OF OFFSPRING OF MOTHERS WHO HAD 
PREECLAMPSIA IN PREGNANCY 
458. John Olav Roaldset:  RISK ASSESSMENT OF VIOLENT, SUICIDAL AND SELF-
INJURIOUS BEHAVIOUR IN ACUTE PSYCHIATRY – A BIO-PSYCHO-SOCIAL 
APPROACH 
459. Håvard Dalen: ECHOCARDIOGRAPHIC INDICES OF CARDIAC FUNCTION – NORMAL 
VALUES AND ASSOCIATIONS WITH CARDIAC RISK FACTORS IN A POPULATION 
FREE FROM CARDIOVASCULAR DISEASE, HYPERTENSION AND DIABETES: THE 
HUNT 3 STUDY 
460. Beate André:  CHANGE CAN BE CHALLENGING.  INTRODUCTION TO CHANGES AND 
IMPLEMENTATION OF COMPUTERIZED TECHNOLOGY IN HEALTH CARE 
461. Latha Nrugham:  ASSOCIATES AND PREDICTORS OF ATTEMPTED SUICIDE AMONG 
DEPRESSED ADOLESCENTS – A 6-YEAR PROSPECTIVE STUDY 
462. Håvard Bersås Nordgaard: TRANSIT-TIME FLOWMETRY AND WALL SHEAR STRESS 
ANALYSIS OF CORONARY ARTERY BYPASS GRAFTS – A CLINICAL AND 
EXPERIMENTAL STUDY 
Cotutelle with University of Ghent: Abigail Emily Swillens: A MULTIPHYSICS MODEL FOR  
IMPROVING THE ULTRASONIC ASSESSMENT OF LARGE ARTERIES 
2011 
463. Marte Helene Bjørk: DO BRAIN RHYTHMS CHANGE BEFORE THE MIGRAINE 
ATTACK?  A LONGITUDINAL CONTROLLED EEG STUDY 
464. Carl-Jørgen Arum:  A STUDY OF UROTHELIAL CARCINOMA:  GENE EXPRESSION 
PROFILING, TUMORIGENESIS AND THERAPIES IN ORTHOTOPIC ANIMAL MODELS 
465. Ingunn Harstad:  TUBERCULOSIS INFECTION AND DISEASE AMONG ASYLUM 
SEEKERS IN NORWAY.  SCREENING AND FOLLOW-UP IN PUBLIC HEALTH CARE 
466. Leif Åge Strand:  EPIDEMIOLOGICAL STUDIES AMONG ROYAL NORWEGIAN NAVY 
SERVICEMEN.  COHORT ESTABLISHMENT, CANCER INCIDENCE AND CAUSE-
SPECIFIC MORTALITY 
467. Katrine Høyer Holgersen:  SURVIVORS IN THEIR THIRD DECADE AFTER THE NORTH 
SEA OIL RIG DISASTER OF 1980.  LONG-TERM PERSPECTIVES ON MENTAL HEALTH 
468. MarianneWallenius:  PREGNANCY RELATED ASPECTS OF CHRONIC 
INFLAMMATORY ARTHRITIDES:  DISEASE ONSET POSTPARTUM, PREGNANCY 
OUTCOMES AND FERTILITY.  DATA FROM A NORWEGIAN PATIENT REGISTRY 
LINKED TO THE MEDICAL BIRTH  REGISTRY OF NORWAY 
469. Ole Vegard Solberg: 3D ULTRASOUND AND NAVIGATION – APPLICATIONS IN 
LAPAROSCOPIC SURGERY 
470. Inga Ekeberg Schjerve: EXERCISE-INDUCED IMPROVEMENT OF MAXIMAL OXYGEN 
UPTAKE AND ENDOTHELIAL FUNCTION IN OBESE AND OVERWEIGHT 
INDIVIDUALS ARE DEPENDENT ON EXERCISE-INTENSITY 
471. Eva Veslemøy Tyldum: CARDIOVASCULAR FUNCTION IN PREECLAMPSIA – WITH 
REFERENCE TO ENDOTHELIAL FUNCTION, LEFT VENTRICULAR FUNCTION AND 
PRE-PREGNANCY PHYSICAL ACTIVITY 
472. Benjamin Garzón Jiménez de Cisneros: CLINICAL APPLICATIONS OF MULTIMODAL 
MAGNETIC RESONANCE IMAGING 
473. Halvard Knut Nilsen: ASSESSING CODEINE TREATMENT TO PATIENTS WITH 
CHRONIC NON-MALIGNANT PAIN: NEUROPSYCHOLOGICAL FUNCTIONING, 
DRIVING ABILITY AND WEANING 
474. Eiliv Brenner: GLUTAMATE RELATED METABOLISM IN ANIMAL MODELS OF 
SCHIZOPHRENIA  
475. Egil Jonsbu: CHEST PAIN AND PALPITATIONS IN A CARDIAC SETTING; 
PSYCHOLOGICAL FACTORS, OUTCOME AND TREATMENT 
476. Mona Høysæter Fenstad: GENETIC SUSCEPTIBILITY TO PREECLAMPSIA : STUDIES ON 
THE NORD-TRØNDELAG HEALTH STUDY (HUNT) COHORT, AN AUSTRALIAN/NEW 
ZEALAND FAMILY COHORT AND DECIDUA BASALIS TISSUE 
477. Svein Erik Gaustad: CARDIOVASCULAR CHANGES IN DIVING: FROM HUMAN 
RESPONSE TO CELL FUNCTION 
478. Karin Torvik: PAIN AND QUALITY OF LIFE IN PATIENTS LIVING IN NURSING 
HOMES 
479. Arne Solberg: OUTCOME ASSESSMENTS IN NON-METASTATIC PROSTATE CANCER 
480. Henrik Sahlin Pettersen: CYTOTOXICITY AND REPAIR OF URACIL AND 5-
FLUOROURACIL IN DNA 
481. Pui-Lam Wong: PHYSICAL AND PHYSIOLOGICAL CAPACITY OF SOCCER PLAYERS: 
EFFECTS OF STRENGTH AND CONDITIONING 
482. Ole Solheim: ULTRASOUND GUIDED SURGERY IN PATIENTS WITH INTRACRANIAL 
TUMOURS 
483. Sten Roar Snare: QUANTITATIVE CARDIAC ANALYSIS ALGORITHMS FOR POCKET-
SIZED ULTRASOUND DEVICES 
484. Marit Skyrud Bratlie: LARGE-SCALE ANALYSIS OF ORTHOLOGS AND PARALOGS IN 
VIRUSES AND PROKARYOTES 
485. Anne Elisabeth F. Isern: BREAST RECONSTRUCTION AFTER MASTECTOMY – RISK OF 
RECURRENCE AFTER DELAYED LARGE FLAP RECONSTRUCTION – AESTHETIC 
OUTCOME, PATIENT SATISFACTION, QUALITY OF LIFE AND SURGICAL RESULTS; 
HISTOPATHOLOGICAL FINDINGS AND FOLLOW-UP AFTER PROPHYLACTIC 
MASTECTOMY IN HEREDITARY BREAST CANCER 
486. Guro L. Andersen:  CEREBRAL PALSY IN NORWAY – SUBTYPES, SEVERITY AND 
RISK FACTORS 
487. Frode Kolstad:  CERVICAL DISC DISEASE – BIOMECHANICAL ASPECTS 
488. Bente Nordtug: CARING BURDEN OF COHABITANTS LIVING WITH PARTNERS 
SUFFERING FROM CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR DEMENTIA 
489. Mariann Gjervik Heldahl: EVALUATION OF NEOADJUVANT CHEMOTHERAPY IN 
LOCALLY ADVANCED BREAST CANCER BASED ON MR METHODOLOGY 
490. Lise Tevik Løvseth:  THE SUBJECTIVE BURDEN OF CONFIDENTIALITY  
491. Marie Hjelmseth Aune: INFLAMMATORY RESPONSES AGAINST GRAM NEGATIVE 
BACTERIA INDUCED BY TLR4 AND NLRP12 
492. Tina Strømdal Wik: EXPERIMENTAL EVALUATION OF NEW CONCEPTS IN HIP 
ARTHROPLASTY 
493. Solveig Sigurdardottir:  CLINICAL ASPECTS OF CEREBRAL PALSY IN ICELAND. A 
POPULATION-BASED STUDY OF PRESCHOOL CHILDREN  
494. Arne Reimers: CLINICAL PHARMACOKINETICS OF LAMOTRIGINE 
495. Monica Wegling:  KULTURMENNESKETS BYRDE OG SYKDOMMENS VELSIGNELSE. 
KAN MEDISINSK UTREDNING OG INTERVENSJON HA EN SELVSTENDIG FUNKSJON 
UAVHENGIG AV DET KURATIVE? 
496. Silje Alvestad: ASTROCYTE-NEURON INTERACTIONS IN EXPERIMENTAL MESIAL 
TEMPORAL LOBE EPILEPSY – A STUDY OF UNDERLYING MECHANISMS AND 
POSSIBLE BIOMARKERS OF EPILEPTOGENESIS 
497. Javaid Nauman: RESTING HEART RATE: A MATTER OF LIFE OR DEATH – 
PROSPECTIVE STUDIES OF RESTING HEART RATE AND CARDIOVASCULAR RISK 
(THE HUNT STUDY, NORWAY) 
498. Thuy Nguyen: THE ROLE OF C-SRC TYROSINE KINASE IN ANTIVIRAL IMMUNE 
RESPONSES 
499. Trine Naalsund Andreassen: PHARMACOKINETIC, PHARMACODYNAMIC AND 
PHARMACOGENETIC ASPECTS OF OXYCODONE TREATMENT IN CANCER PAIN 
500. Eivor Alette Laugsand: SYMPTOMS IN PATIENTS RECEIVING OPIOIDS FOR CANCER 
PAIN – CLINICAL AND PHARMACOGENETIC ASPECTS 
501. Dorthe Stensvold: PHYSICAL ACTIVITY, CARDIOVASCULAR HEALTH AND 
LONGEVITY IN PATIENTS WITH METABOLIC SYNDROME 
502. Stian Thoresen Aspenes: PEAK OXYGEN UPTAKE AMONG HEALTHY ADULTS – 
CROSS-SECTIONAL DESCRIPTIONS AND PROSPECTIVE ANALYSES OF PEAK 
OXYGEN UPTAKE, PHYSICAL ACTIVITY AND CARDIOVASCULAR RISK FACTORS 
IN HEALTHY ADULTS (20-90 YEARS) 
503. Reidar Alexander Vigen:  PATHOBIOLOGY OF GASTRIC CARCINOIDS AND 
ADENOCARCINOMAS IN RODENT MODELS AND PATIENTS.  STUDIES OF 
GASTROCYSTOPLASTY, GENDER-RELATED FACTORS, AND AUTOPHAGY 
504. Halvard Høilund-Kaupang:  MODELS AND METHODS FOR INVESTIGATION OF 
REVERBERATIONS IN NONLINEAR ULTRASOUND IMAGING     
505. Audhild Løhre: WELLBEING AMONG SCHOOL CHILDREN IN GRADES 1-10:  
PROMOTING AND ADVERSE FACTORS 
506. Torgrim Tandstad:  VOX POPULI.  POPULATION-BASED OUTCOME STUDIES IN 
TESTICULAR CANCER 
507. Anna Brenne Grønskag:  THE EPIDEMIOLOGY OF HIP FRACTURES AMONG ELDERLY 
WOMEN IN NORD-TRØNDELAG.  HUNT 1995-97, THE NORD-TRØNDELAG HEALTH 
STUDY 
508. Kari Ravndal Risnes: BIRTH SIZE AND ADULT MORTALITY: A SYSTEMATIC REVIEW 
AND A LONG-TERM FOLLOW-UP OF NEARLY 40 000 INDIVIDUALS BORN AT         
ST. OLAV UNIVERSITY HOSPITAL IN TRONDHEIM 1920-1960 
509. Hans Jakob Bøe: LONG-TERM POSTTRAUMATIC STRESS AFTER DISASTER – A 
CONTROLLED STUDY OF SURVIVORS’ HEALTH 27 YEARS AFTER THE CAPSIZED 
NORTH SEA OIL RIG 
510. Cathrin Barbara Canto,  Cotutelle with University of Amsterdam: LAYER SPECIFIC 
INTEGRATIVE PROPERTIES OF ENTORHINAL PRINCIPAL NEURONS 
511. Ioanna Sandvig: THE ROLE OF OLFACTORY ENSHEATHING CELLS, MRI, AND 
BIOMATERIALS IN TRANSPLANT-MEDIATED CNS REPAIR 
512. Karin Fahl Wader:  HEPATOCYTE GROWTH FACTOR, C-MET AND SYNDECAN-1 IN 
MULTIPLE MYELOMA 
513. Gerd Tranø: FAMILIAL COLORECTAL CANCER 
514. Bjarte Bergstrøm:  INNATE ANTIVIRAL IMMUNITY – MECHANISMS OF THE RIG-I-
MEDIATED RESPONSE  
515. Marie Søfteland Sandvei:  INCIDENCE, MORTALITY, AND RISK FACTORS FOR 
ANEURYSMAL SUBARACHNOID HEMORRHAGE.  PROSPECTIVE ANALYZES OF 
THE HUNT AND TROMSØ STUDIES 
516. Mary-Elizabeth Bradley Eilertsen: CHILDREN AND ADOLESCENTS SURVIVING 
CANCER: PSYCHOSOCIAL HEALTH, QUALITY OF LIFE AND SOCIAL SUPPORT 
517. Takaya Saito:  COMPUTATIONAL ANALYSIS OF REGULATORY MECHANISM AND 
INTERACTIONS OF MICRORNAS 
Godkjent for disputas, publisert post mortem:  Eivind Jullumstrø:  COLORECTAL CANCER AT 
LEVANGER HOSPITAL 1980-2004 
518. Christian Gutvik: A PHYSIOLOGICAL APPROACH TO A NEW DECOMPRESSION 
ALGORITHM USING NONLINEAR MODEL PREDICTIVE CONTROL 
519. Ola Storrø:  MODIFICATION OF ADJUVANT RISK FACTOR BEHAVIOURS FOR 
ALLERGIC DISEASE AND ASSOCIATION BETWEEN EARLY GUT MICROBIOTA AND 
ATOPIC SENSITIZATION AND ECZEMA.  EARLY LIFE EVENTS DEFINING THE 
FUTURE HEALTH OF OUR CHILDREN 
520. Guro Fanneløb Giskeødegård: IDENTIFICATION AND CHARACTERIZATION OF 
PROGNOSTIC FACTORS IN BREAST CANCER USING MR METABOLOMICS 
521. Gro Christine Christensen Løhaugen: BORN PRETERM WITH VERY LOW BIRTH WEIGHT 
– NEVER ENDING COGNITIVE CONSEQUENCES? 
522. Sigrid Nakrem: MEASURING QUALITY OF CARE IN NURSING HOMES – WHAT 
MATTERS?  
523. Brita Pukstad:  CHARACTERIZATION OF INNATE INFLAMMATORY RESPONSES IN 
ACUTE AND CHRONIC WOUNDS 
2012 
524. Hans H. Wasmuth:  ILEAL POUCHES 
525. Inger Økland: BIASES IN SECOND-TRIMESTER ULTRASOUND DATING RELATED TO 
PREDICTION MODELS AND FETAL MEASUREMENTS 
526. Bjørn Mørkedal:  BLOOD PRESSURE, OBESITY, SERUM IRON AND LIPIDS AS RISK 
FACTORS OF ISCHAEMIC HEART DISEASE 
527. Siver Andreas Moestue: MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF 
BREAST CANCER THROUGH A COMBINATION OF MR IMAGING, 
TRANSCRIPTOMICS AND METABOLOMICS  
528. Guro Aune:  CLINICAL, PATHOLOGICAL, AND MOLECULAR CLASSIFICATION OF 
OVARIAN CARCINOMA 
529. Ingrid Alsos Lian:  MECHANISMS INVOLVED IN THE PATHOGENESIS OF PRE-
ECLAMPSIA AND FETAL GROWTH RESTRICTION.   TRANSCRIPTIONAL ANALYSES 
OF PLACENTAL AND DECIDUAL TISSUE 
530. Karin Solvang-Garten:  X-RAY REPAIR CROSS-COMPLEMENTING PROTEIN 1 – THE 
ROLE AS A SCAFFOLD PROTEIN IN BASE EXCISION REPAIR AND SINGLE STRAND 
BREAK REPAIR 
531. Toril Holien: BONE MORPHOGENETIC PROTEINS AND MYC IN MULTIPLE 
MYELOMA 
532. Rooyen Mavenyengwa:  STREPTOCOCCUS AGALACTIAE IN PREGNANT WOMEN IN 
ZIMBABWE:  EPIDEMIOLOGY AND SEROTYPE MARKER CHARACTERISTICS 
533. Tormod Rimehaug:  EMOTIONAL DISTRESS AND PARENTING AMONG COMMUNITY 
AND CLINIC PARENTS 
534. Maria Dung Cao: MR METABOLIC CHARACTERIZATION OF LOCALLY ADVANCED 
BREAST CANCER – TREATMENT EFFECTS AND PROGNOSIS 
535. Mirta Mittelstedt Leal de Sousa: PROTEOMICS ANALYSIS OF PROTEINS INVOLVED IN 
DNA BASE REPAIR AND CANCER THERAPY 
536. Halfdan Petursson:  THE VALIDITY AND RELEVANCE OF INTERNATIONAL 
CARDIOVASCULAR DISEASE PREVENTION GUIDELINES FOR GENERAL PRACTICE 
537. Marit By Rise: LIFTING THE VEIL FROM USER PARTICIPATION IN CLINICAL WORK 
– WHAT IS IT AND DOES IT WORK? 
538. Lene Thoresen:  NUTRITION CARE IN CANCER PATIENTS. NUTRITION ASSESSMENT: 
DIAGNOSTIC CRITERIA AND THE ASSOCIATION TO SURVIVAL AND HEALTH-
RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED COLORECTAL 
CARCINOMA 
539. Berit Doseth:  PROCESSING OF GENOMIC URACIL IN MAN AND MOUSE 
540. Gro Falkenér Bertheussen: PHYSICAL ACTIVITY AND HEALTH IN A GENERAL 
POPULATION AND IN CANCER SURVIVORS – METHODOLOGICAL, 
OBSERVATIONAL AND CLINICAL ASPECTS 
541. Anne Kari Knudsen:  CANCER PAIN CLASSIFICATION 
542. Sjur Urdson Gjerald:  A FAST ULTRASOUND SIMULATOR 
543. Harald Edvard Mølmen Hansen: CARDIOVASCULAR EFFECTS OF HIGH INTENSITY 
AEROBIC INTERVAL TRAINING IN HYPERTENSITIVE PATIENTS, HEALTHY AGED 
AND YOUNG PERSONS 
544. Sasha Gulati: SURGICAL RESECTION OF HIGH-GRADE GLIOMAS 
545. John Chr. Fløvig:  FREQUENCY AND EFFECT OF SUBSTANCES AND PSYCHOACTIVE 
MEDICATIONS THE WEEK BEFORE ADMISSION TO AN ACUTE PSYCHIATRIC 
DEPARTMENT 
546. Kristin Moksnes Husby: OPTIMIZING OPIOID TREATMENT FOR CANCER PAIN – 
CLINICAL AND PHARMACOLOGICAL ASPECTS 
547. Audun Hanssen-Bauer: X-RAY REPAIR CROSS-COMPLEMENTING PROTEIN 1 
ASSOCIATED MULTIPROTEIN COMPLEXES IN BASE EXCISION REPAIR 
548. Marit Saunes:  ECZEMA IN CHILDREN AND ADOLESCENTS – EPIDEMIOLOGY, 
COURSE AND IMPACT.  THE PREVENTION OF ALLERGY AMONG CHILDREN IN 
TRONDHEIM (PACT) STUDY, YOUNG-HUNT 1995-97 
549. Guri Kaurstad:  CARDIOMYOCYTE FUNCTION AND CALCIUM HANDLING IN ANIMAL 
MODELS OF INBORN AND ACQUIRED MAXIMAL OXYGEN UPTAKE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
